



# DHS SCIENCE AND TECHNOLOGY

## Master Question List for COVID-19 (caused by SARS-CoV-2)

Weekly Report

21 July 2020

For comments or questions related to the contents of this document, please contact the DHS S&T Hazard Awareness & Characterization Technology Center at [HACTechnologyCenter@hq.dhs.gov](mailto:HACTechnologyCenter@hq.dhs.gov).



**Homeland  
Security**

Science and Technology

DHS Science and Technology Directorate | MOBILIZING INNOVATION FOR A SECURE WORLD

**CLEARED FOR PUBLIC RELEASE**

## FOREWORD

The Department of Homeland Security (DHS) is paying close attention to the evolving Coronavirus Infectious Disease (COVID-19) situation in order to protect our nation. DHS is working very closely with the Centers for Disease Control and Prevention (CDC), other federal agencies, and public health officials to implement public health control measures related to travelers and materials crossing our borders from the affected regions.

Based on the response to a similar product generated in 2014 in response to the Ebolavirus outbreak in West Africa, the DHS Science and Technology Directorate (DHS S&T) developed the following “master question list” that quickly summarizes what is known, what additional information is needed, and who may be working to address such fundamental questions as, “What is the infectious dose?” and “How long does the virus persist in the environment?” The Master Question List (MQL) is intended to quickly present the current state of available information to government decision makers in the operational response to COVID-19 and allow structured and scientifically guided discussions across the federal government without burdening them with the need to review scientific reports, and to prevent duplication of efforts by highlighting and coordinating research.

The information contained in the following table has been assembled and evaluated by experts from publicly available sources to include reports and articles found in scientific and technical journals, selected sources on the internet, and various media reports. It is intended to serve as a “quick reference” tool and should not be regarded as comprehensive source of information, nor as necessarily representing the official policies, either expressed or implied, of the DHS or the U.S. Government. DHS does not endorse any products or commercial services mentioned in this document. All sources of the information provided are cited so that individual users of this document may independently evaluate the source of that information and its suitability for any particular use. This document is a “living document” that will be updated as needed when new information becomes available.

The Department of Homeland Security Science and Technology Directorate is committed to providing access to our web pages for individuals with disabilities, both members of the public and federal employees. If the format of any elements or content within this document interferes with your ability to access the information, as defined in the Rehabilitation Act, please contact the Hazard Awareness & Characterization Technology Center for assistance by emailing [HACTechnologyCenter@hq.dhs.gov](mailto:HACTechnologyCenter@hq.dhs.gov). A member of our team will contact you within 5 business days. To enable us to respond in a manner most helpful to you, please indicate the nature of your accessibility problem, the preferred format in which to receive the material, the web address (<https://www.dhs.gov/publication/st-master-question-list-covid-19>) or name of the document of the material (Master Question List for COVID-19) with which you are having difficulty, and your contact information.

## **Table of Contents**

<b>Infectious Dose – How much agent will make a healthy individual ill? .....</b>	<b>3</b>
<p>The human infectious dose of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unknown by all exposure routes. Studies from other animal models are used as surrogates for humans. Based on primate models, the inhalation median infectious dose (ID<sub>50</sub>) in humans is likely less than 10,000 PFU, and possibly less than 1,000 PFU. Identifying the infectious dose for humans by the various routes through which we become infected is critical to the effective development of computational models to predict risk, develop diagnostics and countermeasures, and effective decontamination strategies. Animal studies are a plausible surrogate.</p>	
<b>Transmissibility – How does it spread from one host to another? How easily is it spread? .....</b>	<b>4</b>
<p>SARS-CoV-2 is passed easily between humans, likely through close contact with relatively large droplets and possibly through smaller aerosolized particles. Individuals can transmit SARS-CoV-2 to others before they have symptoms. Undetected cases play a major role in transmission, and most cases are not reported.<sup>611</sup> Individuals who have recovered clinically, but test positive, appear unable to transmit COVID-19. The relative contribution of different routes of transmission, such as close contact and droplet transmission versus aerosol transmission and contaminated objects and surfaces (fomites), is unknown and requires additional research.</p>	
<b>Host Range – How many species does it infect? Can it transfer from species to species? .....</b>	<b>5</b>
<p>SARS-CoV-2 is closely related to other coronaviruses circulating in bats in Southeast Asia. Previous coronaviruses have passed through an intermediate mammal host before infecting humans, but the identity of the SARS-CoV-2 intermediate host is unknown. SARS-CoV-2 uses the same receptor for cell entry as the SARS-CoV-1 coronavirus that circulated in 2002/2003. To date, ferrets, mink, hamsters, cats, and primates have been shown to be susceptible to SARS-CoV-2 infection. It is unknown whether these animals can transmit infection to humans. Several animal models have been developed to recreate human-like illness, though to date they have been infected with high dose exposures. Lower dose studies may better replicate human disease acquisition.</p>	
<b>Incubation Period – How long after infection do symptoms appear? Are people infectious during this time?.....</b>	<b>6</b>
<p>The majority of individuals develop symptoms within 14 days of exposure. For most people, it takes at least 2 days to develop symptoms, and on average symptoms develop 5 days after exposure. Incubating individuals can transmit disease for several days before symptom onset. Some individuals never develop symptoms but can still transmit disease. The incubation period is well-characterized. Patients may be infectious, however, for days before symptoms develop.</p>	
<b>Clinical Presentation – What are the signs and symptoms of an infected person? .....</b>	<b>7</b>
<p>Approximately 40% of cases are asymptomatic.<sup>397</sup> Most symptomatic cases are mild, but severe disease can be found in any age group.<sup>4</sup> Older individuals and those with underlying medical conditions are at higher risk of serious illness and death. The case fatality rate (CFR) varies substantially by patient age and underlying comorbidities.<sup>570</sup> Additional studies on vulnerable subpopulations are required. Children are susceptible to COVID-19,<sup>142</sup> though generally show milder<sup>95, 332</sup> or no symptoms. The true case fatality rate is unknown, as the exact number of cases is uncertain. Testing priorities and case definitions vary by location. The proportion of asymptomatic infections is not known.</p>	
<b>Protective Immunity – How long does the immune response provide protection from reinfection? .....</b>	<b>8</b>
<p>Infected patients show productive immune responses, but the duration of any protection is unknown. Initial evidence suggests that the neutralizing antibody response does not last more than a few months, though this varies by severity. Currently, there is no evidence that recovered patients can be reinfected with SARS-CoV-2. As the pandemic continues, long-term monitoring of immune activity and reinfection status is needed.</p>	
<b>Clinical Diagnosis – Are there tools to diagnose infected individuals? When during infection are they effective? .....</b>	<b>9</b>
<p>Diagnosis relies on identifying the genetic signature of the virus in patient nose, throat, or sputum samples, or by identifying SARS-CoV-2 antibodies in individuals exposed to the virus. Confirmed cases are still underreported. Validated serological (antibody) assays are being used to help determine who has been exposed to SARS-CoV-2. Serological evidence of exposure does not indicate immunity.</p>	

In general, PCR tests appear to be sensitive and specific, though confirmation of symptoms via chest CT is recommended. The sensitivity and specificity of serological testing methods is variable, and additional work needs to be done to determine factors that affect test accuracy.

**Medical Treatments – Are there effective treatments?.....10**

Treatment for COVID-19 is primarily supportive care,<sup>201, 351</sup> and no single standard of care exists. Drug trials are ongoing. Remdesivir shows promise for reducing symptom duration<sup>41</sup> and mortality<sup>188</sup> in humans. Hydroxychloroquine is associated with risk of cardiac arrhythmias and provides limited to no clinical benefit at this time. Dexamethasone may significantly reduce mortality in severely ill and ventilated patients. Other pharmaceutical interventions are being investigated. Additional information on treatment efficacy is required, particularly from large randomized clinical trials.

**Vaccines – Are there effective vaccines?.....11**

Work is ongoing to develop and produce a SARS-CoV-2 vaccine (e.g., Operation Warp Speed),<sup>38, 206, 209-211, 386</sup> Early results are being released, but evidence should be considered preliminary until larger trials are completed. Published results from randomized clinical trials (Phase I – III) are needed.

**Non-pharmaceutical Interventions – Are public health control measures effective at reducing spread?.....12**

Broad-scale control measures such as stay-at-home orders are effective at reducing transmission. Research is needed to help plan for easing of restrictions. Testing is critical, and synchronized interventions may help. As different US states have implemented differing control measures at various times, a comprehensive analysis of social distancing efficacy has not yet been conducted.

**Environmental Stability – How long does the agent live in the environment?.....13**

SARS-CoV-2 can persist on surfaces for at least 3 days and on the surface of a surgical mask for up to 7 days depending on conditions. If aerosolized intentionally, SARS-CoV-2 is stable for at least several hours. The seasonality of COVID-19 transmission is unknown. SARS-CoV-2 on surfaces is inactivated rapidly with sunlight. Additional testing on SARS-CoV-2, as opposed to surrogate viruses, is needed to support initial estimates of stability. Tests quantifying infectivity, rather than the presence of viral RNA, are needed.

**Decontamination – What are effective methods to kill the agent in the environment? .....14**

Soap and water, as well as common alcohol and chlorine-based cleaners, hand sanitizers, and disinfectants are effective at inactivating SARS-CoV-2 on hands and surfaces. Additional decontamination studies, particularly with regard to PPE and other items in short supply, are needed.

**PPE – What PPE is effective, and who should be using it? .....15**

The effectiveness of PPE for SARS-CoV-2 is currently unknown, and data from other related coronaviruses are used for guidance. Healthcare workers are at high risk of acquiring COVID-19, even with recommended PPE. Most PPE recommendations have not been made on SARS-CoV-2 data, and comparative efficacy of different PPE for different tasks (e.g., intubation) is unknown. Identification of efficacious PPE for healthcare workers is critical due to their high rates of infection.

**Forensics – Natural vs intentional use? Tests to be used for attribution. ....16**

All current evidence supports the natural emergence of SARS-CoV-2 via a bat and possible intermediate mammal species. Identifying the intermediate species between bats and humans would aid in reducing potential spillover from a natural source. Wide sampling of bats, other wild animals, and humans is needed to address the origin of SARS-CoV-2.

**Genomics – How does the disease agent compare to previous strains? .....17**

Current evidence suggests that SARS-CoV-2 accumulates substitutions and mutations at a similar rate as other coronaviruses. Mutations and deletions in specific portions of the SARS-CoV-2 genome have not been linked to any changes in transmission or disease severity, though modeling work is attempting to identify possible changes. Research linking genetic changes to differences in phenotype (e.g., transmissibility, virulence, progression in patients) is needed.

**Forecasting – What forecasting models and methods exist?.....18**

Forecasts differ in how they handle public health interventions such as shelter-in-place orders and tracking how methods change in the near future will be important for understanding limitations going forward.

Updated 7/21/2020

Infectious Dose – How much agent will make a healthy individual ill?
<b>What do we know?</b>
<p><b>The human infectious dose of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is unknown by all exposure routes. Studies from other animal models are used as surrogates for humans. Based on primate models, the inhalation median infectious dose (ID<sub>50</sub>) in humans is likely less than 10,000 PFU, and possibly less than 1,000 PFU.</b></p> <p><i>Non-human primates</i></p> <ul style="list-style-type: none"> <li>• A total dose of approximately 700,000 plaque-forming units (PFU) of the novel coronavirus SARS-CoV-2 infected cynomolgus macaques via combination intranasal and intratracheal exposure (10<sup>6</sup> TCID<sub>50</sub> total dose).<sup>452</sup> Macaques did not exhibit clinical symptoms, but shed virus from the nose and throat.<sup>452</sup></li> <li>• Rhesus and cynomolgus macaques showed mild to moderate clinical infections at doses of 4.75x10<sup>6</sup> PFU (SARS-CoV-2 delivered through several routes), while common marmosets developed mild infections when exposed to 1.0x10<sup>6</sup> PFU intranasally.<sup>331</sup></li> <li>• Rhesus macaques are effectively infected with SARS-CoV-2 via the ocular conjunctival and intratracheal route at a dose of approximately 700,000 PFU (10<sup>6</sup> TCID<sub>50</sub>).<sup>135</sup> Rhesus macaques infected with 2,600,000 TCID<sub>50</sub> of SARS-CoV-2 by the intranasal, intratracheal, oral and ocular routes combined recapitulate moderate human disease.<sup>380</sup></li> <li>• African green monkeys replicate aspects of human disease, including severe pathological symptoms (exposed to 500,000 PFU via intranasal and intratracheal routes),<sup>577</sup> mild clinical symptoms (aerosol exposures between 5,000 and 16,000 PFU),<sup>213</sup> and acute respiratory distress syndrome (ARDS), with small particle aerosol exposure doses as low as 2,000 PFU.<sup>51</sup></li> <li>• Aerosol exposure of three primate species (African green monkeys, cynomolgus macaques, and rhesus macaques) via a Collision nebulizer resulted in mild clinical disease in all animals with doses between 28,700 and 48,600 PFU.<sup>251</sup></li> </ul> <p><i>Rodents</i></p> <ul style="list-style-type: none"> <li>• Golden Syrian hamsters exposed to 80,000 TCID<sub>50</sub> (~56,000 PFU) via the intranasal route developed clinical symptoms reminiscent of mild human infections (all hamsters infected).<sup>489</sup> In a separate study, immunosuppressed Golden Syrian hamsters showed severe clinical symptoms (including death) after exposure to 100-10,000 PFU via intranasal challenge.<sup>59</sup></li> <li>• Golden Syrian hamsters infected with 100,000 PFU intranasally exhibited mild clinical symptoms and developed neutralizing antibodies,<sup>91</sup> and were also capable of infecting individuals in separate cages. In another study, older hamsters had more severe symptoms and developed fewer neutralizing antibodies than younger hamsters.<sup>399</sup></li> <li>• Mice genetically modified to express the human ACE2 receptor (transgenic hACE2 mice) were inoculated intranasally with 100,000 TCID<sub>50</sub> (~70,000 PFU), and all mice developed pathological symptoms consistent with COVID-19.<sup>34</sup></li> <li>• Transgenic (hACE2) mice became infected after timed aerosol exposure (36 TCID<sub>50</sub>/minute) to between 900 and 1080 TCID<sub>50</sub> (~630-756 PFU). All mice (4/4) exposed for 25-30 minutes became infected, while no mice (0/8) became infected after exposure for 0-20 minutes (up to 720 TCID<sub>50</sub>, ~504 PFU).<sup>35</sup> Key methodological details (e.g., particle size, quantification of actual aerosol dose) are missing from the study's report.</li> <li>• Transgenic (hACE2) mice exposed intranasally to 400,000 PFU of SARS-CoV-2 develop clinical and pathological symptoms seen in humans.<sup>507</sup></li> </ul> <p><i>Other animal models</i></p> <ul style="list-style-type: none"> <li>• Ferrets infected with 316,000 TCID<sub>50</sub><sup>263</sup> or 600,000 TCID<sub>50</sub><sup>443</sup> of SARS-CoV-2 by the intranasal route show similar symptoms to human disease.<sup>263, 443</sup> Uninfected ferrets in direct contact with infected ferrets test positive and show disease as early as 2 days post-contact.<sup>263</sup> In one study, direct contact was required to transfer infection between ferrets,<sup>263</sup> however, transmission without direct contact was found in another study.<sup>443</sup></li> <li>• In a ferret study, 1 in 6 individuals exposed to 10<sup>2</sup> PFU via the intranasal route became infected, while 12 out of 12 individuals exposed to &gt;10<sup>4</sup> PFU became infected.<sup>462</sup></li> <li>• Domestic cats exposed to 100,000 PFU of SARS-CoV-2 via the intranasal route developed severe pathological symptoms including lesions in the nose, throat, and lungs.<sup>487</sup> In a separate study, infected cats showed no clinical signs, but were able to shed virus and transmit to other cats.<sup>54</sup></li> </ul> <p><i>Related Coronaviruses</i></p> <ul style="list-style-type: none"> <li>• The infectious dose for severe acute respiratory syndrome coronavirus 1 (SARS-CoV-1) in mice is estimated to be between 67-540 PFU (average 240 PFU, intranasal route).<sup>130, 132</sup></li> <li>• Genetically modified mice expressing DPP4 exposed intranasally to doses of Middle East respiratory syndrome coronavirus (MERS-CoV) between 100 and 500,000 PFU show signs of infection. Infection with higher doses result in severe syndromes.<sup>13, 113, 301, 620</sup></li> </ul>
<b>What do we need to know?</b>
<p><b>Identifying the infectious dose for humans by the various routes through which we become infected is critical to the effective development of computational models to predict risk, develop diagnostics and countermeasures, and effective decontamination strategies. Animal studies are a plausible surrogate.</b></p> <ul style="list-style-type: none"> <li>• Human infectious dose by aerosol, surface contact (fomite), fecal-oral routes, and other potential routes of exposure</li> <li>• Most appropriate animal model(s) to estimate the human infectious dose for SARS-CoV-2</li> </ul>

Transmissibility – How does it spread from one host to another? How easily is it spread?
<b>What do we know?</b>
<p><b>SARS-CoV-2 is passed easily between humans, likely through close contact with relatively large droplets and possibly through smaller aerosolized particles.</b></p> <ul style="list-style-type: none"> <li>As of 7/21/2020, pandemic COVID-19 has caused 14,730,716 infections and 610,587 deaths<sup>244</sup> in 188 countries and territories.<sup>80, 478, 566</sup> There are 3,831,450 confirmed COVID-19 cases across all 50 US states, with 140,909 deaths.<sup>244</sup></li> <li>Initial high-quality estimates of human transmissibility (<math>R_0</math>) range from 2.2 to 3.1,<sup>346, 408, 447, 585, 619</sup> though recent estimates suggest that early transmission rates were higher.<sup>467</sup> Transmission rates can vary substantially among neighboring populations.<sup>191, 547</sup> The majority of new infections come from relatively few infectious individuals.<sup>10, 152</sup></li> <li>SARS-CoV-2 is believed to spread through close contact and droplet transmission,<sup>85</sup> with fomite transmission<sup>247</sup> and close-contact aerosol transmission likely.<sup>20, 60, 200, 375</sup> On 7/9/2020, the WHO acknowledged that aerosol transmission is plausible, and could not be ruled out in all cases.<sup>568</sup></li> <li>SARS-CoV-2 replicates in the upper respiratory tract,<sup>222</sup> and infectious virus is detectable in throat and lung tissue for at least 8 days.<sup>572</sup> Respiratory fluids from severely ill patients contained higher viral RNA loads than respiratory fluids from mildly ill patients,<sup>623</sup> but similar viral RNA loads have been found in asymptomatic and symptomatic individuals.<sup>290</sup></li> <li>Contamination of patient rooms with aerosolized SARS-CoV-2 in the human respirable range (0.25-2.5 <math>\mu\text{m}</math>) indicates the potential for airborne transmission.<sup>324</sup> Viral RNA was detected up to 4 meters from ICU patient beds.<sup>203</sup> To date infectious virus has not been isolated from aerosol samples.<sup>469</sup></li> <li>SARS-CoV-2 may be spread by conversation and exhalation.<sup>7, 299, 469, 499</sup> A preliminary study in China detailing a restaurant-associated outbreak supports transmission via aerosol.<sup>309</sup> Contact tracing in Japan has identified clusters associated with large gatherings in bars, restaurants, music festivals, and other social activities involving close contact.<sup>606</sup> <b>Clusters of COVID-19 cases tend to come from indoor locations such as bars<sup>292</sup> and offices.<sup>409</sup></b></li> <li>Experimentally infected ferrets were able to transmit SARS-CoV-2 to other ferrets through the air (ferrets in an adjacent enclosure, separated by 10 cm).<sup>442</sup> Similar results have been documented in transgenic mice.<sup>35</sup></li> <li><b>At least one case of vertical transmission has been confirmed from mother to infant prior to birth,<sup>533</sup> though most evidence suggests this is rare.</b><sup>97, 102, 105, 476, 515, 597, 602</sup></li> <li>SARS-CoV-2 RNA has been found in semen from both clinically symptomatic and recovered cases,<sup>300</sup> but the potential for sexual transmission is unknown. Infectious SARS-CoV-2 has been cultured from patient feces<sup>590</sup> and urine.<sup>505</sup></li> <li><b>Older children (&gt;10 years old) appear to transmit SARS-CoV-2 as frequently as adults, while younger children (&lt;10 years old) appear to transmit infection less often.<sup>410</sup> These estimates, however, were generated during school closures, and may underestimate the risk of infection from school-age children.</b></li> </ul> <p><b>Individuals can transmit SARS-CoV-2 to others before they have symptoms.</b></p> <ul style="list-style-type: none"> <li>Individuals may be infectious for 1-3 days prior to symptom onset,<sup>553</sup> and culturable virus has been found up to 6 days prior to symptom onset.<sup>26</sup> Pre-symptomatic<sup>52, 270, 498, 504, 594, 622</sup> or asymptomatic<sup>33, 227, 336</sup> patients can transmit SARS-CoV-2, and asymptomatic individuals shed virus for as long as mildly symptomatic individuals.<sup>327</sup> At least 12% of all cases are estimated to be due to asymptomatic transmission.<sup>145</sup> It has been estimated that 23-56% of infections may be caused by pre-symptomatic transmission.<sup>76, 216, 321</sup> Individuals are most infectious before symptoms begin and within 5 days of symptom onset,<sup>104</sup> and pre-symptomatic individuals contribute to environmental contamination.<sup>245</sup></li> <li>Attack rates of the virus are higher among household members than casual contacts.<sup>64, 484</sup> The attack rate ranges from 11%,<sup>46</sup> 16%,<sup>305</sup> and 38%<sup>454</sup> of household members, with rates increasing with age.<sup>454</sup> The attack rate for children is low in households with an adult COVID-19 case (6.1% overall), and is lowest for children &lt;5 years old (1.3%).<sup>607</sup> Individuals transmit infection to household members before they exhibit symptoms at least as often as they do after symptoms develop.<sup>248</sup> Transmission rates are high in confined areas such as prisons.<sup>465</sup></li> </ul> <p><b>Undetected cases play a major role in transmission, and most cases are not reported.<sup>611</sup></b></p> <ul style="list-style-type: none"> <li>Models suggest up to 86% of early COVID-19 cases in China were undetected, and these infections were the source for 79% of reported cases.<sup>304</sup> Models estimate that the true number of cases may be approximately 11 times greater than the reported number of cases in the UK,<sup>599</sup> and 5 to 10 times greater than the reported number of cases in the US.<sup>249, 461, 490</sup></li> </ul> <p><b>Individuals who have recovered clinically, but test positive, appear unable to transmit COVID-19.</b></p> <ul style="list-style-type: none"> <li>Individuals who have clinically recovered from COVID-19, but later show PCR positive tests, are likely not infectious.<sup>260</sup></li> </ul>
<b>What do we need to know?</b>
<p><b>The relative contribution of different routes of transmission, such as close contact and droplet transmission versus aerosol transmission and contaminated objects and surfaces (fomites), is unknown and requires additional research.</b></p> <ul style="list-style-type: none"> <li>Capability of SARS-CoV-2 to be transmitted by contact with fomites (phones, doorknobs, surfaces, clothing, etc.)</li> <li>Is sexual transmission possible?</li> <li>Is it possible to determine the route by which someone became infected by the clinical presentation or progression of disease?</li> </ul>

Host Range – How many species does it infect? Can it transfer from species to species?
<b>What do we know?</b>
<p><b>SARS-CoV-2 is closely related to other coronaviruses circulating in bats in Southeast Asia. Previous coronaviruses have passed through an intermediate mammal host before infecting humans, but the identity of the SARS-CoV-2 intermediate host is unknown.</b></p> <ul style="list-style-type: none"> <li>• Early genomic analysis indicates similarity to SARS-CoV-1,<sup>627</sup> with a suggested bat origin.<sup>114, 627</sup></li> <li>• Positive samples from the South China Seafood Market strongly suggests a wildlife source,<sup>87</sup> though it is possible that the virus was circulating in humans before the disease was associated with the seafood market.<sup>39, 115, 592, 603</sup></li> <li>• Analysis of SARS-CoV-2 genomes suggests that a non-bat intermediate species is responsible for the beginning of the outbreak.<sup>451</sup> The identity of the intermediate host remains unknown.<sup>308, 315, 317</sup></li> <li>• Viruses similar to SARS-CoV-2 were present in pangolin samples collected several years ago,<sup>283</sup> and pangolins positive for coronaviruses related to SARS-CoV-2 exhibited clinical symptoms such as cough and shortness of breath.<sup>307</sup> Additionally, there is evidence of vertical transmission in pangolins, suggesting circulation in natural populations.<sup>307</sup></li> <li>• However, a survey of 334 pangolins did not identify coronavirus nucleic acid in ‘upstream’ market chain samples, suggesting that positive samples from pangolins may be the result of exposure to infected humans, wildlife or other animals within the wildlife trade network. These data suggest that pangolins are incidental hosts of coronaviruses.<sup>293</sup> Additional research is needed to identify whether pangolins are a natural host of SARS-COV-2-related coronaviruses.</li> </ul> <p><b>SARS-CoV-2 uses the same receptor for cell entry as the SARS-CoV-1 coronavirus that circulated in 2002/2003.</b></p> <ul style="list-style-type: none"> <li>• Experiments show that SARS-CoV-2 Spike (S) receptor-binding domain binds the human cell receptor (ACE2) stronger than SARS-CoV-1,<sup>580</sup> potentially explaining its high transmissibility. The same work suggests that differences between SARS-CoV-2 and SARS-CoV-1 Spike proteins may limit the therapeutic ability of SARS antibody treatments.<sup>580</sup></li> <li>• Modeling of SARS-CoV-2 Spike and ACE2 proteins suggests that SARS-CoV-2 can bind and infect human, bat, civet, monkey and swine cells.<sup>537</sup> Host range predictions based on structural modeling, however, are difficult,<sup>177</sup> and additional animal studies are needed to better define the host range.</li> <li>• In vitro experiments suggest a broad host range for SARS-CoV-2, with more than 44 potential animal hosts, based on viral binding to species-specific ACE2 orthologs.<sup>322</sup> The host range is predicted to be limited primarily to mammals.</li> <li>• Genetic and protein analysis of primates suggests that African and Asian primates are likely more susceptible to SARS-CoV-2, while South and Central American primates are likely less susceptible.<sup>361</sup> Identifying the SARS-CoV-2 host range is important for identifying animal reservoirs.</li> <li>• Changes in proteolytic cleavage of the Spike protein can also affect cell entry and animal host range, in addition to receptor binding.<sup>362</sup></li> </ul> <p><b>To date, ferrets, mink, hamsters, cats, and primates have been shown to be susceptible to SARS-CoV-2 infection. It is unknown whether these animals can transmit infection to humans.</b></p> <ul style="list-style-type: none"> <li>• Animal model studies suggest that Golden Syrian hamsters, primates, and ferrets may be susceptible to infection.<sup>91, 263</sup> In the Netherlands, farmed mink developed breathing and gastrointestinal issues, which was diagnosed as SARS-CoV-2 infection.<sup>1</sup> It is thought that an infected mink has transmitted SARS-CoV-2 to a human.<sup>278</sup> Golden Syrian hamsters are able to infect other hamsters via direct contact and close quarters aerosol transmission.<sup>489</sup></li> <li>• Domestic cats are susceptible to infection with SARS-CoV-2 (100,000-520,000 PFU via the intranasal route<sup>487</sup> or a combination of routes<sup>205</sup>), and can transmit the virus to other cats via droplet or short-distance aerosol.<sup>487</sup> Dogs exposed to SARS-CoV-2 produced anti-SARS-CoV-2 antibodies<sup>54</sup> but exhibited no clinical symptoms.<sup>487, 494</sup></li> <li>• Wild cats (tigers)<sup>552</sup> can be infected with SARS-CoV-2, although their ability to spread to humans is unknown.<sup>347, 616</sup> Two cases have been confirmed of pet domestic cats infected with SARS-CoV-2.<sup>79</sup></li> <li>• Ducks, chickens, and pigs remained uninfected after experimental SARS-CoV-2 exposure (30,000 CFU for ducks and chickens, 100,000 PFU for pigs, all via intranasal route).<sup>487</sup> There is currently no evidence that SARS-CoV-2 infects livestock.<sup>233</sup></li> <li>• Pigs and chickens were not susceptible to SARS-CoV-2 infection when exposed to an intranasal dose of 10<sup>5</sup> TCID<sub>50</sub> (~70,000 PFU), confirmed by lack of positive swab and tissue samples.<sup>473</sup> Fruit bats and ferrets were susceptible to this same exposure.<sup>473</sup></li> <li>• Chicken, turkey, duck, quail, and geese were not susceptible to SARS-CoV-2 after experimental exposures.<sup>503</sup></li> </ul>
<b>What do we need to know?</b>
<p><b>Several animal models have been developed to recreate human-like illness, though to date they have been infected with high dose exposures. Lower dose studies may better replicate human disease acquisition.</b></p> <ul style="list-style-type: none"> <li>• What is the intermediate host(s)?</li> <li>• Can infected animals transmit to humans (e.g., pet cats to humans)?</li> <li>• Can SARS-CoV-2 circulate in animal reservoir populations, potentially leading to future spillover events?</li> </ul>

Incubation Period – How long after infection do symptoms appear? Are people infectious during this time?
<b>What do we know?</b>
<p><b>The majority of individuals develop symptoms within 14 days of exposure. For most people, it takes at least 2 days to develop symptoms, and on average symptoms develop 5 days after exposure. Incubating individuals can transmit disease for several days before symptom onset. Some individuals never develop symptoms but can still transmit disease.</b></p> <ul style="list-style-type: none"> <li>• The incubation period of COVID-19 is between 5<sup>289</sup> and 6<sup>554</sup> days.<sup>598</sup> Fewer than 2.5% of infected individuals show symptoms sooner than 2 days after exposure.<sup>289</sup></li> <li>• There is evidence that younger and older individuals have longer COVID-19 incubation periods, creating a U-shaped relationship between incubation period length and patient age.<sup>271</sup></li> <li>• Individuals can test positive for COVID-19 even if they lack clinical symptoms.<sup>33, 90, 201, 514, 622</sup></li> <li>• Individuals can be infectious while asymptomatic,<sup>85, 456, 514, 622</sup> and asymptomatic and pre-symptomatic individuals have similar amounts of virus in the nose and throat compared to symptomatic patients.<sup>26, 262, 630</sup></li> <li>• Peak infectiousness may be during the incubation period, one day before symptoms develop.<sup>216</sup> Infectious virus has been cultured in patients up to 6 days before the development of symptoms.<sup>26</sup></li> <li>• Infectious period is unknown, but possibly up to 10-14 days.<sup>5, 304, 478</sup></li> <li>• Asymptomatic individuals are estimated to be infectious for a median of 9.5 days.<sup>225</sup></li> <li>• On average, there are approximately 4<sup>145</sup> to 7.5<sup>303</sup> days between symptom onset in successive cases of a single transmission chain (i.e., the serial interval). Based on data from 339 transmission chains in China, the mean serial interval is between 4.6<sup>598</sup> and 5.29 days.<sup>144</sup></li> <li>• Children are estimated to shed virus for 15 days on average, with asymptomatic individuals shedding virus for less time (11 days) than symptomatic individuals (17 days).<sup>333</sup></li> <li>• Most hospitalized individuals are admitted within 8-14 days of symptom onset.<sup>625</sup></li> <li>• Asymptomatic and mildly ill patients who test positive for SARS-CoV-2 presence take less time to test negative than severely ill patients.<sup>295</sup></li> <li>• Patients infected by asymptomatic or young (&lt;20 years old) individuals may take longer to develop symptoms than those infected by other groups of individuals.<sup>554</sup></li> <li>• Viral RNA loads in the upper respiratory tract tend to peak within a few days of symptom onset and become undetectable approximately two weeks after symptoms begin.<sup>535</sup> The duration of the infectious period is unknown,<sup>535</sup> though patients can test positive for SARS-CoV-2 viral RNA for extended periods of time, particularly in stool samples.</li> </ul>
<b>What do we need to know?</b>
<p><b>The incubation period is well-characterized. Patients may be infectious, however, for days before symptoms develop.</b></p> <ul style="list-style-type: none"> <li>• What is the average infectious period during which individuals can transmit the disease?</li> <li>• How infectious are asymptomatic and pre-symptomatic individuals compared to mildly, moderately, or severely ill patients?</li> </ul>



Clinical Presentation – What are the signs and symptoms of an infected person?
<b>What do we know?</b>
<p><b>Approximately 40% of cases are asymptomatic.<sup>397</sup> Most symptomatic cases are mild, but severe disease can be found in any age group.<sup>4</sup> Older individuals and those with underlying medical conditions are at higher risk of serious illness and death.</b></p> <ul style="list-style-type: none"> <li>• Between 16% and 58% of patients are asymptomatic throughout the course of their infection.<sup>66, 290, 295, 371, 388, 509, 519</sup></li> <li>• Most symptomatic COVID-19 cases are mild (81%, n=44,000 cases).<sup>514, 569</sup> Initial COVID-19 symptoms include fever (87.9% overall, but only 44-52% present with fever initially),<sup>24, 201</sup> cough (67.7%),<sup>201</sup> fatigue, shortness of breath, headache, and reduced lymphocyte count.<sup>86, 93, 226</sup> Chills, muscle pain, headache, sore throat, and loss of taste or smell<sup>415, 596</sup> are also possible COVID-19 symptoms.<sup>86</sup> GI symptoms are present in approximately 9% of patients,<sup>453</sup> <b>but may be more common in severe cases.</b><sup>257</sup> Neurological symptoms such as agitation,<sup>217</sup> loss of coordination,<sup>348</sup> and stroke<sup>529</sup> may present with COVID-19,<sup>413</sup> may be more common in severe cases,<sup>122</sup> and neurological involvement (e.g., encephalitis) can be seen in brain tissue on autopsy.<sup>534</sup> Ocular issues<sup>587</sup> and skin lesions<sup>178</sup> may also be symptoms of COVID-19.<sup>55</sup> There are concerns that COVID-19 can lead to new-onset diabetes.<sup>458</sup></li> <li>• COVID-19 symptoms, especially fatigue and shortness of breath, commonly persist for several months after initial onset.<sup>74</sup></li> <li>• Complications include acute respiratory distress syndrome (ARDS, 17-29% of hospitalized patients, leading to death in 4-15% of cases),<sup>101, 226, 540</sup> pneumonia,<sup>404</sup> cardiac injury (20%),<sup>488</sup> secondary infection, kidney damage,<sup>25, 501</sup> arrhythmia, sepsis, stroke (1.6% of hospitalized patients),<sup>365</sup> and shock.<sup>201, 226, 540, 625</sup> Most deaths are caused by respiratory failure or respiratory failure combined with heart damage.<sup>457</sup> Half of hospitalized COVID-19 patients show abnormal heart scans.<sup>147</sup></li> <li>• Clinically, COVID-19 appears to present as three different phenotypes, including ARDS.<sup>450</sup></li> <li>• Approximately 15% of hospitalized patients are classified as severe,<sup>201, 514</sup> and approximately 5% of patients are admitted to the ICU.<sup>201, 514</sup> Patient deterioration can be rapid.<sup>196</sup> The survival rate of patients requiring mechanical ventilation varies widely (e.g., 35%,<sup>232</sup> 70%,<sup>28</sup> 75.5%<sup>444</sup>). Higher SARS-CoV-2 viral RNA load on admission (measured by RT-PCR cycle threshold values) have been associated with greater risk of intubation and death.<sup>341</sup></li> <li>• Recent evidence suggests that SARS-CoV-2 may attack blood vessels in the lung, leading to clotting complications and ARDS.<sup>9, 530</sup> Clotting may be associated with severely ill COVID-19 patients<sup>265</sup> and those with ARDS,<sup>122</sup> and affects multiple human organ systems.<sup>435</sup> COVID-19 patients should be monitored for possible thrombosis.<sup>298</sup> In autopsies of several COVID-19 patients, there was evidence of diffuse alveolar damage (DAD)<sup>471</sup> and increased blood clotting.<sup>472</sup></li> <li>• COVID-19 patients undergoing unrelated surgical procedures have high levels of postoperative complications and death.<sup>384</sup></li> </ul> <p><b>The case fatality rate(CFR) varies substantially by patient age and underlying comorbidities.<sup>570</sup></b></p> <ul style="list-style-type: none"> <li>• Cardiovascular disease, obesity,<sup>11, 421</sup> hypertension,<sup>614</sup> diabetes, and respiratory conditions all increase the CFR.<sup>514, 625</sup> Hypertension and obesity are common in the US<sup>180</sup> and contribute to mortality.<sup>25, 406</sup></li> <li>• Individuals &gt;60 are at higher risk of death, and the CFR for individuals &gt;85 is between 10 and 27%.<sup>514, 625</sup> In a small study, men exhibited more severe symptoms and died at higher rates than women.<sup>246</sup> The effect of comorbidities on the likelihood of severe symptoms is higher for men.<sup>363</sup></li> </ul> <p><b>Additional studies on vulnerable subpopulations are required.</b></p> <ul style="list-style-type: none"> <li>• Black, Asian, and Minority Ethnic (BAME) populations acquire SARS-CoV-2 infection at higher rates than other groups<sup>403</sup> and are disproportionately represented in hospitalized populations.<sup>180, 426</sup> African American communities contribute disproportionately to the number of deaths in the US.<sup>219, 369</sup> Hospitalization rates in Native American, Hispanic, and Black populations are 4-5 times higher than those in non-Hispanic white populations.<sup>82</sup> In the US, Hispanic and Black patients tend to die at younger ages than white patients.<sup>579</sup></li> <li>• Pregnant women appear to develop severe symptoms at the same rate as the general population<sup>100, 255, 609</sup> or at a slightly elevated rate.<sup>150</sup> Severe symptoms in pregnant women may be associated with underlying conditions such as obesity.<sup>325</sup> There is some evidence that rates of stillbirth and preterm delivery have increased during the COVID-19 pandemic, though these instances have not been conclusively linked to maternal COVID-19 infection.<sup>261</sup> More work is needed.</li> </ul> <p><b>Children are susceptible to COVID-19,<sup>142</sup> though generally show milder<sup>95, 332</sup> or no symptoms.</b></p> <ul style="list-style-type: none"> <li>• Between 21-28% of children may be asymptomatic.<sup>332, 411, 428</sup> Most symptomatic children present with mild or moderate symptoms,<sup>195, 411</sup> with few exhibiting severe or clinical illness.<sup>584</sup></li> <li>• Severe symptoms in children are possible<sup>320</sup> and more likely in those with complex medical histories<sup>482</sup> or underlying conditions such as obesity.<sup>608</sup> Infant deaths have been recorded.<sup>62, 332</sup></li> <li>• The WHO<sup>565</sup> and US CDC<sup>243</sup> have issued case definitions for a rare condition in children (termed Pediatric Multi-System Inflammatory Syndrome)<sup>190</sup> linked to COVID-19 infection.<sup>448</sup></li> </ul>
<b>What do we need to know?</b>
<p><b>The true case fatality rate is unknown, as the exact number of cases is uncertain. Testing priorities and case definitions vary by location. The proportion of asymptomatic infections is not known.</b></p> <ul style="list-style-type: none"> <li>• How long does it take for infected individuals to recover outside of a healthcare setting?</li> <li>• What proportion of infected individuals are asymptomatic? Does this vary by age, location, or comorbidities?</li> </ul>

Protective Immunity – How long does the immune response provide protection from reinfection?
<b>What do we know?</b>
<p><b>Infected patients show productive immune responses, but the duration of any protection is unknown. Initial evidence suggests that the neutralizing antibody response does not last more than a few months, though this varies by severity.</b></p> <ul style="list-style-type: none"> <li>• In a small comparison series (n=74), both asymptomatic and mildly symptomatic individuals showed reductions in IgG antibody levels 8 weeks after infection.<sup>327</sup> The correlation to long-term immunity is unknown.</li> <li>• In a larger study (n=175), most patients developed neutralizing antibodies within 10-15 days after disease onset. Elderly patients had significantly higher neutralizing antibody titers than younger patients.<sup>582</sup> In a separate study, elderly patients also showed higher viral loads than younger patients.<sup>518</sup> Approximately half of infected individuals on an aircraft carrier developed detectable neutralizing antibody responses to SARS-CoV-2.<sup>415</sup></li> <li>• In a study of 285 COVID-19 patients, 100% developed antiviral immunoglobulin-G within 19 days of symptom onset.<sup>326</sup> The neutralizing ability of these antibodies was not tested.<sup>326</sup> In a smaller in vitro study (n=23 patients), levels of antibodies (immunoglobulins M and G) were positively correlated with SARS-CoV-2 neutralizing ability.<sup>518</sup> In a smaller study of 44 patients, plasma from 91% demonstrated SARS-CoV-2 neutralizing ability, appearing ~8 days after symptom onset.<sup>508</sup></li> <li>• In a small study (n=26 mild cases), researchers found prolonged persistence of SARS-CoV-2 antibodies and SARS-CoV-2 RNA for up to 50 days.<sup>539</sup></li> <li>• A small subset of COVID-19 patients in China (8%) did not develop a serological response to infection, though the potential for reinfection in these patients is unknown.<sup>582</sup> Similarly, between 16.7% (for IgG) and 51.7% (for IgM) of patients in a separate study did not exhibit any immune response, in terms of production of those two types of antibodies.<sup>511</sup></li> <li>• In a study of 221 COVID-19 patients, levels of two types of antibodies (IgM and IgG) were not associated with the severity of symptoms.<sup>224</sup> However, in a smaller study, patients with severe disease showed stronger antibody responses than those with non-severe symptoms.<sup>518</sup></li> <li>• Severely ill individuals develop higher levels of neutralizing antibodies<sup>314</sup> and greater T-cell response frequencies<sup>479</sup> than mildly symptomatic or asymptomatic individuals.</li> <li>• The early recovery phase of COVID-19 patients is characterized by inflammatory immune response,<sup>556</sup> suggesting the potential for adverse reactions after clinical improvement.</li> <li>• Two studies identified key components of the adaptive immune system (CD4<sup>+</sup> T cells) in the majority of recovered COVID-19 patients, and these cells reacted to SARS-CoV-2 Spike protein.<sup>57, 198</sup> These studies also identified Spike protein responses in CD4<sup>+</sup> T cells of ~30-40% of unexposed patients,<sup>198</sup> suggesting some cross-reactivity between other circulating human coronaviruses and SARS-CoV-2.<sup>57, 198</sup> <a href="#">Long-lasting T-cell responses have been seen in SARS-CoV-1 patients, and T-cell cross-reactivity between other coronaviruses and SARS-CoV-2 suggest additional immune protection.</a><sup>291</sup> The strength and duration of any T-cell derived protection is currently unknown.</li> </ul> <p><b>Currently, there is no evidence that recovered patients can be reinfected with SARS-CoV-2.</b></p> <ul style="list-style-type: none"> <li>• Two studies suggest limited reinfection potential in macaques. In the first, two experimentally infected macaques were not capable of being reinfected 28 days after their primary infection resolved.<sup>136</sup> In the second, rhesus macaques exposed to different doses of SARS-CoV-2 via the intranasal and intratracheal routes (10<sup>4</sup> – 10<sup>6</sup> PFU) developed pathological infection and were protected upon secondary challenge 35 days after initial exposure.<sup>92</sup></li> <li>• Ferrets infected with 10<sup>2</sup>-10<sup>4</sup> PFU were protected from acute lung injury following secondary challenge with SARS-CoV-2 28 days after initial exposure, but they did exhibit clinical symptoms such as lethargy and ruffled fur.<sup>462</sup> Cats exposed to SARS-CoV-2 after initial recovery did not shed virus, suggesting some protective effect of primary infection.<sup>54</sup></li> <li>• According to the WHO, there is no evidence of re-infection with SARS-CoV-2 after recovery.<sup>288</sup></li> <li>• Patients can test positive via PCR for up to 37 days after symptoms appear,<sup>625</sup> and after recovery and hospital discharge.<sup>284</sup></li> </ul> <p><b>The strength and duration of any immunity after initial COVID-19 infection is unknown.</b><sup>16, 562</sup></p> <ul style="list-style-type: none"> <li>• In a small study (n=65), 95% of patients developed neutralizing antibodies within 8 days of symptom onset,<sup>480</sup> but neutralizing antibody titers declined substantially when assayed after 60 days.<sup>480</sup> Individuals with more severe infections developed higher neutralizing antibody levels that persisted longer than those with asymptomatic or mild infections.<sup>480</sup> Protective antibody immunity may depend on the severity of initial infection, and may not persist for more than a few months, which is consistent with observations in other human coronaviruses.</li> <li>• In a 35-year study of 10 men, immunity to seasonal coronaviruses waned after one year.<sup>148</sup> Reinfection was observed between one and three years after initial infection.<sup>148</sup></li> <li>• Previous studies on coronavirus immunity suggest that neutralizing antibodies may wane after several years.<sup>69, 586</sup></li> </ul>
<b>What do we need to know?</b>
<p><b>As the pandemic continues, long-term monitoring of immune activity and reinfection status is needed.</b></p> <ul style="list-style-type: none"> <li>• How long does the immune response last? Is there evidence of waning immunity?</li> <li>• Can humans become reinfected, or are reports of reinfection vestiges from initial infection?</li> <li>• How do different components of the immune response contribute to long-term protection?</li> </ul>

Clinical Diagnosis – Are there tools to diagnose infected individuals? When during infection are they effective?
<b>What do we know?</b>
<p><b>Diagnosis relies on identifying the genetic signature of the virus in patient nose, throat, or sputum samples, or by identifying SARS-CoV-2 antibodies in individuals exposed to the virus. Confirmed cases are still underreported.</b></p> <ul style="list-style-type: none"> <li>• The US CDC has expanded testing criteria to include symptomatic patients at clinician discretion.<sup>37</sup></li> <li>• PCR protocols and primers have been widely shared internationally.<sup>77, 117, 303, 486, 561, 567</sup> PCR-based diagnostic assays are unable to differentiate between active and inactive virus.</li> <li>• A combination of pharyngeal (throat) RT-PCR and chest tomography is recommended,<sup>440</sup> <b>particularly when results from one test are inconclusive.</b><sup>274</sup> A single throat swab detects 78.2% of infections, and duplicate tests identify 86.2% of infections.<sup>440</sup> PCR tests using saliva are at least as effective as those using nasopharyngeal swabs.<sup>98, 589</sup> Evaluation of seven RT-PCR diagnostic test kits in China showed high overall accuracy, but some variability among test kits.<sup>538</sup></li> <li>• Nasal and pharyngeal swabs may be less effective as diagnostic specimens than sputum and bronchoalveolar lavage fluid,<sup>545</sup> although evidence is mixed.<sup>572</sup> Combination RT-PCR and serology (antibody) testing may increase the ability to diagnose patients with mild symptoms, or identify patients at higher risk of severe disease.<sup>621</sup> Assays targeting antibodies against the nucleocapsid protein (N) instead of the Spike protein (S) of SARS-CoV-2 may improve detection.<sup>63</sup></li> <li>• The timing of diagnostic PCR tests impacts results. The false-negative rate for RT PCR tests is lowest between 7 and 9 days after exposure, and PCR tests are more likely to give false-negative results before symptoms begin (within 4 days of exposure) and more than 14 days after exposure.<sup>281</sup></li> <li>• The FDA issued an Emergency Use Authorization for an antigen-based diagnostic assay, limited to use in certified laboratories (clinical laboratory improvement amendments, CLIA).<sup>157</sup></li> <li>• The FDA released an Emergency Use Authorization enabling laboratories to develop and use tests in-house for patient diagnosis.<sup>162</sup> Tests from the US CDC are available to states.<sup>77, 85</sup> Rapid test kits have been produced by universities and industry.<sup>44, 49, 125, 160, 532</sup> Home tests are being developed, though they cannot be used for diagnosis and have not been approved by the FDA.<sup>381-382, 407</sup> The US CDC is developing serological tests to assess SARS-CoV-2 exposure prevalence.<sup>253</sup></li> <li>• Artificial intelligence algorithms were able to improve the ability of radiologists to distinguish COVID-19 pneumonia from non-COVID-19 pneumonia on chest CT scans.<sup>32</sup></li> <li>• The CRISPR-Cas12a system is being used to develop fluorescence-based COVID-19 diagnostic tests.<sup>229</sup></li> <li>• Deaths due to COVID-19 are underreported. In New York City, up to 5,293 (22%) of period-specific excess deaths are unexplained and could be related to the pandemic.<sup>395</sup> COVID-19 related deaths in the US were likely underestimated by up to 35% in March through late April.<sup>576</sup> More work is needed.</li> <li>• Immunological indicators<sup>30, 151, 215, 228, 423, 506, 541</sup> and fasting blood glucose levels<sup>544</sup> may help differentiate between severe and non-severe cases, and decision-support tools for diagnosing severe infections have been developed.<sup>583</sup></li> <li>• <b>Individuals who test positive again after hospital discharge were more likely to have had short hospital stays, be younger than 18, and have had mild or moderate COVID-19 symptoms.</b><sup>605</sup> Such “re-positive” patients had the same levels of antibodies as those testing negative after discharge and experienced no additional clinical symptoms.<sup>605</sup></li> </ul> <p><b>Validated serological (antibody) assays are being used to help determine who has been exposed to SARS-CoV-2. Serological evidence of exposure does not indicate immunity.</b></p> <ul style="list-style-type: none"> <li>• Repeated serological testing is necessary to identify asymptomatic<sup>425</sup> and other undetected patients at locations like skilled nursing facilities.<sup>468</sup> Exclusively testing symptomatic healthcare workers is likely to exclude a large fraction of COVID-19 positive personnel.<sup>500</sup></li> <li>• Research has shown high variability in the ability of tests (ELISA<sup>394</sup> and lateral flow assays) by different manufacturers to accurately detect positive and negative cases (sensitivity and specificity, respectively).<sup>287, 557</sup> The FDA has recommended against the use of several dozen serological diagnostic assays based on failure to conform to updated regulatory requirements.<sup>159</sup> Researchers have designed a standardized ELISA procedure for SARS-CoV-2 serology samples.<sup>266</sup></li> <li>• Meta-analysis suggests that lateral flow assays (LFIA) are less accurate than ELISA or chemiluminescent methods (CLIA), but that the target of serological studies (e.g., IgG or IgM) does not affect accuracy.<sup>311</sup> Additionally, most reported serological studies suffer from bias related to selected patients, limiting their applicability to general populations.<sup>311</sup></li> <li>• The false positive rate of serological assays may account for a substantial portion of reported exposures,<sup>42</sup> particularly if the true proportion of positive patients is low.</li> </ul>
<b>What do we need to know?</b>
<p><b>In general, PCR tests appear to be sensitive and specific, though confirmation of symptoms via chest CT is recommended. The sensitivity and specificity of serological testing methods is variable, and additional work needs to be done to determine factors that affect test accuracy.</b></p> <ul style="list-style-type: none"> <li>• How many serological tests need to be done to obtain an accurate picture of underlying exposure?</li> <li>• What fraction of exposed individuals fail to develop antibody responses that are the target of serological assays?</li> </ul>

Medical Treatments – Are there effective treatments?
<b>What do we know?</b>
<p><b>Treatment for COVID-19 is primarily supportive care,<sup>201, 351</sup> and no single standard of care exists. Drug trials are ongoing. Remdesivir shows promise for reducing symptom duration<sup>41</sup> and mortality<sup>188</sup> in humans.</b></p> <ul style="list-style-type: none"> <li>• Remdesivir can reduce the duration of symptoms in infected individuals, from 15 days to 11 days on average (compared to controls).<sup>41</sup> Remdesivir received an Emergency Use Authorization from FDA<sup>387</sup> and is recommended for use in the EU.<sup>571</sup></li> <li>• A press release reports that remdesivir reduced 14-day mortality in COVID-19 patients across racial and ethnic groups when compared to standard of care alone, though concerns exist regarding the appropriate control group.<sup>188</sup></li> <li>• <a href="#">A randomized clinical trial of remdesivir found no significant clinical benefits (n=237 patients), though the trial ended early and there were differences in the treatment vs. placebo patient populations.</a><sup>549</sup> In a separate clinical trial of severe COVID-19 patients, the effects of remdesivir were inconclusive due to a limitation in the study sample size.<sup>550</sup></li> </ul> <p><b>Hydroxychloroquine is associated with risk of cardiac arrhythmias and provides limited to no clinical benefit at this time.</b></p> <ul style="list-style-type: none"> <li>• <a href="#">Two new studies, including a randomized trial of non-hospitalized patients, found no clinical benefits to hydroxychloroquine.</a><sup>221, 496</sup> Several large clinical trials have stopped administering hydroxychloroquine due to lack of efficacy.<sup>212, 220, 383</sup> Other existing studies have found no benefit of hydroxychloroquine (with or without azithromycin)<sup>17, 94, 99, 183, 268, 340, 342, 512</sup> as well as cardiac side effects<sup>43, 110, 186, 241, 343, 364</sup> and elevated risk of mortality.<sup>340</sup> Individuals taking hydroxychloroquine for autoimmune disorders were not protected from COVID-19,<sup>184</sup> though sample sizes were limited. Patients given hydroxychloroquine after exposure to COVID-19 were not protected from disease.<sup>56</sup> The FDA revoked its EUA for hydroxychloroquine on 6/15/20.<sup>156</sup></li> <li>• Initial results purporting benefits of hydroxychloroquine and azithromycin<sup>182</sup> have been called into question. One small clinical trial (n=62) suggests that hydroxychloroquine can reduce recovery time compared to control group,<sup>103</sup> but lacks key methodological details.<sup>103</sup> A small retrospective study (n=48) found benefits to hydroxychloroquine, though details on patient study population selection were limited.<sup>601</sup> A larger retrospective study (n=2,541) found that hydroxychloroquine reduced mortality.<sup>27</sup> However, concerns still exist over the patient selection protocol and the time-course of the study.<sup>294</sup></li> </ul> <p><b>Dexamethasone may significantly reduce mortality in severely ill and ventilated patients.</b></p> <ul style="list-style-type: none"> <li>• A press release from the RECOVERY trial (n=2,104) indicates substantial reductions in mortality for ventilated patients given the steroid dexamethasone, and smaller reductions in mortality for patients receiving supplemental oxygen.<sup>2</sup> Dexamethasone did not reduce mortality in patients who did not need oxygen or mechanical ventilation.<sup>2</sup></li> </ul> <p><b>Other pharmaceutical interventions are being investigated.</b></p> <ul style="list-style-type: none"> <li>• Several studies of methylprednisolone suggest clinical benefits in severely ill patients (e.g., reduction in ventilator use, mortality), but have not been tested separately from other standard-of-care treatments.<sup>118, 345, 466, 470</sup> Providing anti-inflammatory treatments in the first few days of hospital admission may be beneficial.<sup>368</sup></li> <li>• There is evidence for efficacy of several interferon-based treatments, including interferon beta-1b,<sup>231</sup> interferon beta-1a,<sup>129</sup> and interferon alpha-2b.<sup>418</sup> In these studies, interferons were generally administered with other treatments. <a href="#">A press release suggests that an inhaled interferon beta reduced the need for mechanical ventilation.</a><sup>424</sup></li> <li>• Small, observational studies have found benefits of tocilizumab<sup>167, 214, 455, 497, 593</sup> in severe COVID-19 patients, and Phase II trial results show limited reductions in mortality.<sup>420</sup> Tocilizumab efficacy may depend on C-reactive protein levels<sup>175, 350</sup> and may be more beneficial when administered early.<sup>194, 377</sup> Tocilizumab has been associated with reduced risk of severe illness<sup>23, 267</sup> and death,<sup>377</sup> but also an increased risk of secondary (non-COVID-19) infection.<sup>202</sup> Other trials have found benefits of itolizumab<sup>48</sup> but no consistent benefits from sarilumab.<sup>437</sup></li> <li>• Limited, preliminary evidence from clinical trials supports the efficacy of favipiravir,<sup>96</sup> intravenous immunoglobulin,<sup>72</sup> baricitinib,<sup>70</sup> ivermectin,<sup>432</sup> and pidotimod.<sup>521</sup> Lenzilumab, a monoclonal antibody, showed benefits to oxygenation levels in severely ill patients (n=12).<sup>513</sup> There is no clinical benefit from combination ritonavir/lopinavir.<sup>71, 197, 310</sup> Phase II clinical trial results for the kinase inhibitor ruxolitinib showed few severe side effects and suggested benefits in terms of symptom duration and mortality.<sup>73</sup> High doses of chloroquine diphosphate were associated with lethality in severely ill patients.<sup>53</sup></li> <li>• The anticoagulant heparin is being used to mitigate risks of pulmonary embolism.<sup>151</sup> Systemic anticoagulant use was associated with reduced mortality rates in severely ill patients.<sup>405</sup></li> <li>• Passive antibody therapy (convalescent serum)<sup>75</sup> is being given to patients,<sup>161</sup> appears safe,<sup>254</sup> and several small trials (&lt;50 patients) suggest benefits from convalescent patient plasma for infected patients.<sup>153, 319, 339, 349, 464, 483, 485</sup> Clinical trial results (n=103) showed no significant benefits of plasma therapy, though the sample size was low.<sup>302</sup> Another randomized trial with convalescent plasma was halted due to similar neutralizing antibody levels in enrolled recipients and donors.<sup>187</sup></li> </ul>
<b>What do we need to know?</b>
<p><b>Additional information on treatment efficacy is required, particularly from large randomized clinical trials.</b></p> <ul style="list-style-type: none"> <li>• Do monoclonal antibodies exhibit any efficacy in human trials?</li> <li>• Are there treatments that reduce the development of severe symptoms when administered early?</li> <li>• Do androgen levels in males alter disease severity?<sup>193, 374, 536</sup></li> </ul>

Vaccines – Are there effective vaccines?
<b>What do we know?</b>
<p><b>Work is ongoing to develop and produce a SARS-CoV-2 vaccine (e.g., Operation Warp Speed).<sup>38, 206, 209-211, 386</sup> Early results are being released, but evidence should be considered preliminary until larger trials are completed.</b></p> <p><i>Phase III Trials (testing for efficacy):</i></p> <ul style="list-style-type: none"> <li>• Moderna has registered for Phase III trials of its COVID-19 vaccine, which will target 30,000 participants.<sup>373</sup></li> <li>• University of Oxford’s ChAdOx1 candidate (now called AZD1222) has begun Phase II/III human trials.<sup>401</sup></li> <li>• <a href="#">Sinovac will begin Phase III trials of its CoronaVac candidate in healthcare professionals.</a><sup>491</sup></li> <li>• <a href="#">Sinopharm will begin Phase III trials of its inactivated SARS-CoV-2 vaccine candidate.</a><sup>36</sup></li> </ul> <p><i>Phase II Trials (initial testing for efficacy, continued testing for safety):</i></p> <ul style="list-style-type: none"> <li>• CanSino’s Ad5-nCoV adenovirus vaccine candidate has advanced to Phase II human trials.<sup>312</sup> China has given approval to vaccinate members of its military with the product.<sup>318</sup></li> <li>• Moderna has begun its Phase II trial of mRNA-1273 with 600 participants.<sup>353</sup></li> <li>• Sinovac reported no severe adverse events among 600 Phase II participants given their CoronaVac candidate (inactivated virus), and 90% of patients developed neutralizing antibodies 14 days after administration.<sup>493</sup></li> <li>• Sinopharm (with the Wuhan Institute of Biological Products) reported neutralizing antibody development in all 1,120 participants given its inactivated virus vaccine (two times, 14 days apart) with no severe adverse events.<sup>313</sup></li> <li>• Inovio has registered for a Phase II trial of their INO-4800 DNA vaccine candidate.<sup>237</sup></li> </ul> <p><i>Phase I Trials (initial testing for safety):</i></p> <ul style="list-style-type: none"> <li>• mRNA vaccines developed by several groups are currently being tested in Phase I trials, including CureVac (candidate is CVnCoV),<sup>123</sup> the Chinese Academy of Military Sciences (ARCoV),<sup>134</sup> BioNTech and Pfizer (BNT162 program),<sup>422</sup> and Moderna (mRNA-1273).<sup>372</sup> Data from a Phase I trial of Moderna’s mRNA-1273 candidate suggest that the vaccine is well-tolerated by human subjects, and induces an antibody response against SARS-CoV-2.<sup>240</sup> Preliminary Phase I/II results for BioNTech’s BNT162b1 mRNA candidate show mild side effects in low dose groups, and patients generated neutralizing antibodies at 21 days post vaccination.<sup>379</sup></li> <li>• Adenovirus-based vaccines from several groups are being tested in Phase I trials, including CanSino (Ad5-nCoV),<sup>628</sup> Johnson and Johnson (Ad.26-COV2-S),<sup>250</sup> the University of Oxford (ChAdOx1, now called AZD1222),<sup>527</sup> and Gamaleya Research Institute of Epidemiology and Microbiology (Gam-COVID-Vac Lyo).<sup>564</sup> Phase I trial results for the CanSino vaccine (Ad5-nCoV) showed few severe adverse reactions in humans within 28 days of follow-up (side effects included fever [sometimes severe], fatigue, headache, and muscle pain).<sup>628</sup> Immune responses were found in most patients, peaking at 14 days for T-cells and 28 days for antibodies.<sup>628</sup> <a href="#">In Phase I/II trials, the ChAdOx-1 COVID-19 (AZD1222) vaccine showed a tolerable safety profile and most recipients developed positive T-cell and neutralizing antibody responses.</a><sup>174</sup></li> <li>• Several groups have developed heat-inactivated vaccine candidates, including the Chinese Academy of Medical Sciences,<sup>477</sup> the Beijing Institute of Biological Products,<sup>427</sup> the Wuhan Institute of Biological Products,<sup>588</sup> Immunitor LLC (V-Sars),<sup>360</sup> and Sinovac Biotech (CoronaVac).<sup>492</sup> Sinovac Biotech has reported that their inactivated virus vaccine (CoronaVac) shows protective effects in rhesus macaques, particularly at high vaccine doses.<sup>179</sup></li> <li>• Several groups are developing recombinant subunit vaccines, including Vaxine Pty (Covax-19),<sup>531</sup> Clover Biopharmaceuticals (SCB-2019),<sup>359</sup> Novavax (NVX-CoV2373),<sup>355</sup> and the Chinese Academy of Sciences (RBD-Dimer).<sup>328</sup> <a href="#">The University of Queensland has started Phase I trials of its UQ vaccine candidate, which uses Spike protein subunits.</a><sup>429</sup></li> <li>• Several groups are testing DNA vaccines in Phase I trials, including Inovio (INO-4800),<sup>236</sup> Genexine (GX-19)<sup>185</sup> and AnGes (AG0301-COVID19).<sup>22</sup> Results from Inovio’s INO-4800 show no serious adverse side effects and high immunogenicity.<sup>236</sup></li> <li>• Imperial College London is beginning Phase I/II trials of their RNA vaccine candidate, LNP-nCoVsnRNA.<sup>392</sup></li> <li>• Shenzhen Geno-Immune Medical Institute is testing its aAPC<sup>358</sup> and lentiviral (LV-SMENP-DC)<sup>356</sup> vaccines.</li> <li>• Symvivo Corporation (Canada) will begin a Phase I trial of its oral bacTRL-Spike vaccine candidate.<sup>354</sup></li> <li>• Aivita will begin a Phase Ib/II clinical trial of its DC-ATA candidate, comprised of dendritic cells and SARS-CoV-2 antigens.<sup>357</sup></li> <li>• Medicago will begin the Phase I trials of their vaccine, a plant-derived virus-like-particle candidate.<sup>352</sup></li> <li>• Phase I/II trials are beginning for vaccine candidates from Zydus Cadila (ZyCoV-D, DNA plasmid)<sup>631</sup> and Bharat (Covaxin, inactivated rabies virus used as carrier for SARS-CoV-2 proteins).<sup>155</sup></li> </ul> <p><i>Non-target vaccines</i></p> <ul style="list-style-type: none"> <li>• The potential benefits of non-SARS-CoV-2 vaccines, such as <i>Bacillus Calmette-Guerin</i> (BCG), are under investigation.<sup>154, 481</sup></li> </ul>
<b>What do we need to know?</b>
<p><b>Published results from randomized clinical trials (Phase I – III) are needed.</b></p> <ul style="list-style-type: none"> <li>• Safety of candidate vaccines in humans and animals</li> <li>• Efficacy of candidate vaccines in humans and animals</li> <li>• Length of any vaccine-derived immunity</li> <li>• Evidence for vaccine-derived enhancement (immunopotentiality)</li> </ul>

Non-pharmaceutical Interventions – Are public health control measures effective at reducing spread?
<b>What do we know?</b>
<p><b>Broad-scale control measures such as stay-at-home orders are effective at reducing transmission.</b></p> <ul style="list-style-type: none"> <li>• Social distancing and other policies are estimated to have reduced COVID-19 spread by 44% in Hong Kong<sup>121</sup> and reduced spread throughout China,<sup>276, 280, 282, 329, 344, 543</sup> Europe,<sup>181, 259</sup> and the US.<sup>275</sup> Restrictive lockdowns in China are estimated to have reduced disease transmission within only a few days<sup>629</sup> by reducing contacts.<sup>612</sup> In China, modeling suggests that a one-day delay in implementing control measures increased the time needed to curtail an outbreak by 2.4 days.<sup>143</sup> In the US, each day of delay in emergency declarations and school closures was associated with a 5-6% increase in mortality.<sup>600</sup></li> <li>• Modeling demonstrates that multifaceted restrictions and quarantines in China reduced the <math>R_0</math> of SARS-CoV-2 from greater than 3 to less than 1 between January 23 and February 5.<sup>402</sup> Additionally, movement restrictions and other control measures helped limit the amount of time where community transmission was possible (i.e., <math>R_0 &gt; 1</math>).<sup>613</sup></li> <li>• A US county-level model found that shelter in place orders (SIPOs) and restaurant and bar closures were associated with large reductions in exponential growth rate of cases.<sup>119</sup> School closures and cancellation of large gatherings had smaller effects.<sup>119</sup> Similarly, researchers found that a larger number of public health interventions in place was strongly associated with lower COVID-19 growth rates in the next week.<sup>256</sup> Individual behaviors such as wearing face coverings and practicing social distancing have been associated with reduced risk of COVID-19 infection.<sup>415</sup></li> <li>• Mobility<sup>171, 286</sup> and physical contact rates<sup>242</sup> decline after public health control measures are implemented. Mobility reductions in the US have been associated with significant reductions in COVID-19 case growth.<sup>31</sup> Modeling suggests that on their own, travel restrictions delay peak prevalence by only a few days but do not limit epidemic size.<sup>15</sup></li> <li>• Models indicate that a combination of school closures, work restrictions, and other measures are required to effectively limit transmission.<sup>166, 272</sup> School closures alone appear insufficient.<sup>239, 282</sup></li> <li>• Non-pharmaceutical interventions in China did not reduce transmission equally across all groups.<sup>402</sup></li> <li>• Two modeling studies identified large reductions in transmission due to country lockdowns<sup>173</sup> and other social distancing measures,<sup>223</sup> with substantial variation in the efficacy of particular policies in different countries.<sup>173, 223</sup></li> <li>• Contact tracing to identify infected individuals reduces the amount of time infectious individuals can transmit disease in a population and increases the time between successive cases.<sup>46</sup> Robust contact tracing and case finding may be needed to control COVID-19 in the US, but requires additional resources.<sup>551</sup> In South Korea, early implementation of rapid contact tracing, testing, and quarantine of confirmed and suspected cases was able to reduce the transmission rate of COVID-19.<sup>504</sup> Modeling studies suggest that contact tracing combined with high levels of testing may limit COVID-19 resurgence once initial social distancing policies are relaxed.<sup>14, 168</sup> Contact tracing is likely to be more effective when conducted in combination with other control measures such as expanded testing and physical distancing.<sup>279</sup></li> </ul> <p><b>Research is needed to help plan for easing of restrictions. Testing is critical, and synchronized interventions may help.</b></p> <ul style="list-style-type: none"> <li>• Relaxing public health interventions is projected to increase cases and deaths.<sup>126, 524</sup> As of 7/21/2020, 41 US states are experiencing increases in the average daily rate of new confirmed cases, and 26 US states are experiencing increases in the average daily rate of new COVID-19 deaths (for the prior 14 days).<sup>391</sup></li> <li>• Modeling suggests that optimal control policies involve quickly quarantining infected individuals, and that periods of social distancing or lock-down may be effective in reducing overall exposure from asymptomatic or unconfirmed cases.<sup>520</sup> Testing is critical to balancing public health and economic costs.<sup>520</sup> Rolling interventions, whereby social distancing measures are put into place every few weeks, may keep healthcare demand below a critical point.<sup>599</sup> <a href="#">Undetected cases can lead to elevated risk of re-emergence after restrictions are lifted, highlighting the need for robust testing strategies.</a><sup>207</sup></li> <li>• <a href="#">Synchronizing public health interventions and lockdowns across US state lines may reduce the total number of interventions necessary to eliminate transmission as COVID-19 cases continue to resurge.</a><sup>459</sup></li> <li>• Modeling indicates that COVID-19 is likely to become endemic in the US population, with regular, periodic outbreaks, and that additional social or physical distancing measures may be required for several years to keep cases below critical care capacity in absence of a vaccine or effective therapeutic.<sup>264</sup> Results depend on the duration of immunity after exposure.<sup>264</sup></li> <li>• Balancing control measures to maintain <math>R_0</math> below 1 may be more efficient than allowing <math>R_0</math> to increase above 1.<sup>296</sup></li> <li>• The WHO has released guidelines on public health strategy,<sup>560</sup> and Johns Hopkins released a report outlining how to re-open certain categories of activities (e.g., schools, restaurants, events) while reducing COVID-19 risk.<sup>449</sup></li> <li>• Surveys indicate that the majority of Americans were complying with non-pharmaceutical interventions.<sup>124</sup> <a href="#">In the US, mask use increased after recommendations from the White House Task force and CDC.</a><sup>170</sup></li> </ul>
<b>What do we need to know?</b>
<p><b>As different US states have implemented differing control measures at various times, a comprehensive analysis of social distancing efficacy has not yet been conducted.</b></p> <ul style="list-style-type: none"> <li>• What are plausible options for relaxing social distancing and other intervention measures without resulting in a resurgence of COVID-19 cases?</li> <li>• How is COVID-19 incidence changing in states that have begun easing movement and activity restrictions?</li> </ul>

Environmental Stability – How long does the agent live in the environment?
<b>What do we know?</b>
<p><b>SARS-CoV-2 can persist on surfaces for at least 3 days and on the surface of a surgical mask for up to 7 days depending on conditions. If aerosolized intentionally, SARS-CoV-2 is stable for at least several hours. The seasonality of COVID-19 transmission is unknown. SARS-CoV-2 on surfaces is inactivated rapidly with sunlight.</b></p> <p><i>SARS-CoV-2 Data</i></p> <ul style="list-style-type: none"> <li>• In simulated saliva on stainless steel surfaces, SARS-CoV-2 exhibits negligible decay over 60 minutes in darkness, but loses 90% of infectivity every 6.8-12.8 minutes, depending on the intensity of simulated UVB radiation levels.<sup>436</sup></li> <li>• The Department of Homeland Security (DHS) developed a data-based model for SARS-CoV-2 decay on inert surfaces (stainless steel, ABS plastic and nitrile rubber) at varying temperature and relative humidity. This model estimates virus decay in the absence of exposure to direct sunlight.<sup>140</sup></li> <li>• SARS-CoV-2 can persist on plastic and metal surfaces between 3 days (21-23°C, 40% RH)<sup>526</sup> and 7 days (22°C, 65% RH). Infectious virus can be recovered from a surgical mask after 7 days (22°C, 65% RH).<sup>109</sup></li> <li>• At room temperature (22°C), SARS-CoV-2 remains detectable (via plaque assay) on paper currency for up to 24 hours, on clothing for up to 4 hours, and on skin for up to 96 hours.<sup>208</sup> Persistence is reduced with warmer temperatures (37°C), and enhanced at colder temperatures (4°C).<sup>208</sup></li> <li>• SARS-CoV-2 persists for less than 3 days within the pages of library books, and for less than 1 day on the exterior of book and DVD covers.<sup>3</sup></li> <li>• Both temperature and humidity contribute to SARS-CoV-2 survival on nonporous surfaces, with cooler, less humid environments facilitating survival (stainless steel, ABS plastic, and nitrile rubber; indoors only; simulated saliva matrix).<sup>50</sup></li> <li>• Experimental studies using SARS-CoV-2 aerosols (1.78-1.96 µm mass median aerodynamic diameter in artificial saliva matrix) found that simulated sunlight rapidly inactivates the virus, with 90% reductions in infectious concentration after 6 minutes in high-intensity sunlight (similar to mid-June) and 19 minutes in low-intensity sunlight (similar to early March or October).<sup>475</sup> In dark conditions, the half-life of aerosolized SARS-CoV-2 is approximately 86 minutes in simulated saliva matrix.<sup>475</sup> Humidity had no significant impact on aerosolized virus survival.<sup>475</sup></li> <li>• DHS developed a tool for estimating the decay of airborne SARS-CoV-2 in different environmental conditions.<sup>139</sup></li> <li>• SARS-CoV-2 has an aerosol half-life of 2.7 hours (particles &lt;5 µm, tested at 21-23°C and 65% RH).<sup>526</sup></li> <li>• Research suggests SARS-CoV-2 retains infectivity as an aerosol for up to 16 hours in appropriate conditions (23°C, 53% RH, no sunlight).<sup>164</sup></li> <li>• SARS-CoV-2 is susceptible to heat treatment (70°C) but can persist for at least two weeks at refrigerated temperatures (4°C).<sup>109, 434</sup></li> <li>• SARS-CoV-2 genetic material (RNA) was detected in symptomatic and asymptomatic cruise ship passenger rooms up to 17 days after cabins were vacated. The infectiousness of this material is not known.<sup>376</sup></li> <li>• In a preliminary study, SARS-CoV-2 stability was enhanced when present with bovine serum albumin, which is commonly used to represent sources of protein found in human sputum.<sup>412</sup></li> <li>• No strong evidence exists showing a reduction in transmission with seasonal increase in temperature and humidity.<sup>335</sup> Modeling suggests that even accounting for potential reductions in transmission due to weather and behavioral changes, public health interventions will still need to be in effect to limit COVID-19 transmission.<sup>366</sup></li> <li>• A recent study determined that approximately 0.1-1% of initial SARS-CoV-2 inoculated on plastic, stainless steel, glass, ceramics, wood, latex gloves, cotton, paper, and surgical masks remained after 48 hours.<sup>323</sup> Approximately 0.1% of SARS-CoV-2 remains in fecal matter after 6 hours.<sup>323</sup> Approximately 0.1% of SARS-CoV-2 in human urine persists after 4-5 days.<sup>323</sup></li> <li>• RNA in clinical samples collected in viral transport medium is stable at 18-25°C or 2-8°C for up to 21 days without impacting real-time RT-PCR results.<sup>495</sup> RNA in clinical samples is also stable at 4°C for up for 4 weeks with regard to quantitative RT-PCR testing (given that the sample contains 5,000 copies/mL). Separately, storage of RNA in PBS at room-temperature (18-25°C) resulted in unstable sample concentrations.<sup>417</sup></li> <li>• SARS-CoV-2 was detectable on wooden chopsticks used by symptomatic and asymptomatic COVID-19 patients, though sample sizes were small and no efforts were made to isolate infectious virus.<sup>334</sup></li> </ul>
<b>What do we need to know?</b>
<p><b>Additional testing on SARS-CoV-2, as opposed to surrogate viruses, is needed to support initial estimates of stability. Tests quantifying infectivity, rather than the presence of viral RNA, are needed.</b></p> <ul style="list-style-type: none"> <li>• Duration of SARS-CoV-2 infectivity via fomites and surfaces (contact hazard)</li> <li>• Stability of SARS-CoV-2 on PPE (e.g., Tyvek)</li> <li>• Stability of SARS-CoV-2 in food (to date, no known infections from contaminated food).<sup>558</sup></li> </ul>

Decontamination – What are effective methods to kill the agent in the environment?
<b>What do we know?</b>
<p><b>Soap and water, as well as common alcohol and chlorine-based cleaners, hand sanitizers, and disinfectants are effective at inactivating SARS-CoV-2 on hands and surfaces.</b></p> <p><i>SARS-CoV-2</i></p> <ul style="list-style-type: none"> <li>Alcohol-based hand rubs are effective at inactivating SARS-CoV-2.<sup>277</sup></li> <li>Chlorine bleach (1%, 2%), 70% ethanol and 0.05% chlorhexidine are effective against live virus in lab tests.<sup>108</sup></li> <li>Twice-daily cleaning with sodium dichloroisocyanurate decontaminated surfaces in COVID-19 patient hospital rooms.<sup>396</sup></li> <li>EPA has released a list of SARS-CoV-2 disinfectants, but most solutions were not tested on SARS-CoV-2.<sup>12</sup> <a href="#">Several solutions have been tested against SARS-CoV-2 and found to be effective, including those based on para-chloro-meta-xyleneol, salicylic acid, and quaternary ammonium compounds.</a><sup>235</sup> Two of these products, Lysol Disinfectant Spray (EPA Reg No. 777-99) and Lysol Disinfectant Max Cover Mist (EPA Reg No. 777-127) have specifically been approved for SARS-CoV-2 decontamination.<sup>337</sup></li> <li>Oral antiseptic rinses used in pre-procedural rinses for dentistry containing povidone-iodine (PVP-I) are effective decontaminants of SARS-CoV-2, with 15-sec and 30-sec contact times completely inactivating SARS-CoV-2 at concentrations above 0.5% in lab tests.<sup>47</sup></li> <li>Holder pasteurization of donor breast milk spiked with SARS-CoV-2 rendered the virus inactive, demonstrating that standard decontamination procedures are effective at reducing risk of COVID-19 risk in infants via donor breast milk.<sup>523</sup></li> <li><a href="#">Efforts are ongoing to create paint-on surfaces that can rapidly inactivate SARS-CoV-2.</a><sup>40</sup></li> <li>Researchers have identified four methods capable of decontaminating N95 respirators while maintaining physical integrity (fit factor): UV radiation, heating to 70°C, and vaporized hydrogen peroxide (VHP).<sup>169</sup> Ethanol (70%) was associated with loss of physical integrity.<sup>169</sup></li> <li>Hydrogen peroxide vapor (VHP) can repeatedly decontaminate N95 respirators.<sup>445</sup> Devices capable of decontaminating 80,000 masks per day have been granted Emergency Use Authorization from the FDA.<sup>157</sup></li> <li>The FDA has issued an Emergency Use Authorization for a system capable of decontaminating ten N95 masks at a time using devices already present in many US hospitals.<sup>58</sup></li> <li><a href="#">Respirator decontamination methods such as VHP appear to maintain filtration efficiency after repeated decontamination cycles.</a><sup>416</sup> <a href="#">Several decontamination methods, including VHP, moist heat, and UVC, are capable of decontaminating N95 respirators for 10-20 cycles without loss of fit or filtration efficiency.</a><sup>6</sup></li> </ul> <p><i>Other Coronaviruses</i></p> <ul style="list-style-type: none"> <li>Chlorine-based<sup>564</sup> and ethanol-based<sup>116</sup> solutions are recommended.</li> <li>Heat treatment (56°C) is sufficient to kill coronaviruses,<sup>431, 624</sup> though effectiveness depends partly on protein in the sample.<sup>431</sup></li> <li>70% ethanol, 50% isopropanol, sodium hypochlorite (0.02% bleach), and UV radiation can inactivate several coronaviruses (MHV and CCV).<sup>463</sup></li> <li>Ethanol-based biocides effectively disinfect coronaviruses dried on surfaces, including ethanol containing gels similar to hand sanitizer.<sup>230, 573</sup></li> <li>Surface spray disinfectants such as Mikrobac, Dismozon, and Korsolex are effective at reducing infectivity of the closely related SARS-CoV-1 after 30 minutes of contact.<sup>430</sup></li> <li>Coronaviruses may be resistant to heat inactivation for up to 7 days when stabilized in stool.<sup>516-517</sup></li> <li>Coronaviruses are more stable in matrixes such as respiratory sputum.<sup>146</sup></li> </ul>
<b>What do we need to know?</b>
<p><b>Additional decontamination studies, particularly with regard to PPE and other items in short supply, are needed.</b></p> <ul style="list-style-type: none"> <li>What is the minimal contact time for disinfectants?</li> <li>Does contamination with human fluids/waste alter disinfectant efficacy profiles?</li> <li>How effective is air filtration at reducing transmission in healthcare, airplanes, and public spaces?</li> <li>Are landfills and wastewater treatment plants effective at inactivating SARS-CoV-2?</li> <li>Is heat or UV decontamination effective to clean N95 masks, respirators and other types of PPE for multi-use?</li> </ul>



PPE – What PPE is effective, and who should be using it?
<b>What do we know?</b>
<p><b>The effectiveness of PPE for SARS-CoV-2 is currently unknown, and data from other related coronaviruses are used for guidance. Healthcare workers are at high risk of acquiring COVID-19, even with recommended PPE.</b></p> <ul style="list-style-type: none"> <li>Healthcare worker illnesses<sup>514</sup> demonstrates human-to-human transmission despite isolation, PPE, and infection control.<sup>474</sup> Risk of transmission to healthcare workers is high, with up to 20% of healthcare workers in Lombardy, Italy becoming infected.<sup>439</sup> Over 50% of US healthcare workers infected with COVID-19 report work in a healthcare setting as their single source of exposure.<sup>65</sup> Hospital-acquired infection rates fell after introduction of comprehensive infection control measures, including expanded testing and use of PPE for all patient contacts.<sup>446</sup> <a href="#">Universal masking policies also reduced the rate of new healthcare worker infections.</a><sup>546</sup></li> <li>A modeling study suggests that healthcare workers are primarily at risk from droplet and inhalation exposure (compared to contact with fomites), with greater risk while in closer proximity to patients.<sup>252</sup></li> <li>“Healthcare personnel entering the room [of SARS-CoV-2 patients] should use standard precautions, contact precautions, airborne precautions, and use eye protection (e.g., goggles or a face shield).”<sup>83</sup> WHO indicates healthcare workers should wear clean long-sleeve gowns as well as gloves.<sup>563</sup> PPE that covers all skin may reduce exposure to pathogens.<sup>165, 555</sup></li> <li>Respirators (NIOSH-certified N95, EUFFP2 or equivalent) are recommended for those dealing with possible aerosols.<sup>564</sup> Additional protection, such as a Powered Air Purifying Respirator (PAPR) with a full hood, should be considered for high-risk procedures (i.e., intubation, ventilation).<sup>61</sup></li> <li>KN95 respirators are, under certain conditions, approved for use under FDA Emergency Use Authorization.<sup>158</sup> On May 7, the FDA rescinded a number of KN95 models that no longer meet the EUA criteria and are no longer authorized.<sup>163</sup></li> <li>A study suggests that P100 respirators with removable filter cartridges have similar filtration efficiency compared to N95 respirators and could plausibly be used if N95 respirators were in short supply. The study used an experimental setup with aerosolized simulant, not human testing.<sup>414</sup></li> <li>Particular care should be taken with “duckbill” N95 respirators, which may fail fit tests after repeated doffing.<sup>133</sup> Dome-shaped N95 respirators also failed fit tests after extended use.<sup>133</sup></li> </ul> <p><b>Masks may be effective at slowing transmission.</b></p> <ul style="list-style-type: none"> <li>On 4/3/2020, the US CDC recommended wearing cloth face masks in public where social distancing measures are difficult to maintain.<sup>84</sup> The WHO recommends that the general population wear non-medical masks when in public settings and when physical distancing is difficult, and that vulnerable populations (e.g., elderly) wear medical masks when close contact is likely.<sup>559</sup> Infected individuals wearing facemasks in the home before the onset of symptoms was associated with a reduction in household transmission.<sup>548</sup></li> <li>Modeling suggests that widespread use of facemasks is effective at reducing transmission.<sup>385</sup></li> <li>A meta-analysis of SARS-CoV-1, MERS, and COVID-19 transmission events found evidence that wearing face masks and eye protection were each associated with lower risk of transmission.<sup>111</sup> N95 respirators were associated with a larger reduction in transmission risk compared to surgical face masks.<sup>111</sup> Physical distance (&gt;1 or 2 meters) was also associated with lower transmission risk.<sup>111</sup> In a separate meta-analysis, N95 respirators were found to be beneficial for reducing the occurrence of respiratory illness in health care professionals including influenza, though surgical masks were similarly effective for influenza.<sup>393</sup> N95 respirators were associated with large reductions (up to 80%) in SARS-CoV-1 infections.<sup>393</sup></li> <li>Surgical face masks, respirators and homemade face masks may prevent transmission of coronaviruses from infectious individuals (with or without symptoms) to other individuals.<sup>128, 297, 525</sup> Surgical masks were associated with a significant reduction in the amount of seasonal coronavirus (not SARS-CoV-2) expressed as aerosol particles (&lt;5 μm).<sup>297</sup></li> <li>The efficacy of homemade PPE, made with T-shirts, bandanas, or similar materials, is less than standard PPE, but may offer some protection if no other options are available.<sup>112, 127, 441</sup> The filtering efficiency of homemade mask materials is variable. Some non-standard materials (e.g., cotton, cotton hybrids) may be able to filter out &gt;90% of simulant particles &gt;0.3μm,<sup>269</sup> while other materials (e.g., T-shirt, vacuum cleaner bag, towels) appear to have lower filtration efficacy (~35-62%).<sup>542</sup> Of 42 homemade materials tested, the three with the greatest filtration efficiencies were layered cotton with raised visible fibers,<sup>510</sup> though homemade materials were not as effective as surgical or N95 masks.</li> </ul>
<b>What do we need to know?</b>
<p><b>Most PPE recommendations have not been made on SARS-CoV-2 data, and comparative efficacy of different PPE for different tasks (e.g., intubation) is unknown. Identification of efficacious PPE for healthcare workers is critical due to their high rates of infection.</b></p> <ul style="list-style-type: none"> <li>What is the importance of aerosol transmission (particles &lt;5μm)? What is the effective distance of spread via droplet or aerosol?</li> <li>How effective are barriers such as N95 respirators or surgical masks for SARS-CoV-2?</li> <li>What is the appropriate PPE for first responders? Airport screeners?</li> <li>What are proper procedures for reducing spread and transmission rates in medical facilities?</li> <li>How effective are homemade masks at reducing SARS-CoV-2 transmission?</li> </ul>

Forensics – Natural vs intentional use? Tests to be used for attribution.
<b>What do we know?</b>
<p><b>All current evidence supports the natural emergence of SARS-CoV-2 via a bat and possible intermediate mammal species.</b></p> <ul style="list-style-type: none"> <li>• Genomic analysis places SARS-CoV-2 into the beta-coronavirus clade, with close relationship to bat coronaviruses. The SARS-CoV-2 virus is distinct from SARS-CoV-1 and MERS viruses.<sup>141</sup></li> <li>• Genomic analysis suggests that SARS-CoV-2 is a natural variant and is unlikely to be human-derived or otherwise created by “recombination” with other circulating strains of coronavirus.<sup>18, 627</sup></li> <li>• Comparing genomes of multiple coronaviruses using machine-learning has identified key genomic signatures shared among high case fatality rate coronaviruses (SARS-CoV-1, SARS-CoV-2, MERS) and animal counterparts.<sup>204</sup> These data further suggest that SARS-CoV-2 emergence is the result of natural emergence and that there is a potential for future zoonotic transmission of additional pathogenic strains to humans.<sup>204</sup></li> <li>• Deletion mutants were identified at low levels in human clinical samples, suggesting that the PRRA furin cleavage site alone is not fully responsible for human infection, but does confer a fitness advantage in the human host.<sup>575</sup> Additional whole-genome sequencing in humans would help to confirm this finding.</li> <li>• Genomic data support at least two plausible origins of SARS-CoV-2: “(i) natural selection in a non-human animal host prior to zoonotic transfer, and (ii) natural selection in humans following zoonotic transfer.”<sup>18</sup> Both scenarios are consistent with the observed genetic changes found in all known SARS-CoV-2 isolates.</li> <li>• Some SARS-CoV-2 genomic evidence indicates a close relationship with pangolin coronaviruses,<sup>574</sup> and data suggest that pangolins may be a natural host for beta-coronaviruses.<sup>315, 317</sup> Genomic evidence suggests a plausible recombination event between a circulating coronavirus in pangolins and bats could be the source of SARS-CoV-2.<sup>306, 591</sup> Emerging studies are showing that bats are not the only reservoir of SARS-like coronaviruses.<sup>617</sup> Additional research is needed.</li> <li>• There are multiple studies showing that the SARS-CoV-2 S protein receptor binding domain, the portion of the protein responsible for binding the human receptor ACE2, was acquired through recombination between coronaviruses from pangolins and bats.<sup>19, 306, 316, 617</sup> These studies suggest that pangolins may have played an intermediate role in the adaptation of SARS-CoV-2 to be able to bind to the human ACE2 receptor. Additional research is needed.</li> <li>• A novel bat coronavirus (RmYN02) has been identified in China with an insertion in the viral furin cleavage site. While distinct from the insertion in SARS-CoV-2, this evidence shows that such insertions can occur naturally.<sup>626</sup></li> <li>• Additionally, “[...] SARS-CoV-2 is not derived from any previously used virus backbone,” reducing the likelihood of laboratory origination,<sup>18</sup> and “[...] genomic evidence does not support the idea that SARS-CoV-2 is a laboratory construct, [though] it is currently impossible to prove or disprove the other theories of its origin.”<sup>18</sup></li> <li>• Work with other coronaviruses has indicated that heparan sulfate dependence can be an indicator of prior cell passage, due to a mutation in the previous furin enzyme recognition motif.<sup>131</sup></li> </ul>
<b>What do we need to know?</b>
<p><b>Identifying the intermediate species between bats and humans would aid in reducing potential spillover from a natural source. Wide sampling of bats, other wild animals, and humans is needed to address the origin of SARS-CoV-2.</b></p> <ul style="list-style-type: none"> <li>• What tests for attribution exist for coronavirus emergence?</li> <li>• What is the identity of the intermediate species?</li> <li>• Are there closely related circulating coronaviruses in bats or other animals with the novel PRRA cleavage site found in SARS-CoV-2?</li> </ul>

Genomics – How does the disease agent compare to previous strains?
<b>What do we know?</b>
<p><b>Current evidence suggests that SARS-CoV-2 accumulates substitutions and mutations at a similar rate as other coronaviruses. Mutations and deletions in specific portions of the SARS-CoV-2 genome have not been linked to any changes in transmission or disease severity, though modeling work is attempting to identify possible changes.</b></p> <ul style="list-style-type: none"> <li>• There have been no documented cases of SARS-CoV-2 prior to December 2019. Preliminary genomic analyses, however, suggest that the first human cases of SARS-CoV-2 emerged between 10/19/2019 – 12/17/2019.<sup>21, 39, 433</sup></li> <li>• Analysis of more than 7,000 SARS-CoV-2 genome samples provides an estimated mutation rate of <math>6 \times 10^{-4}</math> nucleotides per genome per year.<sup>528</sup> The same analysis estimates the emergence of SARS-CoV-2 in humans between October and December 2019.<sup>528</sup> This aligns with the first known human cases in China in early December 2019, in Europe in late December 2019,<sup>138</sup> circulation in the US (Washington State) in February 2020,<sup>578</sup> and circulation in Mexico in March, 2020.<sup>510</sup> In both California<sup>137</sup> and New York City,<sup>192</sup> phylogenetic evidence supports multiple introductions of SARS-CoV-2 from both inside and outside the US.</li> <li>• Despite evidence of variation in the genome<sup>89</sup> and areas under positive selection,<sup>68</sup> there are no known associations between particular mutations and changes in transmission or virulence.<sup>67</sup> Thus, there is currently no evidence of distinct SARS-CoV-2 phenotypes at this time.<sup>338, 528</sup> Research attempting to define clades or subgroups of SARS-CoV-2 based solely on genomic features has suffered from limited data<sup>604</sup> and sampling bias.<sup>176</sup> In 94 COVID-19 patients, there was no association between viral genotype and clinical severity.<sup>618</sup></li> <li>• Phylogenetic and clinical analysis suggests the D614G mutation in the Spike protein is associated with higher rates of SARS-CoV-2 transmission, but no change in clinical severity in infected patients.<sup>273</sup> However, it is difficult to determine whether this mutation is overrepresented due to founder effects, or whether it truly spreads more rapidly than other isolates. Preliminary experimental evidence suggests that this mutation increases infectivity in cell lines, but additional animal model work is needed to confirm the effect of this mutation on transmission.<sup>615</sup></li> <li>• Recent analysis of &gt;16,000 genomes of SARS-CoV-2 suggests two major introductions in the US, one associated with the West coast and one with the Eastern portion of the US.<sup>378</sup></li> <li>• A genome-wide association study in humans identified two loci corresponding to higher risk of severe COVID-19 (3p.21.31 and 9q34.2), including one associated with blood type.<sup>149</sup> Individuals with type-O blood showed reduced risk of severe disease, while individuals with type-A blood showed an increased risk.<sup>149</sup></li> <li>• SARS-CoV-2 is acquiring nucleotide changes at a rate that suggests the virus is undergoing purifying selection (that the genome is stabilizing toward a common genome).<sup>581</sup> Low genetic diversity early in the epidemic suggests that SARS-CoV-2 was capable of jumping to human and other mammalian hosts,<sup>581</sup> and that additional jumps into humans from reservoir species may occur.</li> <li>• Phylogenetics suggest that SARS-CoV-2 is of bat origin, but is closely related to coronaviruses found in pangolins.<sup>315, 317</sup></li> <li>• The SARS-CoV-2 Spike protein, which mediates entry into host cells and is the major determinant of host range, is very similar to the SARS-CoV-1 Spike protein.<sup>330</sup> The rest of the genome is more closely related to two separate bat<sup>330</sup> and coronaviruses found in pangolins.<sup>317</sup></li> <li>• An analysis of SARS-CoV-2 sequences from Singapore has identified a large nucleotide (382 bp) deletion in ORF-8.<sup>502</sup> In Arizona, researchers identified an 81-base pair deletion (removing 27 amino acids) in the ORF-7a protein, indicating that mutations can be detected by routine sentinel surveillance. The function of these deletions are unknown at this time.<sup>218</sup></li> <li>• A recent report of virus mutations within patients needs more research.<sup>258</sup> Additional analysis of data suggests the results may be due to experimental methods.<sup>189, 595</sup></li> <li>• Structural modeling suggests that observed changes in the genetic sequence of the SARS-CoV-2 Spike protein may enhance binding of the virus to human ACE2 receptors.<sup>398</sup> More specifically, changes to two residues (Q493 and N501) are linked with improving the stability of the virus-receptor binding complex.<sup>398</sup> Additionally, structural modeling identified several existing mutations that may enhance the stability of the receptor binding domain, potentially increasing binding efficacy.<sup>400</sup> Infectivity assays are needed to validate the genotypic changes and possible phenotypic results identified in these studies.</li> <li>• A key difference between SARS-CoV-2 and other beta-coronaviruses is the presence of a polybasic furin cleavage site in the Spike protein (insertion of a PRRA amino acid sequence between S1 and S2).<sup>120</sup></li> <li>• The US CDC is launching a national genomics consortium to assess SARS-CoV-2 genomic changes over time.<sup>78</sup></li> </ul>
<b>What do we need to know?</b>
<p><b>Research linking genetic changes to differences in phenotype (e.g., transmissibility, virulence, progression in patients) is needed.</b></p> <ul style="list-style-type: none"> <li>• Are there similar genomic differences in the progression of coronavirus strains from bat to intermediate species to human?</li> <li>• Are there different strains or clades of circulating virus? If so, do they differ in virulence?</li> <li>• What are the mutations in SARS-CoV-2 that allowed human infection and transmission?</li> </ul>

Forecasting – What forecasting models and methods exist?
<b>What do we know?</b>
<p><b>There are many groups focused on forecasting cases, hospitalizations, or fatalities due to COVID-19. Each model has its own methods and goals, summarized in this section. An evaluation of model performance is beyond the scope of this document. Assumptions and limitations of each model are detailed at the linked reference.</b></p> <p><i>US CDC forecasting</i></p> <p><b>The US CDC is hosting an ongoing forecasting initiative, and provides ensemble forecasts based on the arithmetic mean of participating groups.<sup>81</sup></b></p> <ul style="list-style-type: none"> <li>• Columbia University Model: Spatially-explicit SEIR model incorporating contact rate reductions due to social distancing. Estimates total cases and risk of healthcare overrun.<sup>460</sup></li> <li>• Imperial College London: Week-ahead forecasts of cases, deaths, and transmissibility (<math>R_0</math>) at the country-level. Transmissibility estimates used to forecast incidence based on Poisson renewal process.<sup>45</sup></li> <li>• Institute of Health Metrics and Evaluation (IHME): Mechanistic SEIR model combined with curve-fitting techniques to forecast cases, hospital resource use, and deaths at the state and country level.<sup>234</sup></li> <li>• Los Alamos National Laboratory: Forecasts of state-level cases and deaths based on statistical growth model fit to reported data. Implicitly accounts for effects of social distancing and other control measures.<sup>285</sup></li> <li>• Massachusetts Institute of Technology: Mechanistic SEIR model that forecasts cases, hospitalizations, and deaths. Also includes estimates of intervention measures, allows users to project based on different intervention scenarios (e.g., social distancing lasting for 3 vs. 4 weeks).<sup>370</sup></li> <li>• Northeastern University: Spatially explicit, agent-based epidemic model used to forecast fatalities, hospital resource use, and the cumulative attack rate (proportion of the population infected) for unmitigated and mitigated scenarios.<sup>389</sup></li> <li>• Notre Dame University: Agent-based model forecasting cases and deaths for Midwest states. Includes effectiveness of control measures like social distancing.<sup>419</sup></li> <li>• University of California, Los Angeles: Mechanistic SIR model with statistical optimization to find best-fitting parameter values. Estimates confirmed and active cases, fatalities, and transmission rates at the national and state levels.<sup>522</sup></li> <li>• University of Chicago: Age-structured SEIR model that accounts for asymptomatic individuals and the effectiveness of social distancing policies. Forecasts only for Illinois.<sup>107</sup></li> <li>• University of Geneva: Country-level forecasts of cases, deaths, and transmissibility (<math>R_0</math>). Uses statistical models fit to reported data, not mechanistic models.<sup>172</sup></li> <li>• University of Massachusetts, Amherst: Aggregation of state and national forecasts to create ensemble model.<sup>438</sup></li> <li>• University of Texas, Austin: Machine learning model aimed at identifying links between social distancing measures and changes in death rates. Forecasts fatalities at the state, metropolitan area, and national level. Cannot be used to make projections beyond initial infection wave.<sup>367</sup></li> <li>• Youyang Gu: Mechanistic SEIR model coupled with machine learning algorithms to minimize error between predicted and observed values. Forecasts deaths and infections at the state and national level, including 60 non-US countries. Includes effects of public health control efforts.<sup>199</sup></li> <li>• Auquan: SEIR model used to forecast deaths and illnesses at the country and state level.<sup>29</sup></li> <li>• CovidSim: SEIR model allowing users to simulate the effects of future intervention policies at the state and national level (US only).<sup>106</sup></li> </ul> <p><i>Other forecasting efforts:</i></p> <ul style="list-style-type: none"> <li>• University of Georgia: Statistical models used to estimate the current number of symptomatic and incubating individuals, beyond what is reported (e.g., “nowcasts”). Available at the state and national level for the US.<sup>88</sup></li> <li>• Hospital IQ has a dashboard that forecasts hospital and ICU admissions for each county in the US. Relies in part on IHME forecasts.<sup>238</sup></li> <li>• COVID Act Now: State and county-level dashboard focused on re-opening strategies, showing trends in four metrics related to COVID-19 risk (change in cases, total testing capacity, fraction of positive tests, and availability of ICU beds). Fundamentally uses an SEIR model fit to observed data.<sup>390</sup></li> <li>• Researchers use a rolling window analysis incorporating uncertainty in the generation time distribution to estimate time-varying transmission rates in US states (the effective reproduction number, <math>R_{eff}</math> or <math>R_t</math>).<sup>8</sup></li> </ul>
<b>What do we need to know?</b>
<p><b>Forecasts differ in how they handle public health interventions such as shelter-in-place orders and tracking how methods change in the near future will be important for understanding limitations going forward.</b></p>

Table 1. Definitions of commonly-used acronyms

Acronym/Term	Definition	Description
ACE2	Angiotensin-converting enzyme 2	Acts as a receptor for SARS-CoV and SARS-CoV-2, allowing entry into human cells
Airborne transmission	Aerosolization of infectious particles	Aerosolized particles can spread for long distances (e.g., between hospital rooms via HVAC systems). Particles generally <5 μm.
ARDS	Acute respiratory distress syndrome	Leakage of fluid into the lungs which inhibits respiration and leads to death
Attack rate	Proportion of “at-risk” individuals who develop infection	Defined in terms of “at-risk” population such as schools or households, defines the proportion of individuals in those populations who become infected after contact with an infectious individual
CCV	Canine coronavirus	Canine coronavirus
CFR	Case Fatality Rate	Number of deaths divided by confirmed patients
CoV	Coronavirus	Virus typified by crown-like structures when viewed under electron microscope
COVID-19	Coronavirus disease 19	Official name for the disease caused by the SARS-CoV-2 virus.
Droplet transmission	Sneezing, coughing	Transmission via droplets requires relatively close contact (e.g., within 6 feet)
ELISA	Enzyme-linked immunosorbent assay	Method for serological testing of antibodies
Fomite	Inanimate vector of disease	Surfaces such as hospital beds, doorknobs, healthcare worker gowns, faucets, etc.
HCW	Healthcare worker	Doctors, nurses, technicians dealing with patients or samples
Incubation period	Time between infection and symptom onset	Time between infection and onset of symptoms typically establishes guidelines for isolating patients before transmission is possible
Infectious period	Length of time an individual can transmit infection to others	Reducing the infectious period is a key method of reducing overall transmission; hospitalization, isolation, and quarantine are all effective methods
Intranasal	Agent deposited into external nares of subject	Simulates inhalation exposure by depositing liquid solution of pathogen/virus into the nose of a test animal, where it is then taken up by the respiratory system.
MERS	Middle-East Respiratory Syndrome	Coronavirus with over 2,000 cases in regional outbreak since 2012
MHV	Mouse hepatitis virus	Coronavirus surrogate
Nosocomial	Healthcare- or hospital-associated infections	Characteristic of SARS and MERS outbreaks, lead to refinement of infection control procedures
PCR	Polymerase chain reaction	PCR (or real-time [RT] or quantitative [Q] PCR) is a method of increasing the amount of genetic material in a sample, which is then used for diagnostic testing to confirm the presence of SARS-CoV-2
PFU	Plaque forming unit	Measurement of the number of infectious virus particles as determined by plaque forming assay. A measurement of sample infectivity.
PPE	Personal protective equipment	Gowns, masks, gloves, and any other measures used to prevent spread between individuals
R <sub>0</sub>	Basic reproduction number	A measure of transmissibility. Specifically, the average number of new infections caused by a typical infectious individual in a wholly susceptible population.

Acronym/Term	Definition	Description
SARS	Severe Acute Respiratory Syndrome	Coronavirus with over 8,000 cases in global 2002-2003 outbreak
SARS-CoV-2	Severe acute respiratory syndrome coronavirus 2	Official name for the virus previously known as 2019-nCoV.
SEIR	Susceptible (S), exposed (E), infected (I), and resistant (R)	A type of modeling that incorporates the flow of people between the following states: susceptible (S), exposed (E), infected (I), and resistant (R), and is being used for SARS-CoV-2 forecasting
Serial interval	Length of time between symptom onset of successive cases in a transmission chain	The serial interval can be used to estimate $R_0$ , and is useful for estimating the rate of outbreak spread
SIR	Susceptible (S), infected (I), and resistant (R)	A type of modeling that incorporates the flow of people between the following states: susceptible (S), infected (I), and resistant (R), and is being used for SARS-CoV-2 forecasting
TCID <sub>50</sub>	50% Tissue Culture Infectious Dose	The number of infectious units which will infect 50% of tissue culture monolayers. A measurement of sample infectivity.
Transgenic	Genetically modified	In this case, animal models modified to be more susceptible to MERS and/or SARS by adding proteins or receptors necessary for infection

**Literature Cited:**

1. (U) Coronavirus diagnosed at mink farms in North Brabant. *NOS* 2020. <https://nos.nl/artikel/2331784-coronavirus-vastgesteld-bij-nertsenfokkerijen-in-noord-brabant.html>
2. (U) Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report. *New England Journal of Medicine* 2020. <https://www.nejm.org/doi/full/10.1056/NEJMoa2021436>
3. (U) Research Shows Virus Undetectable on Five Highly Circulated Library Materials After Three Days. Institute for Library and Museum Services: 2020. <https://www.ims.gov/news/research-shows-virus-undetectable-five-highly-circulated-library-materials-after-three-days>
4. (U) Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020. *MMWR* 2020. [https://www.cdc.gov/mmwr/volumes/69/wr/mm6912e2.htm?s\\_cid=mm6912e2\\_w#suggestedcitation](https://www.cdc.gov/mmwr/volumes/69/wr/mm6912e2.htm?s_cid=mm6912e2_w#suggestedcitation)
5. (U) [Wuhan Pneumonia] The Hospital Authority stated that 2 critically ill patients needed external life support treatment. <https://www.singtao.ca/4037242/2020-01-14/news-%E3%80%90%E6%AD%A6%E6%BC%A2%E8%82%BA%E7%82%8E%E3%80%91%E9%86%AB%E7%AE%A1%E5%B1%80%E6%8C%872%E5%90%8D%E9%87%8D%E7%97%87%E7%97%85%E6%82%A3%E9%9C%80%E9%AB%94%E5%A4%96%E7%94%9F%E5%91%BD%E6%94%AF%E6%8C%81%E6%B2%BB%E7%99%82/?variant=zh-hk>.
6. (U) 3M, *Decontamination of 3M Filtering Facepiece Respirators, such as N95 Respirators, in the United States - Considerations*; 3M: 2020. <https://multimedia.3m.com/mws/media/18248690/decontamination-methods-for-3m-filtering-facepiece-respirators-technical-bulletin.pdf>
7. (U) AAAS, You may be able to spread coronavirus just by breathing, new report finds. *Science* 2 April, 2020. <https://www.sciencemag.org/news/2020/04/you-may-be-able-to-spread-coronavirus-just-breathing-new-report-finds>
8. (U) Abbott, S.; Hellewell, J.; Thompson, R.; Sherratt, K.; Gibbs, H.; Bosse, N.; Munday, J.; Meakin, S.; Doughty, E.; Chun, J.; Chan, Y.; Finger, F.; Campbell, P.; Endo, A.; Pearson, C.; Gimma, A.; Russell, T.; null, n.; Flasche, S.; Kucharski, A.; Eggo, R.; Funk, S., Estimating the time-varying reproduction number of SARS-CoV-2 using national and subnational case counts [version 1; peer review: awaiting peer review]. *Wellcome Open Research* 2020, 5 (112). <https://wellcomeopenresearch.org/articles/5-112/v1>
9. (U) Ackermann, M.; Verleden, S. E.; Kuehnel, M.; Haverich, A.; Welte, T.; Laenger, F.; Vanstapel, A.; Werlein, C.; Stark, H.; Tzankov, A.; Li, W. W.; Li, V. W.; Mentzer, S. J.; Jonigk, D., Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. *New England Journal of Medicine* 2020. <https://www.nejm.org/doi/full/10.1056/NEJMoa2015432>
10. (U) Adam, D.; Wu, P.; Wong, J.; Lau, E.; Tsang, T.; Cauchemez, S.; Leung, G.; Cowling, B., Clustering and superspreading potential of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in Hong Kong. 2020.
11. (U) Adams, M.; Katz, D.; Grandpre, J., Updated Estimates of Chronic Conditions Affecting Risk for Complications from Coronavirus Disease, United States. *Emerging Infectious Disease journal* 2020, 26 (9). [https://wwwnc.cdc.gov/eid/article/26/9/20-2117\\_article](https://wwwnc.cdc.gov/eid/article/26/9/20-2117_article)
12. (U) Agency, U. S. E. P., EPA's Registered Antimicrobial Products for Use Against Novel Coronavirus SARS-CoV-2, the Cause of COVID-19. <https://www.epa.gov/pesticide-registration/list-n-disinfectants-use-against-sars-cov-2>.
13. (U) Agrawal, A. S.; Garron, T.; Tao, X.; Peng, B. H.; Wakamiya, M.; Chan, T. S.; Couch, R. B.; Tseng, C. T., Generation of a transgenic mouse model of Middle East respiratory syndrome coronavirus infection and disease. *J Virol* 2015, 89 (7), 3659-70. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4403411/pdf/ziv3659.pdf>

14. (U) Aleta, A.; Martin-Corral, D.; Pastore y Piontti, A.; Ajelli, M.; Litvinova, M.; Chinazzi, M.; Dean, N.; Halloran, M. E.; Longini, I.; Merler, S.; Pentland, A.; Vespignani, A.; Moro, E.; Moreno, Y., Modeling the impact of social distancing, testing, contact tracing and household quarantine on second-wave scenarios of the COVID-19 epidemic. *Preprint* **2020**. [https://www.mobs-lab.org/uploads/6/7/8/7/6787877/tracing\\_main\\_may4.pdf](https://www.mobs-lab.org/uploads/6/7/8/7/6787877/tracing_main_may4.pdf)
15. (U) Aleta, A.; Moreno, Y., Evaluation of the potential incidence of COVID-19 and effectiveness of containment measures in Spain: a data-driven approach. *BMC Medicine* **2020**, *18* (1), 157. <https://doi.org/10.1186/s12916-020-01619-5>
16. (U) Altmann, D. M.; Douek, D. C.; Boyton, R. J., What policy makers need to know about COVID-19 protective immunity. *The Lancet* **2020**. [https://doi.org/10.1016/S0140-6736\(20\)30985-5](https://doi.org/10.1016/S0140-6736(20)30985-5)
17. (U) An, M. H.; Kim, M. S.; park, Y.; Kim, B.-O.; Kang, S. H.; Kimn, W. J.; Park, S. K.; Park, H.-W.; Yang, W.; Jang, J.; Jang, S.; Hwang, T.-H., Treatment Response to Hydroxychloroquine and Antibiotics for mild to moderate COVID-19: a retrospective cohort study from South Korea. *medRxiv* **2020**, 2020.07.04.20146548. <http://medrxiv.org/content/early/2020/07/07/2020.07.04.20146548.abstract>
18. (U) Andersen, K. G.; Rambaut, A.; Lipkin, W. I.; Holmes, E. C.; Garry, R. F., The proximal origin of SARS-CoV-2. *Nature Medicine* **2020**. <https://doi.org/10.1038/s41591-020-0820-9>
19. (U) Andersen, K. G.; Rambaut, A.; Lipkin, W. I.; Holmes, E. C.; Garry, R. F., The proximal origin of SARS-CoV-2. *Nature Medicine* **2020**, *26* (4), 450-452. <https://doi.org/10.1038/s41591-020-0820-9>
20. (U) Anderson, E. L.; Turnham, P.; Griffin, J. R.; Clarke, C. C., Consideration of the Aerosol Transmission for COVID-19 and Public Health. *Risk Analysis* **2020**, *40* (5), 902-907. <https://onlinelibrary.wiley.com/doi/abs/10.1111/risa.13500>
21. (U) Anderson, K., Estimates of the clock and TMRCA for 2019-nCoV based on 27 genomes. <http://virological.org/t/clock-and-tmrca-based-on-27-genomes/347> (accessed 01/26/2020).
22. (U) AnGes, Study of COVID-19 DNA Vaccine (AG0301-COVID19). <https://clinicaltrials.gov/ct2/show/NCT04463472?term=NCT04463472&draw=2&rank=1>.
23. (U) Antony, S. J.; Davis, M. A.; Davis, M. G.; Almaghouth, N. K.; Guevara, R.; Omar, F.; Del Rey, F.; Hassan, A.; Arian, M. U.; Antony, N.; Prakash, B. V., Early use of tocilizumab in the prevention of adult respiratory failure in SARS-CoV-2 infections and the utilization of interleukin-6 levels in the management. *Journal of Medical Virology* **2020**, *n/a* (n/a). <https://doi.org/10.1002/jmv.26288>
24. (U) Arentz, M.; Yim, E.; Klaff, L.; Lokhandwala, S.; Riedo, F. X.; Chong, M.; Lee, M., Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. *JAMA* **2020**. <https://doi.org/10.1001/jama.2020.4326>
25. (U) Argenziano, M. G.; Bruce, S. L.; Slater, C. L.; Tiao, J. R.; Baldwin, M. R.; Barr, R. G.; Chang, B. P.; Chau, K. H.; Choi, J. J.; Gavin, N.; Goyal, P.; Mills, A. M.; Patel, A. A.; Romney, M.-L. S.; Safford, M. M.; Schluger, N. W.; Sengupta, S.; Sobieszczyk, M. E.; Zucker, J. E.; Asadourian, P. A.; Bell, F. M.; Boyd, R.; Cohen, M. F.; Colquhoun, M. I.; Colville, L. A.; de Jonge, J. H.; Dershowitz, L. B.; Dey, S. A.; Eiseman, K. A.; Girvin, Z. P.; Goni, D. T.; Harb, A. A.; Herzik, N.; Householder, S.; Karaaslan, L. E.; Lee, H.; Lieberman, E.; Ling, A.; Lu, R.; Shou, A. Y.; Sisti, A. C.; Snow, Z. E.; Sperring, C. P.; Xiong, Y.; Zhou, H. W.; Natarajan, K.; Hripcsak, G.; Chen, R., Characterization and Clinical Course of 1000 Patients with COVID-19 in New York: retrospective case series. *medRxiv* **2020**, 2020.04.20.20072116. <https://www.medrxiv.org/content/medrxiv/early/2020/04/22/2020.04.20.20072116.full.pdf>
26. (U) Arons, M. M.; Hatfield, K. M.; Reddy, S. C.; Kimball, A.; James, A.; Jacobs, J. R.; Taylor, J.; Spicer, K.; Bardossy, A. C.; Oakley, L. P.; Tanwar, S.; Dyal, J. W.; Harney, J.; Chisty, Z.; Bell, J. M.; Methner, M.; Paul, P.; Carlson, C. M.; McLaughlin, H. P.; Thornburg, N.; Tong, S.; Tamin, A.; Tao, Y.; Uehara, A.; Harcourt, J.; Clark, S.; Brostrom-Smith, C.; Page, L. C.; Kay, M.; Lewis, J.; Montgomery, P.; Stone, N. D.; Clark, T. A.; Honein, M. A.; Duchin, J. S.; Jernigan, J. A., Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility. *New England Journal of Medicine* **2020**. <https://www.nejm.org/doi/full/10.1056/NEJMoa2008457>



27. (U) Arshad, S.; Kilgore, P.; Chaudhry, Z. S.; Jacobsen, G.; Wang, D. D.; Huitsing, K.; Brar, I.; Alangaden, G. J.; Ramesh, M. S.; McKinnon, J. E.; O'Neill, W.; Zervos, M.; Nauriyal, V.; Hamed, A. A.; Nadeem, O.; Swiderek, J.; Godfrey, A.; Jennings, J.; Gardner-Gray, J.; Ackerman, A. M.; Lezotte, J.; Ruhala, J.; Fadel, R.; Vahia, A.; Gudipati, S.; Parraga, T.; Shallal, A.; Maki, G.; Tariq, Z.; Suleyman, G.; Yared, N.; Herc, E.; Williams, J.; Lanfranco, O. A.; Bhargava, P.; Reyes, K.; Chen, A., Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19. *International Journal of Infectious Diseases* **2020**. <https://doi.org/10.1016/j.ijid.2020.06.099>
28. (U) Auld, S.; Caridi-Scheible, M.; Blum, J. M.; Robichaux, C. J.; Kraft, C. S.; Jacob, J. T.; Jabaley, C. S.; Carpenter, D.; Kaplow, R.; Hernandez, A. C.; Adelman, M. W.; Martin, G. S.; Coopersmith, C. M.; Murphy, D. J., ICU and ventilator mortality among critically ill adults with COVID-19. *medRxiv* **2020**, 2020.04.23.20076737. <https://www.medrxiv.org/content/medrxiv/early/2020/04/26/2020.04.23.20076737.full.pdf>
29. (U) Auquan, COVID-19 Dashboard. <https://covid19-infection-model.auquan.com/>.
30. (U) Aziz, M.; Fatima, R.; Assaly, R., Elevated Interleukin-6 and Severe COVID-19: A Meta-Analysis. *J Med Virol* **2020**.
31. (U) Badr, H. S.; Du, H.; Marshall, M.; Dong, E.; Squire, M. M.; Gardner, L. M., Association between mobility patterns and COVID-19 transmission in the USA: a mathematical modelling study. *The Lancet Infectious Diseases* **2020**. [https://doi.org/10.1016/S1473-3099\(20\)30553-3](https://doi.org/10.1016/S1473-3099(20)30553-3)
32. (U) Bai, H. X.; Wang, R.; Xiong, Z.; Hsieh, B.; Chang, K.; Halsey, K.; Tran, T. M. L.; Choi, J. W.; Wang, D. C.; Shi, L. B.; Mei, J.; Jiang, X. L.; Pan, I.; Zeng, Q. H.; Hu, P. F.; Li, Y. H.; Fu, F. X.; Huang, R. Y.; Sebros, R.; Yu, Q. Z.; Atalay, M. K.; Liao, W. H., AI Augmentation of Radiologist Performance in Distinguishing COVID-19 from Pneumonia of Other Etiology on Chest CT. *Radiology* **2020**, 201491.
33. (U) Bai, Y.; Yao, L.; Wei, T.; Tian, F.; Jin, D.-Y.; Chen, L.; Wang, M., Presumed Asymptomatic Carrier Transmission of COVID-19. *JAMA*.
34. (U) Bao, L.; Deng, W.; Huang, B.; Gao, H.; Liu, J.; Ren, L.; Wei, Q.; Yu, P.; Xu, Y.; Qi, F.; Qu, Y.; Li, F.; Lv, Q.; Wang, W.; Xue, J.; Gong, S.; Liu, M.; Wang, G.; Wang, S.; Song, Z.; Zhao, L.; Liu, P.; Zhao, L.; Ye, F.; Wang, H.; Zhou, W.; Zhu, N.; Zhen, W.; Yu, H.; Zhang, X.; Guo, L.; Chen, L.; Wang, C.; Wang, Y.; Wang, X.; Xiao, Y.; Sun, Q.; Liu, H.; Zhu, F.; Ma, C.; Yan, L.; Yang, M.; Han, J.; Xu, W.; Tan, W.; Peng, X.; Jin, Q.; Wu, G.; Qin, C., The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. *Nature* **2020**.
35. (U) Bao, L.; Gao, H.; Deng, W.; Lv, Q.; Yu, H.; Liu, M.; Yu, P.; Liu, J.; Qu, Y.; Gong, S.; Lin, K.; Qi, F.; Xu, Y.; Li, F.; Xiao, C.; Xue, J.; Song, Z.; Xiang, Z.; Wang, G.; Wang, S.; Liu, X.; Zhao, W.; Han, Y.; Wei, Q.; Qin, C., Transmission of SARS-CoV-2 via close contact and respiratory droplets among hACE2 mice. *The Journal of Infectious Diseases* **2020**. <https://doi.org/10.1093/infdis/jiaa281>
36. (U) Barrington, L.; Cornwell, A., China's Sinopharm begins late stage trial of COVID-19 vaccine in UAE. <https://www.reuters.com/article/us-health-coronavirus-emirates-vaccine/chinas-sinopharm-begins-late-stage-trial-of-covid-19-vaccine-in-abu-dhabi-idUSKCN24H14T>.
37. (U) BBC, Coronavirus: California declares emergency after death. *BBC* 2020. <https://www.bbc.com/news/world-us-canada-51740706>
38. (U) BBCNews, Coronavirus: AstraZeneca to begin making potential vaccine. <https://www.bbc.com/news/business-52917118>.
39. (U) Bedford, T.; Neher, R., Genomic epidemiology of novel coronavirus (nCoV) using data from GISAID. <https://nextstrain.org/ncov>.
40. (U) Behzadinasab, S.; Chin, A.; Hosseini, M.; Poon, L. L. M.; Ducker, W. A., A Surface Coating that Rapidly Inactivates SARS-CoV-2. *ACS Applied Materials & Interfaces* **2020**. <https://doi.org/10.1021/acsami.0c11425>
41. (U) Beigel, J. H.; Tomashek, K. M.; Dodd, L. E.; Mehta, A. K.; Zingman, B. S.; Kalil, A. C.; Hohmann, E.; Chu, H. Y.; Luetkemeyer, A.; Kline, S.; Lopez de Castilla, D.; Finberg, R. W.; Dierberg, K.; Tapson, V.; Hsieh, L.; Patterson, T. F.; Paredes, R.; Sweeney, D. A.; Short, W. R.; Touloumi, G.; Lye, D. C.; Ohmagari, N.; Oh,

Updated 7/21/2020

- M.-d.; Ruiz-Palacios, G. M.; Benfield, T.; Fätkenheuer, G.; Kortepeter, M. G.; Atmar, R. L.; Creech, C. B.; Lundgren, J.; Babiker, A. G.; Pett, S.; Neaton, J. D.; Burgess, T. H.; Bonnett, T.; Green, M.; Makowski, M.; Osinusi, A.; Nayak, S.; Lane, H. C., Remdesivir for the Treatment of Covid-19 — Preliminary Report. *New England Journal of Medicine* **2020**. <https://www.nejm.org/doi/full/10.1056/NEJMoa2007764>
42. (U) Bendavid, E.; Mulaney, B.; Sood, N.; Shah, S.; Ling, E.; Bromley-Dulfano, R.; Lai, C.; Weissberg, Z.; Saavedra, R.; Tedrow, J.; Tversky, D.; Bogan, A.; Kupiec, T.; Eichner, D.; Gupta, R.; Ioannidis, J.; Bhattacharya, J., COVID-19 Antibody Seroprevalence in Santa Clara County, California. *medRxiv* **2020**, 2020.04.14.20062463. <https://www.medrxiv.org/content/medrxiv/early/2020/04/17/2020.04.14.20062463.full.pdf>
43. (U) Bessière, F.; Rocca, H.; Delinière, A.; Charrière, R.; Chevalier, P.; Argaud, L.; Cour, M., Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit. *JAMA Cardiology* **2020**. <https://doi.org/10.1001/jamacardio.2020.1787>
44. (U) BGI, BGI Responds to Novel Coronavirus with Real-Time Detection Kits, Deploys Emergency Team to Wuhan. 2020. <https://www.bgi.com/global/company/news/bgi-responds-to-novel-coronavirus-with-real-time-detection-kits-deploys-emergency-team-to-wuhan/>
45. (U) Bhatia, S.; al., e., Short-term forecasts of COVID-19 deaths in multiple countries. <https://mrc-ide.github.io/covid19-short-term-forecasts/index.html#introduction>.
46. (U) Bi, Q.; Wu, Y.; Mei, S.; Ye, C.; Zou, X.; Zhang, Z.; Liu, X.; Wei, L.; Truelove, S. A.; Zhang, T.; Gao, W.; Cheng, C.; Tang, X.; Wu, X.; Wu, Y.; Sun, B.; Huang, S.; Sun, Y.; Zhang, J.; Ma, T.; Lessler, J.; Feng, T., Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study. *Lancet Infect Dis* **2020**. [https://www.thelancet.com/journals/laninf/article/PIIS1473-3099\(20\)30287-5/fulltext](https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(20)30287-5/fulltext)
47. (U) Bidra, A. S.; Pelletier, J. S.; Westover, J. B.; Frank, S.; Brown, S. M.; Tessema, B., Rapid In-Vitro Inactivation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Using Povidone-Iodine Oral Antiseptic Rinse. *Journal of Prosthodontics* **2020**, n/a (n/a). <https://onlinelibrary.wiley.com/doi/abs/10.1111/jopr.13209>
48. (U) Biocon, Clinical Trial Shows Itolizumab Reduces Mortality in Patients Hospitalized with COVID-19. 2020. <https://www.globenewswire.com/news-release/2020/07/13/2060993/0/en/Clinical-Trial-Shows-Itolizumab-Reduces-Mortality-in-Patients-Hospitalized-with-COVID-19.html>
49. (U) Biotech, M., Mesa Biotech Receives Emergency Use Authorization from FDA for a 30 Minute Point of Care Molecular COVID-19 Test. Mesa Biotech: 2020. <https://www.mesabiotech.com/news/euacoronavirus>
50. (U) Biryukov, J.; Boydston, J. A.; Dunning, R. A.; Yeager, J. J.; Wood, S.; Reese, A. L.; Ferris, A.; Miller, D.; Weaver, W.; Zeitouni, N. E.; Phillips, A.; Freeburger, D.; Hooper, I.; Ratnesar-Shumate, S.; Yolitz, J.; Krause, M.; Williams, G.; Dawson, D. G.; Herzog, A.; Dabisch, P.; Wahl, V.; Hevey, M. C.; Altamura, L. A., Increasing Temperature and Relative Humidity Accelerates Inactivation of SARS-CoV-2 on Surfaces. *mSphere* **2020**, 5 (4), e00441-20. <https://msphere.asm.org/content/msph/5/4/e00441-20.full.pdf>
51. (U) Blair, R. V.; Vaccari, M.; Doyle-Meyers, L. A.; Roy, C. J.; Russell-Lodrigue, K.; Fahlberg, M.; Monjure, C. J.; Beddingfield, B.; Plante, K. S.; Plante, J. A.; Weaver, S. C.; Qin, X.; Midkiff, C. C.; Lehmicke, G.; Golden, N.; Threeton, B.; Penney, T.; Allers, C.; Barnes, M. B.; Pattison, M.; Datta, P. K.; Maness, N. J.; Birnbaum, A.; Bohm, R. P.; Rappaport, J., ARDS and Cytokine Storm in SARS-CoV-2 Infected Caribbean Vervets. *bioRxiv* **2020**, 2020.06.18.157933. <http://biorxiv.org/content/early/2020/06/19/2020.06.18.157933.abstract>
52. (U) Böhmer, M. M.; Buchholz, U.; Corman, V. M.; Hoch, M.; Katz, K.; Marosevic, D. V.; Böhm, S.; Woudenberg, T.; Ackermann, N.; Konrad, R.; Eberle, U.; Treis, B.; Dangel, A.; Bengs, K.; Fingerle, V.; Berger, A.; Hörmansdorfer, S.; Ippisch, S.; Wicklein, B.; Grahl, A.; Pörtner, K.; Müller, N.; Zeitlmann, N.; Boender, T. S.; Cai, W.; Reich, A.; An der Heiden, M.; Rexroth, U.; Hamouda, O.; Schneider, J.; Veith, T.;

Updated 7/21/2020

Mühlemann, B.; Wölfel, R.; Antwerpen, M.; Walter, M.; Protzer, U.; Liebl, B.; Haas, W.; Sing, A.; Drosten, C.; Zapf, A., Investigation of a COVID-19 outbreak in Germany resulting from a single travel-associated primary case: a case series. *The Lancet. Infectious diseases* **2020**, S1473-3099(20)30314-5.

<https://pubmed.ncbi.nlm.nih.gov/32422201>

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7228725/>

53. (U) Borba, M. G. S.; Val, F. F. A.; Sampaio, V. S.; Alexandre, M. A. A.; Melo, G. C.; Brito, M.; Mourão, M. P. G.; Brito-Sousa, J. D.; Baía-da-Silva, D.; Guerra, M. V. F.; Hajjar, L. A.; Pinto, R. C.; Balieiro, A. A. S.; Pacheco, A. G. F.; Santos, J. D. O., Jr; Naveca, F. G.; Xavier, M. S.; Siqueira, A. M.; Schwarzbald, A.; Croda, J.; Nogueira, M. L.; Romero, G. A. S.; Bassat, Q.; Fontes, C. J.; Albuquerque, B. C.; Daniel-Ribeiro, C.-T.; Monteiro, W. M.; Lacerda, M. V. G.; Team, f. t. C.-. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. *JAMA Network Open* **2020**, 3 (4), e208857-e208857. <https://doi.org/10.1001/jamanetworkopen.2020.8857>

54. (U) Bosco-Lauth, A. M.; Hartwig, A. E.; Porter, S. M.; Gordy, P. W.; Nehring, M.; Byas, A. D.; VandeWoude, S.; Ragan, I. K.; Maison, R. M.; Bowen, R. A., Pathogenesis, transmission and response to re-exposure of SARS-CoV-2 in domestic cats. *bioRxiv* **2020**, 2020.05.28.120998.

<http://biorxiv.org/content/early/2020/05/29/2020.05.28.120998.abstract>

55. (U) Bouaziz, J.; Duong, T.; Jachiet, M.; Velter, C.; Lestang, P.; Cassius, C.; Arsouze, A.; Domergue Than Trong, E.; Bagot, M.; Begon, E.; Sulimovic, L.; Rybojad, M., Vascular skin symptoms in COVID-19: a french observational study. *Journal of the European Academy of Dermatology and Venereology n/a* (n/a).

<https://onlinelibrary.wiley.com/doi/abs/10.1111/jdv.16544>

56. (U) Boulware, D. R.; Pullen, M. F.; Bangdiwala, A. S.; Pastick, K. A.; Lofgren, S. M.; Okafor, E. C.; Skipper, C. P.; Nascene, A. A.; Nicol, M. R.; Abassi, M.; Engen, N. W.; Cheng, M. P.; LaBar, D.; Lother, S. A.; MacKenzie, L. J.; Drobot, G.; Marten, N.; Zarychanski, R.; Kelly, L. E.; Schwartz, I. S.; McDonald, E. G.; Rajasingham, R.; Lee, T. C.; Hullsiek, K. H., A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. *New England Journal of Medicine* **2020**.

<https://www.nejm.org/doi/full/10.1056/NEJMoa2016638>

57. (U) Braun, J.; Loyal, L.; Frentsch, M.; Wendisch, D.; Georg, P.; Kurth, F.; Hippenstiel, S.; Dingeldey, M.; Kruse, B.; Fauchere, F.; Baysal, E.; Mangold, M.; Henze, L.; Lauster, R.; Mall, M.; Beyer, K.; Roehmel, J.; Schmitz, J.; Miltenyi, S.; Mueller, M. A.; Witzenrath, M.; Suttorp, N.; Kern, F.; Reimer, U.; Wenschuh, H.; Drosten, C.; Corman, V. M.; Giesecke-Thiel, C.; Sander, L.-E.; Thiel, A., Presence of SARS-CoV-2 reactive T cells in COVID-19 patients and healthy donors. *medRxiv* **2020**, 2020.04.17.20061440.

<https://www.medrxiv.org/content/medrxiv/early/2020/04/22/2020.04.17.20061440.full.pdf>

58. (U) Brennan, Z., FDA issues 2nd EUA for decontamination system for N95 masks. *Regulatory Focus* **2020**. <https://www.raps.org/news-and-articles/news-articles/2020/4/fda-issues-2nd-eua-for-decontamination-system-for>

59. (U) Brocato, R.; Principe, L.; Kim, R.; Zeng, X.; Williams, J.; Liu, Y.; Li, R.; Smith, J.; Golden, J.; Gangemi, D.; Youssef, S.; Wang, Z.; Glanville, J.; Hooper, J., Disruption of Adaptive Immunity Enhances Disease in SARS-CoV-2 Infected Syrian Hamsters. *bioRxiv* **2020**, 2020.06.19.161612.

<http://biorxiv.org/content/early/2020/06/19/2020.06.19.161612.abstract>

60. (U) Brosseau, L. M., COMMENTARY: COVID-19 transmission messages should hinge on science.

<http://www.cidrap.umn.edu/news-perspective/2020/03/commentary-covid-19-transmission-messages-should-hinge-science>.

61. (U) Brosseau, L. M.; Jones, R., Commentary: Protecting health workers from airborne MERS-CoV - learning from SARS. <http://www.cidrap.umn.edu/news-perspective/2014/05/commentary-protecting-health-workers-airborne-mers-cov-learning-sars>.

62. (U) Bryner, J., First US infant death linked to COVID-19 reported in Illinois. *LiveScience* 2020. <https://www.livescience.com/us-infant-dies-coronavirus.html>
63. (U) Burbelo, P. D.; Riedo, F. X.; Morishima, C.; Rawlings, S.; Smith, D.; Das, S.; Strich, J. R.; Chertow, D. S.; Davey, R. T.; Cohen, J. I., Detection of Nucleocapsid Antibody to SARS-CoV-2 is More Sensitive than Antibody to Spike Protein in COVID-19 Patients. *J Infect Dis* **2020**.
64. (U) Burke, R. M., Active monitoring of persons exposed to patients with confirmed COVID-19—United States, January–February 2020. *MMWR. Morbidity and mortality weekly report* **2020**, *69*.
65. (U) Burrer, S. L.; de Perio, M. A.; Hughes, M. M.; Kuhar, D. T.; Luckhaupt, S. E.; McDaniel, C. J.; Porter, R. M.; Silk, B.; Stuckey, M. J.; Walters, M., Characteristics of health care personnel with COVID-19—United States, February 12–April 9, 2020. **2020**.
66. (U) Byambasuren, O.; Cardona, M.; Bell, K.; Clark, J.; McLaws, M.-L.; Glasziou, P., Estimating the extent of true asymptomatic COVID-19 and its potential for community transmission: systematic review and meta-analysis. Available at SSRN 3586675 **2020**.
67. (U) Cagliani, R.; Forni, D.; Clerici, M.; Sironi, M., Computational inference of selection underlying the evolution of the novel coronavirus, SARS-CoV-2. *Journal of Virology* **2020**, JVI.00411-20. <https://jvi.asm.org/content/jvi/early/2020/03/27/JVI.00411-20.full.pdf>
68. (U) Cagliani, R.; Forni, D.; Clerici, M.; Sironi, M., Computational inference of selection underlying the evolution of the novel coronavirus, SARS-CoV-2. *J Virol* **2020**.
69. (U) Callow, K.; Parry, H.; Sergeant, M.; Tyrrell, D., The time course of the immune response to experimental coronavirus infection of man. *Epidemiology & Infection* **1990**, *105* (2), 435-446.
70. (U) Cantini, F.; Niccoli, L.; Nannini, C.; Matarrese, D.; Natale, M. E. D.; Lotti, P.; Aquilini, D.; Landini, G.; Cimolato, B.; Pietro, M. A. D.; Trezzi, M.; Stobbione, P.; Frausini, G.; Navarra, A.; Nicastrì, E.; Sotgiu, G.; Goletti, D., Retrospective, multicenter study on the impact of baricitinib in COVID-19 moderate pneumonia. *J Infect* **2020**.
71. (U) Cao, B.; Wang, Y.; Wen, D.; Liu, W.; Wang, J.; Fan, G.; Ruan, L.; Song, B.; Cai, Y.; Wei, M.; Li, X.; Xia, J.; Chen, N.; Xiang, J.; Yu, T.; Bai, T.; Xie, X.; Zhang, L.; Li, C.; Yuan, Y.; Chen, H.; Li, H.; Huang, H.; Tu, S.; Gong, F.; Liu, Y.; Wei, Y.; Dong, C.; Zhou, F.; Gu, X.; Xu, J.; Liu, Z.; Zhang, Y.; Li, H.; Shang, L.; Wang, K.; Li, K.; Zhou, X.; Dong, X.; Qu, Z.; Lu, S.; Hu, X.; Ruan, S.; Luo, S.; Wu, J.; Peng, L.; Cheng, F.; Pan, L.; Zou, J.; Jia, C.; Wang, J.; Liu, X.; Wang, S.; Wu, X.; Ge, Q.; He, J.; Zhan, H.; Qiu, F.; Guo, L.; Huang, C.; Jaki, T.; Hayden, F. G.; Horby, P. W.; Zhang, D.; Wang, C., A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. *New England Journal of Medicine* **2020**. <https://www.nejm.org/doi/full/10.1056/NEJMoa2001282>
72. (U) Cao, W.; Liu, X.; Bai, T.; Fan, H.; Hong, K.; Song, H.; Han, Y.; Lin, L.; Ruan, L.; Li, T., High-dose intravenous immunoglobulin as a therapeutic option for deteriorating patients with Coronavirus Disease 2019. *Open Forum Infectious Diseases* **2020**. <https://doi.org/10.1093/ofid/ofaa102>
73. (U) Cao, Y.; Wei, J.; Zou, L.; Jiang, T.; Wang, G.; Chen, L.; Huang, L.; Meng, F.; Huang, L.; Wang, N.; Zhou, X.; Luo, H.; Mao, Z.; Chen, X.; Xie, J.; Liu, J.; Cheng, H.; Zhao, J.; Huang, G.; Wang, W.; Zhou, J., Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial. *Journal of Allergy and Clinical Immunology* **2020**. <http://www.sciencedirect.com/science/article/pii/S0091674920307387>
74. (U) Carfi, A.; Bernabei, R.; Landi, F.; Group, f. t. G. A. C.-P.-A. C. S., Persistent Symptoms in Patients After Acute COVID-19. *JAMA* **2020**. <https://doi.org/10.1001/jama.2020.12603>
75. (U) Casadevall, A.; Pirofski, L.-a., The convalescent sera option for containing COVID-19. *The Journal of Clinical Investigation* **2020**, *130* (4). <https://doi.org/10.1172/JCI138003>
76. (U) Casey, M.; Griffin, J.; McAloon, C. G.; Byrne, A. W.; Madden, J. M.; McEvoy, D.; Collins, A. B.; Hunt, K.; Barber, A.; Butler, F.; Lane, E. A.; O'Brien, K.; Wall, P.; Walsh, K. A.; More, S. J., Estimating pre-symptomatic transmission of COVID-19: a secondary analysis using published data. *medRxiv* **2020**,

2020.05.08.20094870.

<https://www.medrxiv.org/content/medrxiv/early/2020/05/11/2020.05.08.20094870.full.pdf>

77. (U) CDC, 2019 Novel Coronavirus RT-PCR Identification Protocols.

<https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-detection-instructions.html>.

78. (U) CDC, CDC launches national viral genomics consortium to better map SARS-CoV-2 transmission.

Centers for Disease Control and Prevention: 2020. <https://www.cdc.gov/media/releases/2020/p0501-SARS-CoV-2-transmission-map.html>

79. (U) CDC, Confirmation of COVID-19 in Two Pet Cats in New York. Centers for Disease Control and Prevention: 2020. <https://www.cdc.gov/media/releases/2020/s0422-covid-19-cats-NYC.html>

80. (U) CDC, Confirmed 2019-nCoV Cases Globally. <https://www.cdc.gov/coronavirus/2019-ncov/locations-confirmed-cases.html>.

81. (U) CDC, COVID-19 Forecasts. <https://www.cdc.gov/coronavirus/2019-ncov/covid-data/forecasting-us.html>.

82. (U) CDC, COVIDview. <https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/index.html>.

83. (U) CDC, Interim healthcare infection prevention and control recommendations for patients under investigation for 2019 novel coronavirus. <https://www.cdc.gov/coronavirus/2019-ncov/infection-control.html>.

84. (U) CDC, Recommendation Regarding the Use of Cloth Face Coverings, Especially in Areas of Significant Community-Based Transmission. 2020. <https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/cloth-face-cover.html>

85. (U) CDC, Situation summary. <https://www.cdc.gov/coronavirus/2019-nCoV/summary.html>.

86. (U) CDC, Symptoms of Coronavirus. <https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html>.

87. (U) CDC, C., China's CDC detects a large number of new coronaviruses in the South China seafood market in Wuhan [http://www.chinacdc.cn/yw\\_9324/202001/t20200127\\_211469.html](http://www.chinacdc.cn/yw_9324/202001/t20200127_211469.html) (accessed 01/27/2020).

88. (U) CEID, Nowcasts for the US, states, and territories. <http://2019-coronavirus-tracker.com/nowcast.html>.

89. (U) Ceraolo, C.; Giorgi, F. M., Genomic variance of the 2019-nCoV coronavirus. *J Med Virol* **2020**, *92* (5), 522-528.

90. (U) Chan, J. F.-W.; Yuan, S.; Kok, K.-H.; To, K. K.-W.; Chu, H.; Yang, J.; Xing, F.; Liu, J.; Yip, C. C.-Y.; Poon, R. W.-S.; Tsoi, H.-W.; Lo, S. K.-F.; Chan, K.-H.; Poon, V. K.-M.; Chan, W.-M.; Ip, J. D.; Cai, J.-P.; Cheng, V. C.-C.; Chen, H.; Hui, C. K.-M.; Yuen, K.-Y., A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. *The Lancet* **2020**. <https://www.sciencedirect.com/science/article/pii/S0140673620301549>

91. (U) Chan, J. F.; Zhang, A. J.; Yuan, S.; Poon, V. K.; Chan, C. C.; Lee, A. C.; Chan, W. M.; Fan, Z.; Tsoi, H. W.; Wen, L.; Liang, R.; Cao, J.; Chen, Y.; Tang, K.; Luo, C.; Cai, J. P.; Kok, K. H.; Chu, H.; Chan, K. H.; Sridhar, S.; Chen, Z.; Chen, H.; To, K. K.; Yuen, K. Y., Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility. *Clin Infect Dis* **2020**. <https://www.ncbi.nlm.nih.gov/pubmed/32215622>

92. (U) Chandrashekar, A.; Liu, J.; Martinot, A. J.; McMahan, K.; Mercado, N. B.; Peter, L.; Tostanoski, L. H.; Yu, J.; Maliga, Z.; Nekorchuk, M.; Busman-Sahay, K.; Terry, M.; Wrijil, L. M.; Ducat, S.; Martinez, D. R.; Atyeo, C.; Fischinger, S.; Burke, J. S.; Slein, M. D.; Pessaint, L.; Van Ry, A.; Greenhouse, J.; Taylor, T.; Blade, K.; Cook, A.; Finneyfrock, B.; Brown, R.; Teow, E.; Velasco, J.; Zahn, R.; Wegmann, F.; Abbink, P.; Bondzie, E. A.; Dagotto, G.; Gebre, M. S.; He, X.; Jacob-Dolan, C.; Kordana, N.; Li, Z.; Lifton, M. A.; Mahrokhian, S. H.; Maxfield, L. F.; Nityanandam, R.; Nkolola, J. P.; Schmidt, A. G.; Miller, A. D.; Baric, R.

- S.; Alter, G.; Sorger, P. K.; Estes, J. D.; Andersen, H.; Lewis, M. G.; Barouch, D. H., SARS-CoV-2 infection protects against rechallenge in rhesus macaques. *Science* **2020**, eabc4776.  
<https://science.sciencemag.org/content/sci/early/2020/05/19/science.abc4776.full.pdf>
93. (U) Changzheng, L. J. L., Experts in the medical treatment team: Wuhan's unexplained viral pneumonia patients can be controlled more. <https://www.cn-healthcare.com/article/20200110/content-528579.html>.
94. (U) Chen, C.-P.; Lin, Y.-C.; Chen, T.-C.; Tseng, T.-Y.; Wong, H.-L.; Kuo, C.-Y.; Lin, W.-P.; Huang, S.-R.; Wang, W.-Y.; Liao, J.-H.; Liao, C.-S.; Hung, Y.-P.; Lin, T.-H.; Chang, T.-Y.; Hsiao, C.-F.; Huang, Y.-W.; Chung, W.-S.; Cheng, C.-Y.; Cheng, S.-H., A Multicenter, randomized, open-label, controlled trial to evaluate the efficacy and tolerability of hydroxychloroquine and a retrospective study in adult patients with mild to moderate Coronavirus disease 2019 (COVID-19). *medRxiv* **2020**, 2020.07.08.20148841.  
<http://medrxiv.org/content/early/2020/07/10/2020.07.08.20148841.abstract>
95. (U) Chen, C.; Cao, M.; Peng, L.; Guo, X.; Yang, F.; Wu, W.; Chen, L.; Yang, Y.; Liu, Y.; Wang, F., Coronavirus Disease-19 Among Children Outside Wuhan, China. *SSRN* **2020**.  
[https://papers.ssrn.com/sol3/papers.cfm?abstract\\_id=3546071](https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3546071)
96. (U) Chen, C.; Huang, J.; Cheng, Z.; Wu, J.; Chen, S.; Zhang, Y.; Chen, B.; Lu, M.; Luo, Y.; Zhang, J.; Yin, P.; Wang, X., Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. *medRxiv* **2020**, 2020.03.17.20037432.  
<https://www.medrxiv.org/content/medrxiv/early/2020/03/20/2020.03.17.20037432.full.pdf>
97. (U) Chen, H.; Guo, J.; Wang, C.; Luo, F.; Yu, X.; Zhang, W.; Li, J.; Zhao, D.; Xu, D.; Gong, Q., Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. *The Lancet* **2020**, 395 (10226), 809-815.
98. (U) Chen, J. H.-K.; Yip, C. C.-Y.; Poon, R. W.-S.; Chan, K.-H.; Cheng, V. C.-C.; Hung, I. F.-N.; Chan, J. F.-W.; Yuen, K.-Y.; To, K. K.-W., Evaluating the use of posterior oropharyngeal saliva in a point-of-care assay for the detection of SARS-CoV-2. *Emerging Microbes & Infections* **2020**, 1-14.  
<https://doi.org/10.1080/22221751.2020.1775133>
99. (U) CHEN Jun, L. D., LIU Li, LIU Ping, XU Qingnian, XIA Lu, LING Yun, HUANG Dan, SONG Shuli, ZHANG Dandan, QIAN Zhiping, LI Tao, SHEN Yinzong, LU Hongzhou, A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19. *J Zhejiang Univ (Med Sci)* **2020**, 49 (2), 215-219.  
<http://www.zjujournals.com/med/EN/10.3785/j.issn.1008-9292.2020.03.03>
100. (U) Chen, L.; Li, Q.; Zheng, D.; Jiang, H.; Wei, Y.; Zou, L.; Feng, L.; Xiong, G.; Sun, G.; Wang, H.; Zhao, Y.; Qiao, J., Clinical Characteristics of Pregnant Women with Covid-19 in Wuhan, China. *New England Journal of Medicine* **2020**. <https://www.nejm.org/doi/full/10.1056/NEJMc2009226>
101. (U) Chen, N.; Zhou, M.; Dong, X.; Qu, J.; Gong, F.; Han, Y.; Qiu, Y.; Wang, J.; Liu, Y.; Wei, Y.; Xia, J.; Yu, T.; Zhang, X.; Zhang, L., Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet* **2020**.  
<https://www.ncbi.nlm.nih.gov/pubmed/32007143>
102. (U) Chen, Y.; Peng, H.; Wang, L.; Zhao, Y.; Zeng, L.; Gao, H.; Liu, Y., Infants Born to Mothers With a New Coronavirus (COVID-19). *Frontiers in Pediatrics* **2020**, 8 (104).  
<https://www.frontiersin.org/article/10.3389/fped.2020.00104>
103. (U) Chen, Z.; Hu, J.; Zhang, Z.; Jiang, S.; Han, S.; Yan, D.; Zhuang, R.; Hu, B.; Zhang, Z., Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. *medRxiv* **2020**, 2020.03.22.20040758.  
<https://www.medrxiv.org/content/medrxiv/early/2020/04/10/2020.03.22.20040758.full.pdf>
104. (U) Cheng, H.-Y.; Jian, S.-W.; Liu, D.-P.; Ng, T.-C.; Huang, W.-T.; Lin, H.-H.; Team, f. t. T. C.-O. I., Contact Tracing Assessment of COVID-19 Transmission Dynamics in Taiwan and Risk at Different Exposure Periods Before and After Symptom Onset. *JAMA Internal Medicine* **2020**.  
<https://doi.org/10.1001/jamainternmed.2020.2020>

105. (U) Cheruiyot, I.; Henry, B. M.; Lippi, G., Is there evidence of intra-uterine vertical transmission potential of COVID-19 infection in samples tested by quantitative RT-PCR? *Eur J Obstet Gynecol Reprod Biol* **2020**.
106. (U) Chhatwal, J.; Ayer, T.; Linas, B. P. D., O. O.; Mueller, P.; Adey, M.; Ladd, M. A.; Xiao, J. Y. X., COVID-19. <https://www.covid19sim.org/>.
107. (U) Chicago, Forecasting for Illinois SARS-CoV-2 model. [https://github.com/cobeylab/covid\\_IL/tree/master/Forecasting](https://github.com/cobeylab/covid_IL/tree/master/Forecasting).
108. (U) Chin, A.; Chu, J.; Perera, M.; Hui, K.; Yen, H.-L.; Chan, M.; Peiris, M.; Poon, L., Stability of SARS-CoV-2 in different environmental conditions. *medRxiv* **2020**, 2020.03.15.20036673. <https://www.medrxiv.org/content/medrxiv/early/2020/03/27/2020.03.15.20036673.full.pdf>
109. (U) Chin, A. W. H.; Chu, J. T. S.; Perera, M. R. A.; Hui, K. P. Y.; Yen, H.-L.; Chan, M. C. W.; Peiris, M.; Poon, L. L. M., Stability of SARS-CoV-2 in different environmental conditions. *The Lancet Microbe*. [https://doi.org/10.1016/S2666-5247\(20\)30003-3](https://doi.org/10.1016/S2666-5247(20)30003-3)
110. (U) Chong, V. H.; Chong, P. L.; Metussin, D.; Asli, R.; Momin, R. N.; Mani, B. I.; Abdullah, M. S., Conduction abnormalities in hydroxychloroquine add on therapy to lopinavir/ritonavir in COVID-19. *J Med Virol* **2020**.
111. (U) Chu, D. K.; Akl, E. A.; Duda, S.; Solo, K.; Yaacoub, S.; Schünemann, H. J.; Chu, D. K.; Akl, E. A.; El-harakeh, A.; Bognanni, A.; Lotfi, T.; Loeb, M.; Hajizadeh, A.; Bak, A.; Izcovich, A.; Cuello-Garcia, C. A.; Chen, C.; Harris, D. J.; Borowiack, E.; Chamseddine, F.; Schünemann, F.; Morgano, G. P.; Muti Schünemann, G. E. U.; Chen, G.; Zhao, H.; Neumann, I.; Chan, J.; Khabisa, J.; Hneiny, L.; Harrison, L.; Smith, M.; Rizk, N.; Giorgi Rossi, P.; AbiHanna, P.; El-khoury, R.; Stalteri, R.; Baldeh, T.; Piggott, T.; Zhang, Y.; Saad, Z.; Khamis, A.; Reinap, M.; Duda, S.; Solo, K.; Yaacoub, S.; Schünemann, H. J., Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. *The Lancet* **2020**. [https://doi.org/10.1016/S0140-6736\(20\)31142-9](https://doi.org/10.1016/S0140-6736(20)31142-9)
112. (U) Chughtai, A. A.; Seale, H.; MacIntyre, C. R., Use of cloth masks in the practice of infection control—evidence and policy gaps. *Int J Infect Control* **2013**, *9* (3), doi: 10.3396/IJIC.v9i3.020.13.
113. (U) Cockrell, A. S.; Yount, B. L.; Scobey, T.; Jensen, K.; Douglas, M.; Beall, A.; Tang, X.-C.; Marasco, W. A.; Heise, M. T.; Baric, R. S., A mouse model for MERS coronavirus-induced acute respiratory distress syndrome. *Nature microbiology* **2016**, *2* (2), 1-11.
114. (U) Cohen, J., Mining coronavirus genomes for clues to the outbreak's origins. *Science* **2020**. <https://www.sciencemag.org/news/2020/01/mining-coronavirus-genomes-clues-outbreak-s-origins>
115. (U) Cohen, J., Wuhan seafood market may not be source of novel virus spreading globally. <https://www.sciencemag.org/news/2020/01/wuhan-seafood-market-may-not-be-source-novel-virus-spreading-globally> (accessed 01/27/2020).
116. (U) Control, E. E. C. f. D. P. a., *Interim guidance for environmental cleaning in non-healthcare facilities exposed to SARS-CoV-2*; European Centre for Disease Prevention and Control: European Centre for Disease Prevention and Control, 2020. <https://www.ecdc.europa.eu/en/publications-data/interim-guidance-environmental-cleaning-non-healthcare-facilities-exposed-2019#no-link>
117. (U) Corman, V. M.; Landt, O.; Kaiser, M.; Molenkamp, R.; Meijer, A.; Chu, D. K.; Bleicker, T.; Brunink, S.; Schneider, J.; Schmidt, M. L.; Mulders, D. G.; Haagmans, B. L.; van der Veer, B.; van den Brink, S.; Wijsman, L.; Goderski, G.; Romette, J. L.; Ellis, J.; Zambon, M.; Peiris, M.; Goossens, H.; Reusken, C.; Koopmans, M. P.; Drosten, C., Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Euro Surveill* **2020**, *25* (3). <https://www.ncbi.nlm.nih.gov/pubmed/31992387>
118. (U) Corral, L.; Bahamonde, A.; Arnaiz delas Revillas, F.; Gomez-Barquero, J.; Abadia-Otero, J.; Garcia-Ibarbia, C.; Mora, V.; cerezo-hernandez, A.; Hernandez, J. L.; Lopez-Muniz, G.; Hernandez-Blanco, F.; Cifrian, J. M.; Olmos, J. M.; Carrascosa, M.; farinas, m. C.; Riancho, J. A., GLUCOCOVID: A controlled

- trial of methylprednisolone in adults hospitalized with COVID-19 pneumonia. *medRxiv* **2020**, 2020.06.17.20133579. <http://medrxiv.org/content/early/2020/06/18/2020.06.17.20133579.abstract>
119. (U) Courtemanche, C.; Garuccio, J.; Le, A.; Pinkston, J.; Yelowitz, A., Strong Social Distancing Measures In The United States Reduced The COVID-19 Growth Rate. *Health Affairs* **2020**, 10.1377/hlthaff.2020.00608. <https://doi.org/10.1377/hlthaff.2020.00608>
120. (U) Coutard, B.; Valle, C.; de Lamballerie, X.; Canard, B.; Seidah, N.; Decroly, E., The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. *Antiviral research* **2020**, 176, 104742.
121. (U) Cowling, B. J.; Ali, S. T.; Ng, T. W. Y.; Tsang, T. K.; Li, J. C. M.; Fong, M. W.; Liao, Q.; Kwan, M. Y.; Lee, S. L.; Chiu, S. S.; Wu, J. T.; Wu, P.; Leung, G. M., Impact assessment of non-pharmaceutical interventions against COVID-19 and influenza in Hong Kong: an observational study. *medRxiv* **2020**, 2020.03.12.20034660. <https://www.medrxiv.org/content/medrxiv/early/2020/03/16/2020.03.12.20034660.full.pdf>
122. (U) Creel-Bulos, C.; Hockstein, M.; Amin, N.; Melhem, S.; Truong, A.; Sharifpour, M., Acute Cor Pulmonale in Critically Ill Patients with Covid-19. *New England Journal of Medicine* **2020**, e70. <https://www.nejm.org/doi/full/10.1056/NEJMc2010459>
123. (U) CureVac, A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults. <https://clinicaltrials.gov/ct2/show/NCT04449276?term=Curevac&draw=2&rank=2>.
124. (U) Czeisler, M. E.; Tynan, M. A.; Howard, M. E.; al., e., Public Attitudes, Behaviors, and Beliefs Related to COVID-19, Stay-at-Home Orders, Nonessential Business Closures, and Public Health Guidance — United States, New York City, and Los Angeles, May 5–12, 2020. *Morbidity and Mortality Weekly Report* **2020**, 12 June 2020. <https://www.cdc.gov/mmwr/volumes/69/wr/mm6924e1.htm#suggestedcitation>
125. (U) Daily, H., Wuhan Institute of Virology, Chinese Academy of Sciences and others have found that 3 drugs have a good inhibitory effect on new coronavirus. Chen, L., Ed. 2020. [http://news.cnhubei.com/content/2020-01/28/content\\_12656365.html](http://news.cnhubei.com/content/2020-01/28/content_12656365.html)
126. (U) Dandekar, R.; Barbastathis, G., Neural Network aided quarantine control model estimation of global Covid-19 spread. *arXiv preprint arXiv:2004.02752* **2020**.
127. (U) Dato, V. M.; Hostler, D.; Hahn, M. E., Simple respiratory mask. *Emerg Infect Dis* **2006**, 12 (6), 1033-4. <https://www.ncbi.nlm.nih.gov/pubmed/16752475>
128. (U) Davies, A.; Thompson, K. A.; Giri, K.; Kafatos, G.; Walker, J.; Bennett, A., Testing the efficacy of homemade masks: would they protect in an influenza pandemic? *Disaster Med Public Health Prep* **2013**, 7 (4), 413-8. <https://www.ncbi.nlm.nih.gov/pubmed/24229526>
129. (U) Davoudi-Monfared, E.; Rahmani, H.; Khalili, H.; Hajiabdolbaghi, M.; Salehi, M.; Abbasian, L.; Kazemzadeh, H.; Yekaninejad, M. S., Efficacy and safety of interferon beta-1a in treatment of severe COVID-19: A randomized clinical trial. *medRxiv* **2020**, 2020.05.28.20116467. <https://www.medrxiv.org/content/medrxiv/early/2020/05/30/2020.05.28.20116467.full.pdf>
130. (U) De Albuquerque, N.; Baig, E.; Ma, X.; Zhang, J.; He, W.; Rowe, A.; Habal, M.; Liu, M.; Shalev, I.; Downey, G. P.; Gorczynski, R.; Butany, J.; Leibowitz, J.; Weiss, S. R.; McGilvray, I. D.; Phillips, M. J.; Fish, E. N.; Levy, G. A., Murine hepatitis virus strain 1 produces a clinically relevant model of severe acute respiratory syndrome in A/J mice. *J Virol* **2006**, 80 (21), 10382-94. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1641767/pdf/0747-06.pdf>
131. (U) de Haan, C. A. M.; Haijema, B. J.; Schellen, P.; Schreur, P. W.; te Lintelo, E.; Vennema, H.; Rottier, P. J. M., Cleavage of Group 1 Coronavirus Spike Proteins: How Furin Cleavage Is Traded Off against Heparan Sulfate Binding upon Cell Culture Adaptation. *Journal of Virology* **2008**, 82 (12), 6078-6083. <https://jvi.asm.org/content/jvi/82/12/6078.full.pdf>



132. (U) Dediego, M. L.; Pewe, L.; Alvarez, E.; Rejas, M. T.; Perlman, S.; Enjuanes, L., Pathogenicity of severe acute respiratory coronavirus deletion mutants in hACE-2 transgenic mice. *Virology* **2008**, 376 (2), 379-389. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2810402/>
133. (U) Degesys, N. F.; Wang, R. C.; Kwan, E.; Fahimi, J.; Noble, J. A.; Raven, M. C., Correlation Between N95 Extended Use and Reuse and Fit Failure in an Emergency Department. *JAMA* **2020**.  
<https://doi.org/10.1001/jama.2020.9843>
134. (U) Deng, C., China to Fast-Track Coronavirus Vaccine Trial Based on Advanced Genetics Technology <https://www.wsj.com/articles/china-to-fast-track-coronavirus-vaccine-trial-based-on-advanced-genetics-technology-11593180841>.
135. (U) Deng, W.; Bao, L.; Gao, H.; Xiang, Z.; Qu, Y.; Song, Z.; Gong, S.; Liu, J.; Liu, J.; Yu, P.; Qi, F.; Xu, Y.; Li, F.; Xiao, C.; Lv, Q.; Xue, J.; Wei, Q.; Liu, M.; Wang, G.; Wang, S.; Yu, H.; Liu, X.; Zhao, W.; Han, Y.; Qin, C., Ocular conjunctival inoculation of SARS-CoV-2 can cause mild COVID-19 in Rhesus macaques. *bioRxiv* **2020**.
136. (U) Deng, W.; Bao, L.; Liu, J.; Xiao, C.; Liu, J.; Xue, J.; Lv, Q.; Qi, F.; Gao, H.; Yu, P.; Xu, Y.; Qu, Y.; Li, F.; Xiang, Z.; Yu, H.; Gong, S.; Liu, M.; Wang, G.; Wang, S.; Song, Z.; Liu, Y.; Zhao, W.; Han, Y.; Zhao, L.; Liu, X.; Wei, Q.; Qin, C., Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques. *Science* **2020**, eabc5343.  
<https://science.sciencemag.org/content/sci/early/2020/07/01/science.abc5343.full.pdf>
137. (U) Deng, X.; Gu, W.; Federman, S.; du Plessis, L.; Pybus, O. G.; Faria, N.; Wang, C.; Yu, G.; Bushnell, B.; Pan, C.-Y.; Guevara, H.; Sotomayor-Gonzalez, A.; Zorn, K.; Gopez, A.; Servellita, V.; Hsu, E.; Miller, S.; Bedford, T.; Greninger, A. L.; Roychoudhury, P.; Starita, L. M.; Famulare, M.; Chu, H. Y.; Shendure, J.; Jerome, K. R.; Anderson, C.; Gangavarapu, K.; Zeller, M.; Spencer, E.; Andersen, K. G.; MacCannell, D.; Paden, C. R.; Li, Y.; Zhang, J.; Tong, S.; Armstrong, G.; Morrow, S.; Willis, M.; Matyas, B. T.; Mase, S.; Kasirye, O.; Park, M.; Masinde, G.; Chan, C.; Yu, A. T.; Chai, S. J.; Villarino, E.; Bonin, B.; Wadford, D. A.; Chiu, C. Y., Genomic surveillance reveals multiple introductions of SARS-CoV-2 into Northern California. *Science* **2020**, eabb9263.  
<https://science.sciencemag.org/content/sci/early/2020/06/05/science.abb9263.full.pdf>
138. (U) Deslandes, A.; Berti, V.; Tandjaoui-Lambotte, Y.; Alloui, C.; Carbonnelle, E.; Zahar, J. R.; Briclher, S.; Cohen, Y., SARS-CoV-2 was already spreading in France in late December 2019. *International Journal of Antimicrobial Agents* **2020**, 106006.  
<http://www.sciencedirect.com/science/article/pii/S0924857920301643>
139. (U) DHS, Estimated Airborne Decay of SARS-CoV-2. <https://www.dhs.gov/science-and-technology/sars-airborne-calculator>.
140. (U) DHS, Estimated Natural Decay of SARS-CoV-2 (virus that causes COVID-19) on surfaces under a range of temperatures and relative humidity. <https://www.dhs.gov/science-and-technology/sars-calculator>.
141. (U) Dong, N.; Yang, X.; Ye, L.; Chen, K.; Chan, E. W.-C.; Yang, M.; Chen, S., Genomic and protein structure modelling analysis depicts the origin and infectivity of 2019-nCoV, a new coronavirus which caused a pneumonia outbreak in Wuhan, China. *bioRxiv* **2020**, 2020.01.20.913368.  
<https://www.biorxiv.org/content/biorxiv/early/2020/01/22/2020.01.20.913368.full.pdf>
142. (U) Dong, Y.; Mo, X.; Hu, Y.; Qi, X.; Jiang, F.; Jiang, Z.; Tong, S., Epidemiological Characteristics of 2143 Pediatric Patients With 2019 Coronavirus Disease in China. *Pediatrics* **2020**, e20200702.  
<https://pediatrics.aappublications.org/content/pediatrics/early/2020/03/16/peds.2020-0702.full.pdf>
143. (U) Du, Z.; Xu, X.; Wang, L.; Fox, S. J.; Cowling, B. J.; Galvani, A. P.; Meyers, L. A., Effects of Proactive Social Distancing on COVID-19 Outbreaks in 58 Cities, China. *Emerg Infect Dis* **2020**, 26 (9).

144. (U) Du, Z.; Xu, x.; Wu, Y.; Wang, L.; Cowling, B. J.; Meyers, L. A., COVID-19 serial interval estimates based on confirmed cases in public reports from 86 Chinese cities. *medRxiv* **2020**, 2020.04.23.20075796. <https://www.medrxiv.org/content/medrxiv/early/2020/04/27/2020.04.23.20075796.full.pdf>
145. (U) Du, Z.; Xu, X.; Wu, Y.; Wang, L.; Cowling, B. J.; Meyers, L. A., The serial interval of COVID-19 from publicly reported confirmed cases. *medRxiv* **2020**, 2020.02.19.20025452. <https://www.medrxiv.org/content/medrxiv/early/2020/03/13/2020.02.19.20025452.full.pdf>
146. (U) Duan, S.; Zhao, X.; Wen, R.; Huang, J.-j.; Pi, G.; Zhang, S.; Han, J.; Bi, S.; Ruan, L.; Dong, X.-p., Stability of SARS coronavirus in human specimens and environment and its sensitivity to heating and UV irradiation. *Biomedical and environmental sciences: BES* **2003**, 16 (3), 246-255.
147. (U) Dweck, M. R.; Bularga, A.; Hahn, R. T.; Bing, R.; Lee, K. K.; Chapman, A. R.; White, A.; Salvo, G. D.; Sade, L. E.; Pearce, K.; Newby, D. E.; Popescu, B. A.; Donal, E.; Cosyns, B.; Edvardsen, T.; Mills, N. L.; Haugaa, K., Global evaluation of echocardiography in patients with COVID-19. *European Heart Journal - Cardiovascular Imaging* **2020**. <https://doi.org/10.1093/ehjci/jeaa178>
148. (U) Edridge, A. W. D.; Kaczorowska, J.; Hoste, A. C. R.; Bakker, M.; Klein, M.; Jebbink, M. F.; Matsers, A.; Kinsella, C. M.; Rueda, P.; Prins, M.; Sastre, P.; Deijis, M.; Hoek, L. v. d., Coronavirus protective immunity is short-lasting *Pre-print* **2020**. <https://www.medrxiv.org/content/10.1101/2020.05.11.20086439v2.full.pdf>
149. (U) Ellinghaus, D.; Degenhardt, F.; Bujanda, L.; al., e., Genomewide Association Study of Severe Covid-19 with Respiratory Failure. *N Engl J Med* **2020**.
150. (U) Ellington, S., Characteristics of Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status—United States, January 22–June 7, 2020. *MMWR. Morbidity and Mortality Weekly Report* **2020**, 69. [https://www.cdc.gov/mmwr/volumes/69/wr/mm6925a1.htm?s\\_cid=mm6925a1\\_w](https://www.cdc.gov/mmwr/volumes/69/wr/mm6925a1.htm?s_cid=mm6925a1_w)
151. (U) Endeman, H.; van der Zee, P.; van Genderen, M. E.; van den Akker, J. P. C.; Gommers, D., Progressive respiratory failure in COVID-19: a hypothesis. *The Lancet Infectious Diseases* **2020**. [https://doi.org/10.1016/S1473-3099\(20\)30366-2](https://doi.org/10.1016/S1473-3099(20)30366-2)
152. (U) Endo, A.; Abbott, S.; Kucharski, A.; Funk, S., Estimating the overdispersion in COVID-19 transmission using outbreak sizes outside China [version 1; peer review: 1 approved, 1 approved with reservations]. *Wellcome Open Research* **2020**, 5 (67). <https://wellcomeopenresearch.org/articles/5-67/v1>
153. (U) Erkurt, M. A.; Sarici, A.; Berber, İ.; Kuku, İ.; Kaya, E.; Özgül, M., Life-saving effect of convalescent plasma treatment in covid-19 disease: Clinical trial from eastern Anatolia. *Transfus Apher Sci* **2020**, 102867.
154. (U) Escobar, L. E.; Molina-Cruz, A.; Barillas-Mury, C., BCG vaccine protection from severe coronavirus disease 2019 (COVID-19). *Proceedings of the National Academy of Sciences* **2020**, 202008410. <https://www.pnas.org/content/pnas/early/2020/07/07/2008410117.full.pdf>
155. (U) ExpressPharma, Bharat Biotech starts human trials for Covaxin, India's first COVID-19 vaccine. <https://www.expresspharma.in/latest-updates/bharat-biotech-starts-human-trials-for-covaxin-indias-first-covid-19-vaccine/>.
156. (U) FDA, Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquine. U.S. Food and Drug Administration: 2020. <https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-revokes-emergency-use-authorization-chloroquine-and>
157. (U) FDA, *Emergency Use Authorization*; Food and Drug Administration: 2020. <https://www.fda.gov/media/137886/download>
158. (U) FDA, FAQs on Shortages of Surgical Masks and Gowns. <https://www.fda.gov/medical-devices/personal-protective-equipment-infection-control/faqs-shortages-surgical-masks-and-gowns#kn95>.

159. (U) FDA, FAQs on Testing for SARS-CoV-2. <https://www.fda.gov/medical-devices/emergency-situations-medical-devices/faqs-testing-sars-cov-2#nolonger>.
160. (U) FDA, *ID NOW COVID-19*; Food and Drug Administration: 2020. <https://www.fda.gov/media/136525/download>
161. (U) FDA, *Investigational COVID-19 Convalescent Plasma - Emergency INDs*; Food and Drug Administration: 2020. <https://www.fda.gov/vaccines-blood-biologics/investigational-new-drug-ind-or-device-exemption-ide-process-cber/investigational-covid-19-convalescent-plasma-emergency-inds>
162. (U) FDA, Policy for Diagnostics Testing in Laboratories Certified to Perform High Complexity Testing under CLIA prior to Emergency Use Authorization for Coronavirus Disease-2019 during the Public Health Emergency; Immediately in Effect Guidance for Industry and Food and Drug Administration Staff. 2020. <https://www.regulations.gov/docket?D=FDA-2020-D-0987>
163. (U) FDA, Respirator Models Removed from Appendix A. <https://www.fda.gov/media/137928/download> (accessed 05/15/2020).
164. (U) Fears, A.; Klimstra, W.; Duprex, P.; Hartman, A.; Weaver, S.; Plante, K.; Mirchandani, D.; Plante, J. A.; Aguilar, P.; Fernández, D.; Nalca, A.; Totura, A.; Dyer, D.; Kearney, B.; Lackemeyer, M.; Bohannon, J. K.; Johnson, R.; Garry, R.; Reed, D.; Roy, C., Persistence of Severe Acute Respiratory Syndrome Coronavirus 2 in Aerosol Suspensions. *Emerging Infectious Disease journal* **2020**, 26 (9). [https://wwwnc.cdc.gov/eid/article/26/9/20-1806\\_article](https://wwwnc.cdc.gov/eid/article/26/9/20-1806_article)
165. (U) Feldman, O.; Meir, M.; Shavit, D.; Idelman, R.; Shavit, I., Exposure to a Surrogate Measure of Contamination From Simulated Patients by Emergency Department Personnel Wearing Personal Protective Equipment. *JAMA* **2020**. <https://doi.org/10.1001/jama.2020.6633>
166. (U) Ferguson, N.; Laydon, D.; Nedjati-Gilani, G.; Imai, N.; Ainslie, K.; Baguelin, M.; Bhatia, S.; Boonyasiri, A.; Cucunuba, Z.; Cuomo-Dannenburg, G.; Dighe, A.; Dorigatti, I.; Fu, H.; Gaythorpe, K.; Green, W.; Hamlet, A.; Hinsley, W.; Okell, L.; van Elsland, S.; Thompson, H.; Verity, R.; Volz, E.; Wang, H.; Wang, Y.; Walker, P.; Walters, C.; Winskill, P.; Whittaker, C.; Donnelly, C.; Riley, S.; Ghani, A., *Impact of non-pharmaceutical interventions (NPIs) to reduce COVID-19 mortality and healthcare demand*; 2020. <https://www.imperial.ac.uk/media/imperial-college/medicine/sph/ide/gida-fellowships/Imperial-College-COVID19-NPI-modelling-16-03-2020.pdf>
167. (U) Fernández-Ruiz, M.; López-Medrano, F.; Asín, M. A. P.-J.; de la Calle, G. M.; Bueno, H.; Caro-Teller, J. M.; Catalán, M.; de la Calle, C.; García-García, R.; Gómez, C.; Laguna-Goya, R.; Lizasoáin, M.; Martínez-López, J.; Origüen, J.; Pablos, J. L.; Ripoll, M.; Juan, R. S.; Trujillo, H.; Lumbreras, C.; Aguado, J. M.; the, H. O. I. T. f. C.-G., Tocilizumab for the treatment of adult patients with severe COVID-19 pneumonia: a single-center cohort study. *Journal of Medical Virology* **2020**, n/a (n/a). <https://doi.org/10.1002/jmv.26308>
168. (U) Firth, J. A.; Hellewell, J.; Klepac, P.; Kissler, S. M.; Group, C. C.-W.; Kucharski, A. J.; Spurgin, L. G., Combining fine-scale social contact data with epidemic modelling reveals interactions between contact tracing, quarantine, testing and physical distancing for controlling COVID-19. *Preprint* **2020**. [https://cmmid.github.io/topics/covid19/reports/2020\\_05\\_25\\_firth\\_et\\_al\\_manuscript.pdf](https://cmmid.github.io/topics/covid19/reports/2020_05_25_firth_et_al_manuscript.pdf)
169. (U) Fischer, R.; Morris, D. H.; van Doremalen, N.; Sarchette, S.; Matson, J.; Bushmaker, T.; Yinda, C. K.; Seifert, S.; Gamble, A.; Williamson, B.; Judson, S.; de Wit, E.; Lloyd-Smith, J.; Munster, V., Assessment of N95 respirator decontamination and re-use for SARS-CoV-2. *medRxiv* **2020**, 2020.04.11.20062018. <https://www.medrxiv.org/content/medrxiv/early/2020/04/24/2020.04.11.20062018.full.pdf>
170. (U) Fisher, K. A., Factors associated with cloth face covering use among adults during the COVID-19 pandemic—United States, April and May 2020. *MMWR. Morbidity and Mortality Weekly Report* **2020**, 69.
171. (U) Fitzpatrick, J.; DeSalvo, K., Helping public health officials combat COVID-19. Google: 2020. <https://www.blog.google/technology/health/covid-19-community-mobility-reports?hl=en>

172. (U) Flahault, A.; Manetti, E.; Simonson, T.; Lee, G.; Choirat, C., COVID-19 Forecasting.  
<https://renkulab.shinyapps.io/COVID-19-Epidemic-Forecasting/> w e0463e1e/#shiny-tab-about.
173. (U) Flaxman, S.; Mishra, S.; Gandy, A.; Unwin, H. J. T.; Mellan, T. A.; Coupland, H.; Whittaker, C.; Zhu, H.; Berah, T.; Eaton, J. W.; Monod, M.; Perez-Guzman, P. N.; Schmit, N.; Cilloni, L.; Ainslie, K. E. C.; Baguelin, M.; Boonyasiri, A.; Boyd, O.; Cattarino, L.; Cooper, L. V.; Cucunubá, Z.; Cuomo-Dannenburg, G.; Dighe, A.; Djaafara, B.; Dorigatti, I.; van Elsland, S. L.; FitzJohn, R. G.; Gaythorpe, K. A. M.; Geidelberg, L.; Grassly, N. C.; Green, W. D.; Hallett, T.; Hamlet, A.; Hinsley, W.; Jeffrey, B.; Knock, E.; Laydon, D. J.; Nedjati-Gilani, G.; Nouvellet, P.; Parag, K. V.; Siveroni, I.; Thompson, H. A.; Verity, R.; Volz, E.; Walters, C. E.; Wang, H.; Wang, Y.; Watson, O. J.; Winskill, P.; Xi, X.; Walker, P. G. T.; Ghani, A. C.; Donnelly, C. A.; Riley, S. M.; Vollmer, M. A. C.; Ferguson, N. M.; Okell, L. C.; Bhatt, S.; Imperial College, C.-R. T., Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. *Nature* **2020**.  
<https://doi.org/10.1038/s41586-020-2405-7>
174. (U) Folegatti, P. M.; Ewer, K. J.; Aley, P. K.; Angus, B.; Becker, S.; Belij-Rammerstorfer, S.; Bellamy, D.; Bibi, S.; Bittaye, M.; Clutterbuck, E. A.; Dold, C.; Faust, S. N.; Finn, A.; Flaxman, A. L.; Hallis, B.; Heath, P.; Jenkin, D.; Lazarus, R.; Makinson, R.; Minassian, A. M.; Pollock, K. M.; Ramasamy, M.; Robinson, H.; Snape, M.; Tarrant, R.; Voysey, M.; Green, C.; Douglas, A. D.; Hill, A. V. S.; Lambe, T.; Gilbert, S. C.; Pollard, A. J.; Aboagye, J.; Adams, K.; Ali, A.; Allen, E.; Allison, J. L.; Anslow, R.; Arbe-Barnes, E. H.; Babbage, G.; Baillie, K.; Baker, M.; Baker, P.; Baleanu, I.; Ballaminut, J.; Barnes, E.; Barrett, J.; Bates, L.; Batten, A.; Beadon, K.; Beckley, R.; Berrie, E.; Berry, L.; Beveridge, A.; Bewley, K. R.; Bijker, E. M.; Bingham, T.; Blackwell, L.; Blundell, C. L.; Bolam, E.; Boland, E.; Borthwick, N.; Bower, T.; Boyd, A.; Brenner, T.; Bright, P. D.; Brown-O'Sullivan, C.; Brunt, E.; Burbage, J.; Burge, S.; Buttigieg, K. R.; Byard, N.; Cabera Puig, I.; Calvert, A.; Camara, S.; Cao, M.; Cappuccini, F.; Carr, M.; Carroll, M. W.; Carter, V.; Cathie, K.; Challis, R. J.; Chelysheva, I.; Cho, J.-S.; Cicconi, P.; Cifuentes, L.; Clark, H.; Clark, E.; Cole, T.; Colin-Jones, R.; Conlon, C. P.; Cook, A.; Coombes, N. S.; Cooper, R.; Cosgrove, C. A.; Coy, K.; Crocker, W. E. M.; Cunningham, C. J.; Damratoski, B. E.; Dando, L.; Dattoo, M. S.; Davies, H.; De Graaf, H.; Demissie, T.; Di Maso, C.; Dietrich, I.; Dong, T.; Donnellan, F. R.; Douglas, N.; Downing, C.; Drake, J.; Drake-Brockman, R.; Drury, R. E.; Dunachie, S. J.; Edwards, N. J.; Edwards, F. D. L.; Edwards, C. J.; Elias, S. C.; Elmore, M. J.; Emary, K. R. W.; English, M. R.; Fagerbrink, S.; Felle, S.; Feng, S.; Field, S.; Fixmer, C.; Fletcher, C.; Ford, K. J.; Fowler, J.; Fox, P.; Francis, E.; Frater, J.; Furze, J.; Fuskova, M.; Galiza, E.; Gbesemete, D.; Gilbride, C.; Gorini, G.; Goulston, L.; Grabau, C.; Gracie, L.; Gray, Z.; Guthrie, L. B.; Hackett, M.; Halwe, S.; Hamilton, E.; Hamlyn, J.; Hanumunthadu, B.; Harding, I.; Harris, S. A.; Harris, A.; Harrison, D.; Harrison, C.; Hart, T. C.; Haskell, L.; Hawkins, S.; Head, I.; Henry, J. A.; Hill, J.; Hodgson, S. H. C.; Hou, M. M.; Howe, E.; Howell, N.; Hutlin, C.; Ikram, S.; Isitt, C.; Iveson, P.; Jackson, S.; Jackson, F.; James, S. W.; Jenkins, M.; Jones, E.; Jones, K.; Jones, C. E.; Jones, B.; Kailath, R.; Karampatsas, K.; Keen, J.; Kelly, S.; Kelly, D.; Kerr, D.; Kerridge, S.; Khan, L.; Khan, U.; Killen, A.; Kinch, J.; King, T. B.; King, L.; King, J.; Kingham-Page, L.; Klenerman, P.; Knapper, F.; Knight, J. C.; Koleva, S.; Kupke, A.; Larkworthy, C. W.; Larwood, J. P. J.; Laskey, A.; Lawrie, A. M.; Lee, A.; Ngan Lee, K. Y.; Lee, E. A.; Legge, H.; Lelliott, A.; Lemm, N.-M.; Lias, A. M.; Linder, A.; Lipworth, S.; Liu, X.; Liu, S.; Lopez Ramon, R.; Lwin, M.; Mabesa, F.; Madhavan, M.; Mallett, G.; Mansatta, K.; Marcal, I.; Marinou, S.; Marlow, E.; Marshall, J. L.; Martin, J.; McEwan, J.; Meddaugh, G.; Mentzer, A. J.; Mirtorabi, N.; Moore, M.; Moran, E.; Morey, E.; Morgan, V.; Morris, S. J.; Morrison, H.; Morshead, G.; Morter, R.; Mujadidi, Y. F.; Muller, J.; Munera-Huertas, T.; Munro, C.; Munro, A.; Murphy, S.; Muster, V. J.; Mweu, P.; Noé, A.; Nugent, F. L.; Nugent, E.; O'Brien, K.; O'Connor, D.; Oguti, B.; Oliver, J. L.; Oliveira, C.; O'Reilly, P. J.; Osborn, M.; Osborne, P.; Owen, C.; Owens, D.; Owino, N.; Pacurar, M.; Parker, K.; Parracho, H.; Patrick-Smith, M.; Payne, V.; Pearce, J.; Peng, Y.; Peralta Alvarez, M. P.; Perring, J.; Pfafferott, K.; Pipini, D.; Plested, E.; Pluess-Hall, H.; Pollock, K.; Poulton, I.; Presland, L.; Provstgaard-Morys, S.; Pulido, D.; Radia, K.; Ramos Lopez, F.; Rand, J.; Ratcliffe, H.; Rawlinson, T.; Rhead, S.; Riddell, A.; Ritchie, A. J.; Roberts, H.; Robson, J.; Roche, S.; Rohde, C.; Rollier, C. S.; Romani, R.; Rudiansyah, I.; Saich, S.; Sajjad, S.; Salvador, S.; Sanchez Riera, L.; Sanders, H.; Sanders, K.;

Updated 7/21/2020

- Sapaun, S.; Sayce, C.; Schofield, E.; Scream, G.; Selby, B.; Semple, C.; Sharpe, H. R.; Shea, A.; Shelton, H.; Silk, S.; Silva-Reyes, L.; Skelly, D. T.; Smee, H.; Smith, C. C.; Smith, D. J.; Song, R.; Spencer, A. J.; Stafford, E.; Steele, A.; Stefanova, E.; Stockdale, L.; Szigeti, A.; Tahiri-Alaoui, A.; Tait, M.; Talbot, H.; Tanner, R.; Taylor, I. J.; Taylor, V.; Te Water Naude, R.; Thakur, N.; Themistocleous, Y.; Themistocleous, A.; Thomas, M.; Thomas, T. M.; Thompson, A.; Thomson-Hill, S.; Tomlins, J.; Tonks, S.; Towner, J.; Tran, N.; Tree, J. A.; Truby, A.; Turkentine, K.; Turner, C.; Turner, N.; Turner, S.; Tuthill, T.; Ulaszewska, M.; Varughese, R.; Van Doremalen, N.; Veighey, K.; Verheul, M. K.; Vichos, I.; Vitale, E.; Walker, L.; Watson, M. E. E.; Welham, B.; Wheat, J.; White, C.; White, R.; Worth, A. T.; Wright, D.; Wright, S.; Yao, X. L.; Yau, Y., Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. *The Lancet* **2020**. [https://doi.org/10.1016/S0140-6736\(20\)31604-4](https://doi.org/10.1016/S0140-6736(20)31604-4)
175. (U) Formina, D. S.; Lysenko, M.; yana, A.; Beloglazova, I. P.; Mutinova, z. Y.; Poteschkina, N. G.; Samsonova, I. V.; Kruglova, T.; yana, S.; Chernov, A. A.; Karaulov, A. V.; Lederman, M. M., Temporal clinical and laboratory response to interleukin-6 receptor blockade with Tocilizumab in 89 hospitalized patients with COVID-19 pneumonia. *medRxiv* **2020**, 2020.06.12.20122374. <http://medrxiv.org/content/early/2020/06/12/2020.06.12.20122374.abstract>
176. (U) Forster, P.; Forster, L.; Renfrew, C.; Forster, M., Phylogenetic network analysis of SARS-CoV-2 genomes. *Proceedings of the National Academy of Sciences* **2020**, *117* (17), 9241-9243. <https://www.pnas.org/content/pnas/117/17/9241.full.pdf>
177. (U) Frank, H. K.; Enard, D.; Boyd, S. D., Exceptional diversity and selection pressure on SARS-CoV and SARS-CoV-2 host receptor in bats compared to other mammals. *bioRxiv* **2020**, 2020.04.20.051656. <https://www.biorxiv.org/content/biorxiv/early/2020/04/20/2020.04.20.051656.full.pdf>
178. (U) Galván Casas, C.; Català, A.; Carretero Hernández, G.; Rodríguez-Jiménez, P.; Fernández-Nieto, D.; Rodríguez-Villa Lario, A.; Navarro Fernández, I.; Ruiz-Villaverde, R.; Falkenhain-López, D.; Llamas Velasco, M.; García-Gavín, J.; Baniandrés, O.; González-Cruz, C.; Morillas-Lahuerta, V.; Cubiró, X.; Figueras Nart, I.; Selda-Enriquez, G.; Romani, J.; Fustà-Novell, X.; Melian-Olivera, A.; Roncero Riesco, M.; Burgos-Blasco, P.; Sola Ortigosa, J.; Feito Rodriguez, M.; García-Doval, I., Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. *British Journal of Dermatology* **2020**, *183* (1), 71-77. <https://onlinelibrary.wiley.com/doi/abs/10.1111/bjd.19163>
179. (U) Gao, Q.; Bao, L.; Mao, H.; Wang, L.; Xu, K.; Yang, M.; Li, Y.; Zhu, L.; Wang, N.; Lv, Z.; Gao, H.; Ge, X.; Kan, B.; Hu, Y.; Liu, J.; Cai, F.; Jiang, D.; Yin, Y.; Qin, C.; Li, J.; Gong, X.; Lou, X.; Shi, W.; Wu, D.; Zhang, H.; Zhu, L.; Deng, W.; Li, Y.; Lu, J.; Li, C.; Wang, X.; Yin, W.; Zhang, Y.; Qin, C., Rapid development of an inactivated vaccine for SARS-CoV-2. *bioRxiv* **2020**, 2020.04.17.046375. <https://www.biorxiv.org/content/biorxiv/early/2020/04/19/2020.04.17.046375.full.pdf>
180. (U) Garg, S., Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019—COVID-NET, 14 States, March 1–30, 2020. *MMWR. Morbidity and Mortality Weekly Report* **2020**, *69*.
181. (U) Gatto, M.; Bertuzzo, E.; Mari, L.; Miccoli, S.; Carraro, L.; Casagrandi, R.; Rinaldo, A., Spread and dynamics of the COVID-19 epidemic in Italy: Effects of emergency containment measures. *Proceedings of the National Academy of Sciences* **2020**, 202004978. <https://www.pnas.org/content/pnas/early/2020/04/22/2004978117.full.pdf>
182. (U) Gautret, P.; Lagier, J.-C.; Parola, P.; Meddeb, L.; Mailhe, M.; Doudier, B.; Courjon, J.; Giordanengo, V.; Vieira, V. E.; Dupont, H. T., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. *International Journal of Antimicrobial Agents* **2020**, 105949.
183. (U) Geleris, J.; Sun, Y.; Platt, J.; Zucker, J.; Baldwin, M.; Hripcsak, G.; Labella, A.; Manson, D.; Kubin, C.; Barr, R. G.; Sobieszczyk, M. E.; Schluger, N. W., Observational Study of Hydroxychloroquine in

Hospitalized Patients with Covid-19. *New England Journal of Medicine* 2020.

<https://www.nejm.org/doi/full/10.1056/NEJMoa2012410>

184. (U) Gendelman, O.; Amital, H.; Bragazzi, N. L.; Watad, A.; Chodick, G., Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis. *Autoimmunity Reviews* 2020, 102566.

<http://www.sciencedirect.com/science/article/pii/S1568997220301282>

185. (U) Genexine, Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults. <https://clinicaltrials.gov/ct2/show/NCT04445389?term=vaccine&cond=covid-19&draw=3>.

186. (U) Gérard, A.; Romani, S.; Fresse, A.; Viard, D.; Parassol, N.; Granvullemin, A.; Chouchana, L.; Rocher, F.; Drici, M.-D., "Off-label" use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers. *Therapies* 2020.

<http://www.sciencedirect.com/science/article/pii/S0040595720300913>

187. (U) Gharbharan, A.; Jordans, C. C. E.; GeurtsvanKessel, C.; den Hollander, J. G.; Karim, F.; Mollema, F. P. N.; Stalenhoef, J. E.; Dofferhoff, A.; Ludwig, I.; Koster, A.; Hassing, R.-J.; Bos, J. C.; van Pottelberge, G. R.; Vlasveld, I. N.; Ammerlaan, H. S. M.; Segarceanu, E.; Miedema, J.; van der Eerden, M.; Papageorgiou, G.; te Broekhorst, P.; Swaneveld, F. H.; Katsikis, P. D.; Mueller, Y.; Okba, N. M. A.; Koopmans, M. P. G.; Haagmans, B. L.; Rokx, C.; Rijnders, B., Convalescent Plasma for COVID-19. A randomized clinical trial. *medRxiv* 2020, 2020.07.01.20139857.

<http://medrxiv.org/content/early/2020/07/03/2020.07.01.20139857.abstract>

188. (U) Gilead, Gilead Presents Additional Data on Investigational Antiviral Remdesivir for the Treatment of COVID-19. 2020. <https://www.gilead.com/news-and-press/press-room/press-releases/2020/7/gilead-presents-additional-data-on-investigational-antiviral-remdesivir-for-the-treatment-of-covid-19>

189. (U) GitHub Inc., Reproducible analyses for rejecting rare genomic inversions in SARS-CoV-2.

[https://github.com/alexcritschroph/sars\\_cov\\_2\\_inversion](https://github.com/alexcritschroph/sars_cov_2_inversion) (accessed 04 April).

190. (U) Godoy, M., Mystery Inflammatory Syndrome In Kids And Teens Likely Linked To COVID-19. *NPR* 2020. <https://www.npr.org/sections/health-shots/2020/05/07/851725443/mystery-inflammatory-syndrome-in-kids-and-teens-likely-linked-to-covid-19>

191. (U) Goldstein, J., 68% Have Antibodies in This Clinic. Can a Neighborhood Beat a Next Wave? *The New York Times* 2020. <https://www.nytimes.com/2020/07/09/nyregion/nyc-coronavirus-antibodies.html>

192. (U) Gonzalez-Reiche, A. S.; Hernandez, M. M.; Sullivan, M. J.; Ciferri, B.; Alshammary, H.; Obla, A.; Fabre, S.; Kleiner, G.; Polanco, J.; Khan, Z.; Albuquerque, B.; van de Guchte, A.; Dutta, J.; Francoeur, N.; Melo, B. S.; Oussenko, I.; Deikus, G.; Soto, J.; Sridhar, S. H.; Wang, Y.-C.; Twyman, K.; Kasarskis, A.; Altman, D. R.; Smith, M.; Sebra, R.; Aberg, J.; Krammer, F.; García-Sastre, A.; Luksza, M.; Patel, G.; Paniz-Mondolfi, A.; Gitman, M.; Sordillo, E. M.; Simon, V.; van Bakel, H., Introductions and early spread of SARS-CoV-2 in the New York City area. *Science* 2020, eabc1917.

<https://science.sciencemag.org/content/sci/early/2020/05/28/science.abc1917.full.pdf>

193. (U) Goren, A.; Vaño-Galván, S.; Wambier, C. G.; McCoy, J.; Gomez-Zubiaur, A.; Moreno-Arrones, O. M.; Shapiro, J.; Sinclair, R. D.; Gold, M. H.; Kovacevic, M.; Mesinkovska, N. A.; Goldust, M.; Washenik, K., A preliminary observation: Male pattern hair loss among hospitalized COVID-19 patients in Spain – A potential clue to the role of androgens in COVID-19 severity. *Journal of Cosmetic Dermatology* n/a (n/a).

<https://onlinelibrary.wiley.com/doi/abs/10.1111/jocd.13443>

194. (U) Gorgolas, M.; Cabello, A.; Prieto Perez, L.; Villar Alvarez, F.; Alvarez Alvarez, B.; Rodriguez Nieto, M. J.; Carrillo Acosta, I.; Fernandez Ormaechea, I.; Al-Hayani, A.; Carballosa, P.; Calpena Martinez, S.; Ezzine de Blas, F.; Castellanos Gonzalez, M.; Naya Prieto, A.; Lopez de las Heras, M.; Rodriguez Guzman,

- M. J.; Cordero Guijarro, A.; Broncano Lavado, A.; Macias Valcayo, A.; Martin Garcia, M.; Becares Martinez, J.; Fernandez Roblas, R.; Piris Pinilla, M. A.; Fortes Alen, J.; Sanchez Pernaute, O.; Romero Bueno, F.; Heili Frades, S.; Peces Barba Romero, G., Compassionate Use of Tocilizumab in Severe SARS-CoV2 Pneumonia. When late administration is too late. *medRxiv* **2020**, 2020.06.13.20130088. <http://medrxiv.org/content/early/2020/06/16/2020.06.13.20130088.abstract>
195. (U) Götzinger, F.; Santiago-García, B.; Noguera-Julián, A.; al., e., COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study. *The Lancet Child & Adolescent Health* **2020**. [https://doi.org/10.1016/S2352-4642\(20\)30177-2](https://doi.org/10.1016/S2352-4642(20)30177-2)
196. (U) Goyal, P.; Choi, J. J.; Pinheiro, L. C.; Schenck, E. J.; Chen, R.; Jabri, A.; Satlin, M. J.; Campion, T. R.; Nahid, M.; Ringel, J. B.; Hoffman, K. L.; Alshak, M. N.; Li, H. A.; Wehmeyer, G. T.; Rajan, M.; Reshetnyak, E.; Hupert, N.; Horn, E. M.; Martinez, F. J.; Gulick, R. M.; Safford, M. M., Clinical Characteristics of Covid-19 in New York City. *New England Journal of Medicine* **2020**. <https://www.nejm.org/doi/full/10.1056/NEJMc2010419>
197. (U) Griffin, S., Covid-19: Lopinavir-ritonavir does not benefit hospitalised patients, UK trial finds. *BMJ* **2020**, 370, m2650. <http://www.bmj.com/content/370/bmj.m2650.abstract>
198. (U) Grifoni, A.; Weiskopf, D.; Ramirez, S. I.; Mateus, J.; Dan, J. M.; Moderbacher, C. R.; Rawlings, S. A.; Sutherland, A.; Premkumar, L.; Jadi, R. S., Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. *Cell* **1920**.
199. (U) Gu, Y., COVID-19 Projections Using Machine Learning. <https://covid19-projections.com/#view-projections>.
200. (U) Guan, L.; Zhou, L.; Zhang, J.; Peng, W.; Chen, R., More awareness is needed for severe acute respiratory syndrome coronavirus 2019 transmission through exhaled air during non-invasive respiratory support: experience from China. *European Respiratory Journal* **2020**, 55 (3), 2000352. <https://erj.ersjournals.com/content/erj/55/3/2000352.full.pdf>
201. (U) Guan, W.-j.; Ni, Z.-y.; Hu, Y.; Liang, W.-h.; Ou, C.-q.; He, J.-x.; Liu, L.; Shan, H.; Lei, C.-l.; Hui, D. S. C.; Du, B.; Li, L.-j.; Zeng, G.; Yuen, K.-Y.; Chen, R.-c.; Tang, C.-l.; Wang, T.; Chen, P.-y.; Xiang, J.; Li, S.-y.; Wang, J.-l.; Liang, Z.-j.; Peng, Y.-x.; Wei, L.; Liu, Y.; Hu, Y.-h.; Peng, P.; Wang, J.-m.; Liu, J.-y.; Chen, Z.; Li, G.; Zheng, Z.-j.; Qiu, S.-q.; Luo, J.; Ye, C.-j.; Zhu, S.-y.; Zhong, N.-s., Clinical Characteristics of Coronavirus Disease 2019 in China. *New England Journal of Medicine* **2020**, 382, 1708-1720. [https://www.nejm.org/doi/full/10.1056/NEJMoa2002032?query=recirc\\_artType\\_railA\\_article](https://www.nejm.org/doi/full/10.1056/NEJMoa2002032?query=recirc_artType_railA_article)
202. (U) Guaraldi, G.; Meschiari, M.; Cozzi-Lepri, A.; Milic, J.; Tonelli, R.; Menozzi, M.; Franceschini, E.; Cuomo, G.; Orlando, G.; Borghi, V.; Santoro, A.; Di Gaetano, M.; Puzzolante, C.; Carli, F.; Bedini, A.; Corradi, L.; Fantini, R.; Castaniere, I.; Tabbì, L.; Girardis, M.; Tedeschi, S.; Giannella, M.; Bartoletti, M.; Pascale, R.; Dolci, G.; Brugioni, L.; Pietrangelo, A.; Cossarizza, A.; Pea, F.; Clini, E.; Salvarani, C.; Massari, M.; Viale, P. L.; Mussini, C., Tocilizumab in patients with severe COVID-19: a retrospective cohort study. *The Lancet Rheumatology* **2020**. <http://www.sciencedirect.com/science/article/pii/S2665991320301739>
203. (U) Guo, Z.; Wang, Z.; Zhang, S.; Li, X.; Li, L.; Li, C.; Cui, Y.; Fu, R.; Dong, Y.; Chi, X., Aerosol and Surface Distribution of Severe Acute Respiratory Syndrome Coronavirus 2 in Hospital Wards, Wuhan, China, 2020. *Emerging infectious diseases* **2020**, 26 (7).
204. (U) Gussow, A. B.; Auslander, N.; Faure, G.; Wolf, Y. I.; Zhang, F.; Koonin, E. V., Genomic determinants of pathogenicity in SARS-CoV-2 and other human coronaviruses. *Proceedings of the National Academy of Sciences* **2020**, 202008176. <https://www.pnas.org/content/pnas/early/2020/06/09/2008176117.full.pdf>
205. (U) Halfmann, P. J.; Hatta, M.; Chiba, S.; Maemura, T.; Fan, S.; Takeda, M.; Kinoshita, N.; Hattori, S. I.; Sakai-Tagawa, Y.; Iwatsuki-Horimoto, K.; Imai, M.; Kawaoka, Y., Transmission of SARS-CoV-2 in Domestic Cats. *N Engl J Med* **2020**.
206. (U) Hamilton, I. A., Bill Gates is funding new factories for potential coronavirus vaccines. <https://www.weforum.org/agenda/2020/04/bill-gates-7-potential-coronavirus-vaccines>.

207. (U) Hao, X.; Cheng, S.; Wu, D.; Wu, T.; Lin, X.; Wang, C., Reconstruction of the full transmission dynamics of COVID-19 in Wuhan. *Nature* **2020**. <https://doi.org/10.1038/s41586-020-2554-8>
208. (U) Harbourt, D.; Haddow, A.; Piper, A.; Bloomfield, H.; Kearney, B.; Gibson, K.; Minogue, T., Modeling the Stability of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) on Skin, Currency, and Clothing. *medRxiv* **2020**, 2020.07.01.20144253.  
<https://www.medrxiv.org/content/medrxiv/early/2020/07/03/2020.07.01.20144253.full.pdf>
209. (U) Hargreaves, B., Catalent takes on manufacture of J&J's coronavirus vaccine.  
<https://www.biopharma-reporter.com/Article/2020/04/30/Catalent-to-manufacture-Janssen-coronavirus-vaccine>.
210. (U) Hargreaves, B., Lonza and Moderna shoot for billion COVID-19 doses. <https://www.biopharma-reporter.com/Article/2020/05/05/Lonza-and-Moderna-partner-for-COVID-19-vaccine>.
211. (U) Hargreaves, B., Pfizer and BioNTech work to scale up COVID-19 vaccine production.  
<https://www.biopharma-reporter.com/Article/2020/05/11/Pfizer-scales-up-COVID-vaccine-production>.
212. (U) Harris, M.; Bagozzi, D., WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19. Organization, W. H., Ed. 2020. <https://www.who.int/news-room/detail/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19>
213. (U) Hartman, A. L.; Nambulli, S.; McMillen, C. M.; White, A. G.; Tilston-Lunel, N.; Albe, J. R.; Cottle, E. L.; Dunn, M. D.; Frye, L. J.; Gilliland, T. H.; Olsen, E. L.; Malley, K. J.; Schwarz, M. M.; Tomko, J. A.; Walker, R. C.; Xia, M.; Hartman, M. S.; Klein, E.; Scanga, C.; Flynn, J. L.; Klimstra, W. B.; McElroy, A. K.; Reed, D. S.; Duprex, W. P., SARS-CoV-2 infection of African green monkeys results in mild respiratory disease discernible by PET/CT imaging and prolonged shedding of infectious virus from both respiratory and gastrointestinal tracts. *bioRxiv* **2020**, 2020.06.20.137687.  
<http://biorxiv.org/content/early/2020/06/21/2020.06.20.137687.abstract>
214. (U) Hashimoto, S.; Kitajima, H.; Arai, T.; Tamura, Y.; Nagai, T.; Morishita, H.; Matsuoka, H.; Han, Y.; Minamoto, S.; Hirashima, T.; Yamada, T.; Kashiwa, Y.; Kameda, M.; Yamaguchi, S.; Uno, K.; Nakayama, E.; Shioda, T.; Yoshizaki, K.; Kang, S.; Kishimoto, T.; Tanaka, T., A retrospective study evaluating efficacy and safety of compassionate use of tocilizumab in 13 patients with severe-to-critically ill COVID-19: analysis of well-responding cases and rapidly-worsening cases after tocilizumab administration. *medRxiv* **2020**, 2020.06.24.20134288. <http://medrxiv.org/content/early/2020/06/30/2020.06.24.20134288.abstract>
215. (U) He, R.; Lu, Z.; Zhang, L.; Fan, T.; Xiong, R.; Shen, X.; Feng, H.; Meng, H.; Lin, W.; Jiang, W.; Geng, Q., The clinical course and its correlated immune status in COVID-19 pneumonia. *Journal of Clinical Virology* **2020**, *127*, 104361. <http://www.sciencedirect.com/science/article/pii/S1386653220301037>
216. (U) He, X.; Lau, E. H. Y.; Wu, P.; Deng, X.; Wang, J.; Hao, X.; Lau, Y. C.; Wong, J. Y.; Guan, Y.; Tan, X.; Mo, X.; Chen, Y.; Liao, B.; Chen, W.; Hu, F.; Zhang, Q.; Zhong, M.; Wu, Y.; Zhao, L.; Zhang, F.; Cowling, B. J.; Li, F.; Leung, G. M., Temporal dynamics in viral shedding and transmissibility of COVID-19. *Nature Medicine* **2020**. <https://doi.org/10.1038/s41591-020-0869-5>
217. (U) Helms, J.; Kremer, S.; Merdji, H.; Clere-Jehl, R.; Schenck, M.; Kummerlen, C.; Collange, O.; Boulay, C.; Fafi-Kremer, S.; Ohana, M.; Anheim, M.; Meziani, F., Neurologic Features in Severe SARS-CoV-2 Infection. *New England Journal of Medicine* **2020**.  
<https://www.nejm.org/doi/full/10.1056/NEJMc2008597>
218. (U) Holland, L. A.; Kaelin, E. A.; Maqsood, R.; Estifanos, B.; Wu, L. I.; Varsani, A.; Halden, R. U.; Hogue, B. G.; Scotch, M.; Lim, E. S., An 81 base-pair deletion in SARS-CoV-2 ORF7a identified from sentinel surveillance in Arizona (Jan-Mar 2020). *medRxiv* **2020**, 2020.04.17.20069641.  
<https://www.medrxiv.org/content/medrxiv/early/2020/04/22/2020.04.17.20069641.full.pdf>
219. (U) Holmes, L.; Enwere, M.; Williams, J.; Ogundele, B.; Chavan, P.; Piccoli, T.; Chinacherem, C.; Comeaux, C.; Pelaez, L.; Okundaye, O.; Stalnaker, L.; Kalle, F.; Deepika, K.; Philipicien, G.; Poleon, M.; Ogungbade, G.; Elmi, H.; John, V.; Dabney, K. W., Black-White Risk Differentials in COVID-19 (SARS-CoV2) Transmission, Mortality and Case Fatality in the United States: Translational Epidemiologic



- Perspective and Challenges. *International Journal of Environmental Research and Public Health* **2020**, *17* (12), 4322. <https://www.mdpi.com/1660-4601/17/12/4322>
220. (U) Horby, P.; Landray, M., No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19. Randomised Evaluation of COVid-19 thERapY (RECOVERY) Trial: 2020. <https://www.recoverytrial.net/news/statement-from-the-chief-investigators-of-the-randomised-evaluation-of-covid-19-therapy-recovery-trial-on-hydroxychloroquine-5-june-2020-no-clinical-benefit-from-use-of-hydroxychloroquine-in-hospitalised-patients-with-covid-19>
221. (U) Horby, P.; Mafham, M.; Linsell, L.; Bell, J. L.; Staplin, N.; Emberson, J. R.; Wiselka, M.; Ustianowski, A.; Elmahi, E.; Prudon, B.; Whitehouse, A.; Felton, T.; Williams, J.; Faccenda, J.; Underwood, J.; Baillie, J. K.; Chappell, L.; Faust, S. N.; Jaki, T.; Jeffery, K.; Lim, W. S.; Montgomery, A.; Rowan, K.; Tarning, J.; Watson, J. A.; White, N. J.; Juszczak, E.; Haynes, R.; Landray, M. J., Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial. *medRxiv* **2020**, 2020.07.15.20151852. <https://www.medrxiv.org/content/medrxiv/early/2020/07/15/2020.07.15.20151852.full.pdf>
222. (U) Hou, Y. J.; Okuda, K.; Edwards, C. E.; Martinez, D. R.; Asakura, T.; Dinnon, K. H.; Kato, T.; Lee, R. E.; Yount, B. L.; Mascenik, T. M.; Chen, G.; Olivier, K. N.; Ghio, A.; Tse, L. V.; Leist, S. R.; Gralinski, L. E.; Schäfer, A.; Dang, H.; Gilmore, R.; Nakano, S.; Sun, L.; Fulcher, M. L.; Livraghi-Butrico, A.; Nicely, N. I.; Cameron, M.; Cameron, C.; Kelvin, D. J.; de Silva, A.; Margolis, D. M.; Markmann, A.; Bartelt, L.; Zumwalt, R.; Martinez, F. J.; Salvatore, S. P.; Borczuk, A.; Tata, P. R.; Sontake, V.; Kimple, A.; Jaspers, I.; O'Neal, W. K.; Randell, S. H.; Boucher, R. C.; Baric, R. S., SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract. *Cell* **2020**. <http://www.sciencedirect.com/science/article/pii/S0092867420306759>
223. (U) Hsiang, S.; Allen, D.; Annan-Phan, S.; Bell, K.; Bolliger, I.; Chong, T.; Druckenmiller, H.; Huang, L. Y.; Hultgren, A.; Krasovich, E.; Lau, P.; Lee, J.; Rolf, E.; Tseng, J.; Wu, T., The effect of large-scale anti-contagion policies on the COVID-19 pandemic. *Nature* **2020**. <https://doi.org/10.1038/s41586-020-2404-8>
224. (U) Hu, Q.; Cui, X.; Liu, X.; Peng, B.; Jiang, J.; Wang, X.; Li, Y.; Hu, W.; Ao, Z.; Duan, J.; Wang, X.; Zhu, L.; Guo, S.; Wu, G., The production of antibodies for SARS-CoV-2 and its clinical implication. *medRxiv* **2020**, 2020.04.20.20065953. <https://www.medrxiv.org/content/medrxiv/early/2020/04/24/2020.04.20.20065953.full.pdf>
225. (U) Hu, Z.; Song, C.; Xu, C.; Jin, G.; Chen, Y.; Xu, X.; Ma, H.; Chen, W.; Lin, Y.; Zheng, Y.; Wang, J.; Hu, Z.; Yi, Y.; Shen, H., Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. *Science China Life Sciences* **2020**. <https://doi.org/10.1007/s11427-020-1661-4>
226. (U) Huang, C.; Wang, Y.; Li, X.; Ren, L.; Zhao, J.; Hu, Y.; Zhang, L.; Fan, G.; Xu, J.; Gu, X.; Cheng, Z.; Yu, T.; Xia, J.; Wei, Y.; Wu, W.; Xie, X.; Yin, W.; Li, H.; Liu, M.; Xiao, Y.; Gao, H.; Guo, L.; Xie, J.; Wang, G.; Jiang, R.; Gao, Z.; Jin, Q.; Wang, J.; Cao, B., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The Lancet* **2020**. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(20\)30183-5/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30183-5/fulltext)
227. (U) Huang, R.; Xia, J.; Chen, Y.; Shan, C.; Wu, C., A family cluster of SARS-CoV-2 infection involving 11 patients in Nanjing, China. *The Lancet Infectious Diseases* **2020**, *20* (5), 534-535. [https://doi.org/10.1016/S1473-3099\(20\)30147-X](https://doi.org/10.1016/S1473-3099(20)30147-X)
228. (U) Huang, Y.; Lyu, X.; Li, D.; Wang, Y.; Wang, L.; Zou, W.; Wei, Y.; Wu, X., A cohort study of 223 patients explores the clinical risk factors for the severity diagnosis of COVID-19. *medRxiv* **2020**, 2020.04.18.20070656. <https://www.medrxiv.org/content/medrxiv/early/2020/04/24/2020.04.18.20070656.full.pdf>
229. (U) Huang, Z.; Tian, D.; Liu, Y.; Lin, Z.; Lyon, C. J.; Lai, W.; Fusco, D.; Drouin, A.; Yin, X.; Hu, T.; Ning, B., Ultra-sensitive and high-throughput CRISPR-powered COVID-19 diagnosis. *Biosensors and*

*Bioelectronics* **2020**, *164*, 112316.

<http://www.sciencedirect.com/science/article/pii/S0956566320303110>

230. (U) Hulkower, R. L.; Casanova, L. M.; Rutala, W. A.; Weber, D. J.; Sobsey, M. D., Inactivation of surrogate coronaviruses on hard surfaces by health care germicides. *American journal of infection control* **2011**, *39* (5), 401-407. <https://www.sciencedirect.com/science/article/pii/S0196655310009004>
231. (U) Hung, I. F.-N.; Lung, K.-C.; Tso, E. Y.-K.; Liu, R.; Chung, T. W.-H.; Chu, M.-Y.; Ng, Y.-Y.; Lo, J.; Chan, J.; Tam, A. R.; Shum, H.-P.; Chan, V.; Wu, A. K.-L.; Sin, K.-M.; Leung, W.-S.; Law, W.-L.; Lung, D. C.; Sin, S.; Yeung, P.; Yip, C. C.-Y.; Zhang, R. R.; Fung, A. Y.-F.; Yan, E. Y.-W.; Leung, K.-H.; Ip, J. D.; Chu, A. W.-H.; Chan, W.-M.; Ng, A. C.-K.; Lee, R.; Fung, K.; Yeung, A.; Wu, T.-C.; Chan, J. W.-M.; Yan, W.-W.; Chan, W.-M.; Chan, J. F.-W.; Lie, A. K.-W.; Tsang, O. T.-Y.; Cheng, V. C.-C.; Que, T.-L.; Lau, C.-S.; Chan, K.-H.; To, K. K.-W.; Yuen, K.-Y., Triple combination of interferon beta-1b, lopinavir, ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. *The Lancet* **2020**. [https://doi.org/10.1016/S0140-6736\(20\)31042-4](https://doi.org/10.1016/S0140-6736(20)31042-4)
232. (U) ICNARC, *ICNARC report on COVID-19 in critical care, 24 April 2020*; Intensive Care National Audit and Research Centre: 2020. <https://www.icnarc.org/DataServices/Attachments/Download/c5a62b13-6486-ea11-9125-00505601089b>
233. (U) IDEXX, Leading Veterinary Diagnostic Company Sees No COVID-19 Cases in Pets. IDEXX: 2020. <https://www.idexx.com/en/about-idexx/news/no-covid-19-cases-pets/>
234. (U) IHME, COVID-19 Projections. <https://covid19.healthdata.org/united-states-of-america>.
235. (U) Ijaz, M. K.; Nims, R. W.; Whitehead, K.; Srinivasan, V.; Charlesworth, B.; McKinney, J.; Rubino, J. R.; Ripley, M.; Jones, C., Microbicidal Actives with Virucidal Efficacy against SARS-CoV-2. *American Journal of Infection Control* **2020**.
236. (U) Inovio, INOVIO Announces Positive Interim Phase 1 Data For INO-4800 Vaccine for COVID-19 <http://ir.inovio.com/news-releases/news-releases-details/2020/INOVI0-Announces-Positive-Interim-Phase-1-Data-For-INO-4800-Vaccine-for-COVID-19/default.aspx>.
237. (U) Inovio, Safety, Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19. <https://clinicaltrials.gov/ct2/show/NCT04447781?term=NCT04447781&draw=2&rank=1>.
238. (U) IQ, H., COVID-19 Forecast for United States. <https://app.hospiq.com/covid19?region=>.
239. (U) Iwata, K.; Doi, A.; Miyakoshi, C., Was School Closure Effective in Mitigating Coronavirus Disease 2019 (COVID-19)? Time Series Analysis Using Bayesian Inference. **2020**.
240. (U) Jackson, L. A.; Anderson, E. J.; Roupheal, N. G.; Roberts, P. C.; Makhene, M.; Coler, R. N.; McCullough, M. P.; Chappell, J. D.; Denison, M. R.; Stevens, L. J.; Pruijssers, A. J.; McDermott, A.; Flach, B.; Doria-Rose, N. A.; Corbett, K. S.; Morabito, K. M.; O'Dell, S.; Schmidt, S. D.; Swanson, P. A.; Padilla, M.; Mascola, J. R.; Neuzil, K. M.; Bennett, H.; Sun, W.; Peters, E.; Makowski, M.; Albert, J.; Cross, K.; Buchanan, W.; Pikaart-Tautges, R.; Ledgerwood, J. E.; Graham, B. S.; Beigel, J. H., An mRNA Vaccine against SARS-CoV-2 — Preliminary Report. *New England Journal of Medicine* **2020**. <https://www.nejm.org/doi/full/10.1056/NEJMoa2022483>
241. (U) Jankelson, L.; Karam, G.; Becker, M. L.; Chinitz, L. A.; Tsai, M. C., QT prolongation, torsades de pointes and sudden death with short courses of chloroquine or hydroxychloroquine as used in COVID-19: a systematic review. *Heart Rhythm* **2020**.
242. (U) Jarvis, C. I.; Van Zandvoort, K.; Gimma, A.; Prem, K.; Klepac, P.; Rubin, G. J.; Edmunds, W. J., Quantifying the impact of physical distance measures on the transmission of COVID-19 in the UK. *BMC Med* **2020**, *18* (1), 124.
243. (U) Jenco, M., CDC details COVID-19-related inflammatory syndrome in children. *AAP News* 2020. <https://www.aappublications.org/news/2020/05/14/covid19inflammatory051420>

244. (U) JHU, Coronavirus COVID-19 Global Cases by Johns Hopkins CSSE.  
<https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6>.
245. (U) Jiang, F.-C.; Jiang, X.-L.; Wang, Z.-G.; Meng, Z.-H.; Shao, S.-F.; Anderson, B. D.; Ma, M.-J., Detection of Severe Acute Respiratory Syndrome Coronavirus 2 RNA on Surfaces in Quarantine Rooms. *Emerging Infectious Diseases* **2020**, *26*. [https://wwwnc.cdc.gov/eid/article/26/9/20-1435\\_article](https://wwwnc.cdc.gov/eid/article/26/9/20-1435_article)
246. (U) Jin, J.-M.; Bai, P.; He, W.; Wu, F.; Liu, X.-F.; Han, D.-M.; Liu, S.; Yang, J.-K., Gender Differences in Patients With COVID-19: Focus on Severity and Mortality. *Frontiers in Public Health* **2020**, *8* (152).  
<https://www.frontiersin.org/article/10.3389/fpubh.2020.00152>
247. (U) Jing, C.; Wenjie, S.; Jianping, H.; Michelle, G.; Jing, W.; Guiqing, H., Indirect Virus Transmission in Cluster of COVID-19 Cases, Wenzhou, China, 2020. *Emerging Infectious Disease journal* **2020**, *26* (6).  
[https://wwwnc.cdc.gov/eid/article/26/6/20-0412\\_article](https://wwwnc.cdc.gov/eid/article/26/6/20-0412_article)
248. (U) Jing, Q.-L.; Liu, M.-J.; Zhang, Z.-B.; Fang, L.-Q.; Yuan, J.; Zhang, A.-R.; Dean, N. E.; Luo, L.; Ma, M.-M.; Longini, I.; Kenah, E.; Lu, Y.; Ma, Y.; Jalali, N.; Yang, Z.-C.; Yang, Y., Household secondary attack rate of COVID-19 and associated determinants in Guangzhou, China: a retrospective cohort study. *The Lancet Infectious Diseases* **2020**. [https://doi.org/10.1016/S1473-3099\(20\)30471-0](https://doi.org/10.1016/S1473-3099(20)30471-0)
249. (U) Johndrow, J. E.; Lum, K.; Ball, P., Estimating SARS-CoV-2-positive Americans using deaths-only data. *arXiv preprint arXiv:2004.02605* **2020**.
250. (U) Johnson, J., Johnson & Johnson Announces Acceleration of its COVID-19 Vaccine Candidate; Phase 1/2a Clinical Trial to Begin in Second Half of July. <https://www.jnj.com/johnson-johnson-announces-acceleration-of-its-covid-19-vaccine-candidate-phase-1-2a-clinical-trial-to-begin-in-second-half-of-july>.
251. (U) Johnston, S. C.; Jay, A.; Raymond, J. L.; Rossi, F.; Zeng, X.; Scruggs, J.; Dyer, D.; Frick, O.; Moore, J.; Berrier, K.; Esham, H.; Shamblin, J.; Sifford, W.; Fiallos, J.; Klosterman, L.; Stevens, S.; White, L.; Bowling, P.; Garcia, T.; Jensen, C.; Ghering, J.; Nyakiti, D.; Bellanca, S.; Kearney, B.; Giles, W.; Alli, N.; Paz, F.; Akers, K.; Danner, D.; Barth, J.; Johnson, J. A.; Durant, M.; Kim, R.; Pitt, M. L. M.; Nalca, A., Development of a Coronavirus Disease 2019 Nonhuman Primate Model Using Airborne Exposure. *bioRxiv* **2020**, 2020.06.26.174128.  
<http://biorxiv.org/content/early/2020/06/26/2020.06.26.174128.abstract>
252. (U) Jones, R. M., Relative contributions of transmission routes for COVID-19 among healthcare personnel providing patient care. *Journal of Occupational and Environmental Hygiene* **2020**, 1-8.  
<https://doi.org/10.1080/15459624.2020.1784427>
253. (U) Joseph, A., CDC developing serologic tests that could reveal full scope of U.S. coronavirus outbreak. *STAT* **2020**. <https://www.statnews.com/2020/03/11/cdc-developing-serologic-tests-that-could-reveal-full-scope-of-u-s-coronavirus-outbreak/>
254. (U) Joyner, M.; Wright, R. S.; Fairweather, D.; Senefeld, J.; Bruno, K.; Klassen, S.; Carter, R.; Klompas, A.; Wiggins, C.; Shepherd, J. R.; Rea, R.; Whelan, E.; Clayburn, A.; Spiegel, M.; Johnson, P.; Lesser, E.; Baker, S.; Larson, K.; Ripoll Sanz, J.; Andersen, K.; Hodge, D.; Kunze, K.; Buras, M.; Vogt, M.; Herasevich, V.; Dennis, J.; Regimbal, R.; Bauer, P.; Blair, J.; van Buskirk, C.; Winters, J.; Stubbs, J.; Paneth, N.; Casadevall, A., Early Safety Indicators of COVID-19 Convalescent Plasma in 5,000 Patients. *medRxiv* **2020**, 2020.05.12.20099879.  
<https://www.medrxiv.org/content/medrxiv/early/2020/05/14/2020.05.12.20099879.full.pdf>
255. (U) Juan, J.; Gil, M. M.; Rong, Z.; Zhang, Y.; Yang, H.; Poon, L. C. Y., Effects of Coronavirus Disease 2019 (COVID-19) on Maternal, Perinatal and Neonatal Outcomes: a Systematic Review of 266 Pregnancies. *medRxiv* **2020**, 2020.05.02.20088484.  
<https://www.medrxiv.org/content/medrxiv/early/2020/05/06/2020.05.02.20088484.full.pdf>
256. (U) Jüni, P.; Rothenbühler, M.; Bobos, P.; Thorpe, K. E.; da Costa, B. R.; Fisman, D. N.; Slutsky, A. S.; Gesink, D., Impact of climate and public health interventions on the COVID-19 pandemic: A prospective

cohort study. *Canadian Medical Association Journal* **2020**, cmaj.200920.

<https://www.cmaj.ca/content/cmaj/early/2020/05/08/cmaj.200920.full.pdf>

257. (U) Kaafarani, H. M. A.; El Moheb, M.; Hwabejire, J. O.; Naar, L.; Christensen, M. A.; Breen, K.; Gaitanidis, A.; Alser, O.; Mashbari, H.; Bankhead-Kendall, B.; Mokhtari, A.; Maurer, L.; Kapoen, C.; Langeveld, K.; El Hechi, M. W.; Lee, J.; Mendoza, A. E.; Saillant, N. N.; Parks, J.; Fawley, J.; King, D. R.; Fagenholz, P. J.; Velmahos, G. C., Gastrointestinal Complications in Critically Ill Patients With COVID-19. *Annals of Surgery* **2020**, 272 (2), e61-e62.

[https://journals.lww.com/annalsofsurgery/Fulltext/2020/08000/Gastrointestinal\\_Complications\\_in\\_Critically\\_Ill.18.aspx](https://journals.lww.com/annalsofsurgery/Fulltext/2020/08000/Gastrointestinal_Complications_in_Critically_Ill.18.aspx)

258. (U) Karamitros, T.; Papadopoulou, G.; Bousali, M.; Mexias, A.; Tsiodras, S.; Mentis, A., SARS-CoV-2 exhibits intra-host genomic plasticity and low-frequency polymorphic quasispecies. *bioRxiv* **2020**, 2020.03.27.009480. <http://biorxiv.org/content/early/2020/03/28/2020.03.27.009480.abstract>

259. (U) Karnakov, P.; Arampatzis, G.; Kičić, I.; Wermelinger, F.; Wälchli, D.; Papadimitriou, C.; Koumoutsakos, P., Data driven inference of the reproduction number (R0) for COVID-19 before and after interventions for 51 European countries. **2020**.

260. (U) KCDC, Findings from investigation and analysis of re-positive cases. Korean Centers for Disease Control and Prevention: 2020. <https://www.cdc.go.kr/board/board.es?mid=a30402000000&bid=0030>

261. (U) Khalil, A.; von Dadelszen, P.; Draycott, T.; Ugwumadu, A.; O'Brien, P.; Magee, L., Change in the Incidence of Stillbirth and Preterm Delivery During the COVID-19 Pandemic. *JAMA* **2020**.

<https://doi.org/10.1001/jama.2020.12746>

262. (U) Kim, S. E.; Jeong, H. S.; Yu, Y.; Shin, S. U.; Kim, S.; Oh, T. H.; Kim, U. J.; Kang, S. J.; Jang, H. C.; Jung, S. I.; Park, K. H., Viral kinetics of SARS-CoV-2 in asymptomatic carriers and presymptomatic patients. *Int J Infect Dis* **2020**.

263. (U) Kim, Y.-I.; Kim, S.-G.; Kim, S.-M.; Kim, E.-H.; Park, S.-J.; Yu, K.-M.; Chang, J.-H.; Kim, E. J.; Lee, S.; Casel, M. A. B.; Um, J.; Song, M.-S.; Jeong, H. W.; Lai, V. D.; Kim, Y.; Chin, B. S.; Park, J.-S.; Chung, K.-H.; Foo, S.-S.; Poo, H.; Mo, I.-P.; Lee, O.-J.; Webby, R. J.; Jung, J. U.; Choi, Y. K., Infection and Rapid Transmission of SARS-CoV-2 in Ferrets. *Cell Host & Microbe* **2020**.

<http://www.sciencedirect.com/science/article/pii/S1931312820301876>

264. (U) Kissler, S. M.; Tedijanto, C.; Goldstein, E.; Grad, Y. H.; Lipsitch, M., Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. *Science* **2020**, eabb5793.

<https://science.sciencemag.org/content/sci/early/2020/04/14/science.abb5793.full.pdf>

265. (U) Klok, F.; Kruip, M.; van der Meer, N.; Arbous, M.; Gommers, D.; Kant, K.; Kaptein, F.; van Paassen, J.; Stals, M.; Huisman, M., Incidence of thrombotic complications in critically ill ICU patients with COVID-19. *Thrombosis Research* **2020**.

266. (U) Klumpp-Thomas, C.; Kalish, H.; Drew, M.; Hunsberger, S.; Snead, K.; Fay, M. P.; Mehalko, J.; Shunmugavel, A.; Wall, V.; Frank, P.; Denson, J.-P.; Hong, M.; Gulten, G.; Messing, S.; Hicks, J.; Michael, S.; Gillette, W.; Hall, M. D.; Memoli, M.; Esposito, D.; Sadtler, K., Standardization of enzyme-linked immunosorbent assays for serosurveys of the SARS-CoV-2 pandemic using clinical and at-home blood sampling. *medRxiv* **2020**, 2020.05.21.20109280.

<https://www.medrxiv.org/content/medrxiv/early/2020/05/25/2020.05.21.20109280.full.pdf>

267. (U) Knorr, J. P.; Colomy, V.; Mauriello, C. M.; Ha, S., Tocilizumab in patients with severe COVID-19: A single-center observational analysis. *Journal of Medical Virology* **2020**, n/a (n/a).

<https://doi.org/10.1002/jmv.26191>

268. (U) Komissarov, A.; Molodtsov, I.; Ivanova, O.; Maryukhnich, E.; Kudryavtseva, S.; Mazus, A.; Nikonov, E.; Vasilieva, E., Hydroxychloroquine has no effect on SARS-CoV-2 load in nasopharynx of patients with mild form of COVID-19. *medRxiv* **2020**, 2020.06.30.20143289.

<http://medrxiv.org/content/early/2020/07/03/2020.06.30.20143289.abstract>

269. (U) Konda, A.; Prakash, A.; Moss, G. A.; Schmoltdt, M.; Grant, G. D.; Guha, S., Aerosol Filtration Efficiency of Common Fabrics Used in Respiratory Cloth Masks. *ACS Nano* **2020**.  
<https://www.ncbi.nlm.nih.gov/pubmed/32329337>
270. (U) Kong, D.; Zheng, Y.; Wu, H.; Pan, H.; Wagner, A. L.; Zheng, Y.; Gong, X.; Zhu, Y.; Jin, B.; Xiao, W.; Mao, S.; Lin, S.; Han, R.; Yu, X.; Cui, P.; Jiang, C.; Fang, Q.; Lu, Y.; Fu, C., Pre-symptomatic transmission of novel coronavirus in community settings. *Influenza and Other Respiratory Viruses* **2020**, n/a (n/a).  
<https://onlinelibrary.wiley.com/doi/abs/10.1111/irv.12773>
271. (U) Kong, T.-k., Longer incubation period of coronavirus disease 2019 (COVID-19) in older adults. *AGING MEDICINE* **2020**, 3 (2), 102-109. <https://onlinelibrary.wiley.com/doi/abs/10.1002/agm2.12114>
272. (U) Koo, J. R.; Cook, A. R.; Park, M.; Sun, Y.; Sun, H.; Lim, J. T.; Tam, C.; Dickens, B. L., Interventions to mitigate early spread of SARS-CoV-2 in Singapore: a modelling study. *The Lancet Infectious Diseases* **2020**, 20 (6), 678-688. [https://doi.org/10.1016/S1473-3099\(20\)30162-6](https://doi.org/10.1016/S1473-3099(20)30162-6)
273. (U) Korber, B.; Fischer, W. M.; Gnanakaran, S.; Yoon, H.; Theiler, J.; Abfalterer, W.; Hengartner, N.; Giorgi, E. E.; Bhattacharya, T.; Foley, B.; Hastie, K. M.; Parker, M. D.; Partridge, D. G.; Evans, C. M.; Freeman, T. M.; de Silva, T. I.; McDanal, C.; Perez, L. G.; Tang, H.; Moon-Walker, A.; Whelan, S. P.; LaBranche, C. C.; Saphire, E. O.; Montefiori, D. C.; Angyal, A.; Brown, R. L.; Carrilero, L.; Green, L. R.; Groves, D. C.; Johnson, K. J.; Keeley, A. J.; Lindsey, B. B.; Parsons, P. J.; Raza, M.; Rowland-Jones, S.; Smith, N.; Tucker, R. M.; Wang, D.; Wyles, M. D., Tracking changes in SARS-CoV-2 Spike: evidence that D614G increases infectivity of the COVID-19 virus. *Cell* **2020**. <https://doi.org/10.1016/j.cell.2020.06.043>
274. (U) Korevaar, D. A.; Kootte, R. S.; Smits, L. P.; van den Aardweg, J. G.; Bonta, P. I.; Schinkel, J.; Vigeveno, R. M.; van den Berk, I. A. H.; Scheerder, M. J.; Lemkes, B. A.; Goorhuis, A.; Beenen, L. F. M.; Annema, J. T., Added value of chest CT in suspected COVID-19: an analysis of 239 patients. *European Respiratory Journal* **2020**, 2001377.  
<https://erj.ersjournals.com/content/erj/early/2020/06/25/13993003.01377-2020.full.pdf>
275. (U) Korevaar, H. M.; Becker, A. D.; Miller, I. F.; Grenfell, B. T.; Metcalf, C. J. E.; Mina, M. J., Quantifying the impact of US state non-pharmaceutical interventions on COVID-19 transmission. *medRxiv* **2020**, 2020.06.30.20142877.  
<https://www.medrxiv.org/content/medrxiv/early/2020/07/01/2020.06.30.20142877.full.pdf>
276. (U) Kraemer, M. U. G.; Yang, C.-H.; Gutierrez, B.; Wu, C.-H.; Klein, B.; Pigott, D. M.; du Plessis, L.; Faria, N. R.; Li, R.; Hanage, W. P.; Brownstein, J. S.; Layan, M.; Vespignani, A.; Tian, H.; Dye, C.; Pybus, O. G.; Scarpino, S. V., The effect of human mobility and control measures on the COVID-19 epidemic in China. *Science* **2020**, eabb4218.  
<https://science.sciencemag.org/content/sci/early/2020/03/25/science.abb4218.full.pdf>
277. (U) Kratzel, A.; Todt, D.; V'kovski, P.; Steiner, S.; Gultom, M. L.; Thao, T. T. N.; Ebert, N.; Holwerda, M.; Steinmann, J.; Niemeyer, D.; Dijkman, R.; Kampf, G.; Drosten, C.; Steinmann, E.; Thiel, V.; Pfaender, S., Efficient inactivation of SARS-CoV-2 by WHO-recommended hand rub formulations and alcohols. *bioRxiv* **2020**, 2020.03.10.986711.  
<https://www.biorxiv.org/content/biorxiv/early/2020/03/17/2020.03.10.986711.full.pdf>
278. (U) Krever, M.; Picheta, R., A mink may have infected a human with Covid-19, Dutch authorities believe. *CNN* **2020**. <https://edition.cnn.com/2020/05/20/europe/coronavirus-mink-netherlands-testing-intl/index.html>
279. (U) Kucharski, A. J.; Klepac, P.; Conlan, A. J. K.; Kissler, S. M.; Tang, M. L.; Fry, H.; Gog, J. R.; Edmunds, W. J., Effectiveness of isolation, testing, contact tracing, and physical distancing on reducing transmission of SARS-CoV-2 in different settings: a mathematical modelling study. *Lancet Infect Dis* **2020**.
280. (U) Kucharski, A. J.; Russell, T. W.; Diamond, C.; Liu, Y.; Edmunds, J.; Funk, S.; Eggo, R. M.; Sun, F.; Jit, M.; Munday, J. D., Early dynamics of transmission and control of COVID-19: a mathematical modelling study. *The lancet infectious diseases* **2020**.

281. (U) Kucirka, L. M.; Lauer, S. A.; Laeyendecker, O.; Boon, D., Variation in False-Negative Rate of Reverse Transcriptase Polymerase Chain Reaction–Based SARS-CoV-2 Tests by Time Since Exposure. *Annals of Internal Medicine* **2020**, 0 (0), null. <https://www.acpjournals.org/doi/abs/10.7326/M20-1495>
282. (U) Lai, S.; Ruktanonchai, N. W.; Zhou, L.; Prosper, O.; Luo, W.; Floyd, J. R.; Wesolowski, A.; Santillana, M.; Zhang, C.; Du, X.; Yu, H.; Tatem, A. J., Effect of non-pharmaceutical interventions to contain COVID-19 in China. *Nature* **2020**. <https://doi.org/10.1038/s41586-020-2293-x>
283. (U) Lam, T. T.-Y.; Shum, M. H.-H.; Zhu, H.-C.; Tong, Y.-G.; Ni, X.-B.; Liao, Y.-S.; Wei, W.; Cheung, W. Y.-M.; Li, W.-J.; Li, L.-F.; Leung, G. M.; Holmes, E. C.; Hu, Y.-L.; Guan, Y., Identifying SARS-CoV-2 related coronaviruses in Malayan pangolins. *Nature* **2020**. <https://doi.org/10.1038/s41586-020-2169-0>
284. (U) Lan, L.; Xu, D.; Ye, G.; Xia, C.; Wang, S.; Li, Y.; Xu, H., Positive RT-PCR Test Results in Patients Recovered From COVID-19. *Jama* **2020**. <https://jamanetwork.com/journals/jama/fullarticle/2762452>
285. (U) LANL, COVID-19 Confirmed and Forecasted Case Data. <https://covid-19.bsvgateway.org/>.
286. (U) Lasry, A.; Kidder, D.; Hast, M.; Poovey, J.; Sunshine, G.; Zviedrite, N.; Ahmed, F.; Ethier, K. A., Timing of community mitigation and changes in reported COVID-19 and community mobility—four US metropolitan areas, February 26–April 1, 2020. *morbidity and Mortality Weekly Report* **2020**, 69, 451-457. <https://www.cdc.gov/mmwr/volumes/69/wr/mm6915e2.htm>
287. (U) Lassaunière, R.; Frische, A.; Harboe, Z. B.; Nielsen, A. C.; Fomsgaard, A.; Krogfelt, K. A.; Jørgensen, C. S., Evaluation of nine commercial SARS-CoV-2 immunoassays. *medRxiv* **2020**, 2020.04.09.20056325. <https://www.medrxiv.org/content/medrxiv/early/2020/04/10/2020.04.09.20056325.full.pdf>
288. (U) Lau, S., Coronavirus: WHO official says there's no evidence of 'reinfected' patients in China <https://www.scmp.com/news/china/society/article/3074045/coronavirus-who-official-says-theres-no-evidence-reinfected>.
289. (U) Lauer, S. A.; Grantz, K. H.; Bi, Q.; Jones, F. K.; Zheng, Q.; Meredith, H. R.; Azman, A. S.; Reich, N. G.; Lessler, J., The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. *Annals of Internal Medicine* **2020**. <https://doi.org/10.7326/M20-0504>
290. (U) Lavezzo, E.; Franchin, E.; Ciavarella, C.; Cuomo-Dannenburg, G.; Barzon, L.; Del Vecchio, C.; Rossi, L.; Manganelli, R.; Loregian, A.; Navarin, N.; Abate, D.; Sciro, M.; Merigliano, S.; De Canale, E.; Vanuzzo, M. C.; Besutti, V.; Saluzzo, F.; Onelia, F.; Pacenti, M.; Parisi, S.; Carretta, G.; Donato, D.; Flor, L.; Cocchio, S.; Masi, G.; Sperduti, A.; Cattarino, L.; Salvador, R.; Nicoletti, M.; Caldart, F.; Castelli, G.; Nieddu, E.; Labella, B.; Fava, L.; Drigo, M.; Gaythorpe, K. A. M.; Ainslie, K. E. C.; Baguelin, M.; Bhatt, S.; Boonyasiri, A.; Boyd, O.; Cattarino, L.; Ciavarella, C.; Coupland, H. L.; Cucunubá, Z.; Cuomo-Dannenburg, G.; Djafaara, B. A.; Donnelly, C. A.; Dorigatti, I.; van Elsland, S. L.; FitzJohn, R.; Flaxman, S.; Gaythorpe, K. A. M.; Green, W. D.; Hallett, T.; Hamlet, A.; Haw, D.; Imai, N.; Jeffrey, B.; Knock, E.; Laydon, D. J.; Mellan, T.; Mishra, S.; Nedjati-Gilani, G.; Nouvellet, P.; Okell, L. C.; Parag, K. V.; Riley, S.; Thompson, H. A.; Unwin, H. J. T.; Verity, R.; Vollmer, M. A. C.; Walker, P. G. T.; Walters, C. E.; Wang, H.; Wang, Y.; Watson, O. J.; Whittaker, C.; Whittles, L. K.; Xi, X.; Ferguson, N. M.; Brazzale, A. R.; Toppo, S.; Trevisan, M.; Baldo, V.; Donnelly, C. A.; Ferguson, N. M.; Dorigatti, I.; Crisanti, A.; Imperial College, C.-R. T., Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo'. *Nature* **2020**. <https://doi.org/10.1038/s41586-020-2488-1>
291. (U) Le Bert, N.; Tan, A. T.; Kunasegaran, K.; Tham, C. Y. L.; Hafezi, M.; Chia, A.; Chng, M. H. Y.; Lin, M.; Tan, N.; Linstler, M.; Chia, W. N.; Chen, M. I. C.; Wang, L.-F.; Ooi, E. E.; Kalimuddin, S.; Tambyah, P. A.; Low, J. G.-H.; Tan, Y.-J.; Bertoletti, A., SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. *Nature* **2020**. <https://doi.org/10.1038/s41586-020-2550-z>
292. (U) Leclerc, Q.; Fuller, N.; Knight, L.; null, n.; Funk, S.; Knight, G., What settings have been linked to SARS-CoV-2 transmission clusters? [version 2; peer review: 2 approved]. *Wellcome Open Research* **2020**, 5 (83). <https://wellcomeopenresearch.org/articles/5-83/v2>

293. (U) Lee, J.; Hughes, T.; Lee, M.-H.; Field, H.; Rovie-Ryan, J. J.; Sitam, F. T.; Sipangkui, S.; Nathan, S. K. S. S.; Ramirez, D.; Kumar, S. V.; Lasimbang, H.; Epstein, J. H.; Daszak, P., No evidence of coronaviruses or other potentially zoonotic viruses in Sunda pangolins (<em>Manis javanica</em>) entering the wildlife trade via Malaysia. *bioRxiv* **2020**, 2020.06.19.158717.  
<https://www.biorxiv.org/content/biorxiv/early/2020/06/19/2020.06.19.158717.full.pdf>
294. (U) Lee, T. C.; MacKenzie, L. J.; McDonald, E. G.; Tong, S. Y. C., An Observational Cohort Study of Hydroxychloroquine and Azithromycin for COVID-19: (Can't Get No) Satisfaction. *International Journal of Infectious Diseases* **2020**. <https://doi.org/10.1016/j.ijid.2020.06.095>
295. (U) Lee, Y.-H.; Hong, C. M.; Kim, D. H.; Lee, T. H.; Lee, J., Clinical Course of Asymptomatic and Mildly Symptomatic Patients with Coronavirus Disease Admitted to Community Treatment Centers, South Korea. *Emerging Infectious Disease journal* **2020**, 26 (10). [https://wwwnc.cdc.gov/eid/article/26/10/20-1620\\_article](https://wwwnc.cdc.gov/eid/article/26/10/20-1620_article)
296. (U) Leung, K.; Wu, J. T.; Liu, D.; Leung, G. M., First-wave COVID-19 transmissibility and severity in China outside Hubei after control measures, and second-wave scenario planning: a modelling impact assessment. *The Lancet*. [https://doi.org/10.1016/S0140-6736\(20\)30746-7](https://doi.org/10.1016/S0140-6736(20)30746-7)
297. (U) Leung, N. H. L.; Chu, D. K. W.; Shiu, E. Y. C.; Chan, K.-H.; McDevitt, J. J.; Hau, B. J. P.; Yen, H.-L.; Li, Y.; Ip, D. K. M.; Peiris, J. S. M.; Seto, W.-H.; Leung, G. M.; Milton, D. K.; Cowling, B. J., Respiratory virus shedding in exhaled breath and efficacy of face masks. *Nature Medicine* **2020**.  
<https://doi.org/10.1038/s41591-020-0843-2>
298. (U) Levi, M.; Thachil, J.; Iba, T.; Levy, J. H., Coagulation abnormalities and thrombosis in patients with COVID-19. *The Lancet Haematology* **2020**. [https://doi.org/10.1016/S2352-3026\(20\)30145-9](https://doi.org/10.1016/S2352-3026(20)30145-9)
299. (U) Lewis, D., Is the coronavirus airborne? Experts can't agree. *Nature* **2020**. 10.1038/d41586-020-00974-w
300. (U) Li, D.; Jin, M.; Bao, P.; Zhao, W.; Zhang, S., Clinical Characteristics and Results of Semen Tests Among Men With Coronavirus Disease 2019. *JAMA Network Open* **2020**, 3 (5), e208292-e208292.  
<https://doi.org/10.1001/jamanetworkopen.2020.8292>
301. (U) Li, K.; Wohlford-Lenane, C.; Perlman, S.; Zhao, J.; Jewell, A. K.; Reznikov, L. R.; Gibson-Corley, K. N.; Meyerholz, D. K.; McCray, P. B., Jr., Middle East Respiratory Syndrome Coronavirus Causes Multiple Organ Damage and Lethal Disease in Mice Transgenic for Human Dipeptidyl Peptidase 4. *J Infect Dis* **2016**, 213 (5), 712-22. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747621/pdf/jiv499.pdf>
302. (U) Li, L.; Zhang, W.; Hu, Y.; Tong, X.; Zheng, S.; Yang, J.; Kong, Y.; Ren, L.; Wei, Q.; Mei, H.; Hu, C.; Tao, C.; Yang, R.; Wang, J.; Yu, Y.; Guo, Y.; Wu, X.; Xu, Z.; Zeng, L.; Xiong, N.; Chen, L.; Wang, J.; Man, N.; Liu, Y.; Xu, H.; Deng, E.; Zhang, X.; Li, C.; Wang, C.; Su, S.; Zhang, L.; Wang, J.; Wu, Y.; Liu, Z., Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. *JAMA* **2020**.  
<https://doi.org/10.1001/jama.2020.10044>
303. (U) Li, Q.; Guan, X.; Wu, P.; Wang, X.; Zhou, L.; Tong, Y.; Ren, R.; Leung, K. S. M.; Lau, E. H. Y.; Wong, J. Y.; Xing, X.; Xiang, N.; Wu, Y.; Li, C.; Chen, Q.; Li, D.; Liu, T.; Zhao, J.; Liu, M.; Tu, W.; Chen, C.; Jin, L.; Yang, R.; Wang, Q.; Zhou, S.; Wang, R.; Liu, H.; Luo, Y.; Liu, Y.; Shao, G.; Li, H.; Tao, Z.; Yang, Y.; Deng, Z.; Liu, B.; Ma, Z.; Zhang, Y.; Shi, G.; Lam, T. T. Y.; Wu, J. T.; Gao, G. F.; Cowling, B. J.; Yang, B.; Leung, G. M.; Feng, Z., Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. *New England Journal of Medicine* **2020**. <https://www.nejm.org/doi/full/10.1056/NEJMoa2001316>  
<https://www.nejm.org/doi/10.1056/NEJMoa2001316>
304. (U) Li, R.; Pei, S.; Chen, B.; Song, Y.; Zhang, T.; Yang, W.; Shaman, J., Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2). *Science* **2020**, eabb3221.  
<https://science.sciencemag.org/content/sci/early/2020/03/13/science.abb3221.full.pdf>

305. (U) Li, W.; Zhang, B.; Lu, J.; Liu, S.; Chang, Z.; Cao, P.; Liu, X.; Zhang, P.; Ling, Y.; Tao, K.; Chen, J., The characteristics of household transmission of COVID-19. *Clinical Infectious Diseases* **2020**.  
<https://doi.org/10.1093/cid/ciaa450>
306. (U) Li, X.; Giorgi, E. E.; Marichannegowda, M. H.; Foley, B.; Xiao, C.; Kong, X.-P.; Chen, Y.; Gnanakaran, S.; Korber, B.; Gao, F., Emergence of SARS-CoV-2 through recombination and strong purifying selection. *Science Advances* **2020**, eabb9153.  
<https://advances.sciencemag.org/content/advances/early/2020/05/28/sciadv.abb9153.full.pdf>
307. (U) Li, X.; Xiao, K.; Chen, X.; Liang, X.; Zhang, X.; Zhang, Z.; Zhai, J.; Wang, R.; Zhou, N.; Chen, Z.-J.; Su, R.; Zhou, F.; Holmes, E. C.; Irwin, D. M.; Chen, R.-A.; He, Q.; Wu, Y.-J.; Wang, C.; Du, X.-Q.; Peng, S.-M.; Xie, W.-J.; Shan, F.; Li, W.-P.; Dai, J.-W.; Shen, X.; Feng, Y.; Xiao, L.; Chen, W.; Shen, Y., Pathogenicity, tissue tropism and potential vertical transmission of SARS-CoV-2 in Malayan pangolins. *bioRxiv* **2020**, 2020.06.22.164442. <http://biorxiv.org/content/early/2020/06/22/2020.06.22.164442.abstract>
308. (U) Li, X.; Zai, J.; Zhao, Q.; Nie, Q.; Li, Y.; Foley, B. T.; Chaillon, A., Evolutionary history, potential intermediate animal host, and cross-species analyses of SARS-CoV-2. *Journal of Medical Virology* **2020**, n/a (n/a). <https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.25731>
309. (U) Li, Y.; Qian, H.; Hang, J.; Chen, X.; Hong, L.; Liang, P.; Li, J.; Xiao, S.; Wei, J.; Liu, L.; Kang, M., Evidence for probable aerosol transmission of SARS-CoV-2 in a poorly ventilated restaurant. *medRxiv* **2020**, 2020.04.16.20067728.  
<https://www.medrxiv.org/content/medrxiv/early/2020/04/22/2020.04.16.20067728.full.pdf>
310. (U) Li, Y.; Xie, Z.; Lin, W.; Cai, W.; Wen, C.; Guan, Y.; Mo, X.; Wang, J.; Wang, Y.; Peng, P.; Chen, X.; Hong, W.; Xiao, G.; Liu, J.; Zhang, L.; Hu, F.; Li, F.; Zhang, F.; Deng, X.; Li, L., Efficacy and safety of lopinavir/ritonavir or arbidol in adult patients with mild/moderate COVID-19: an exploratory randomized controlled trial. *Med*. <https://doi.org/10.1016/j.medj.2020.04.001>
311. (U) Lisboa Bastos, M.; Tavaziva, G.; Abidi, S. K.; Campbell, J. R.; Haraoui, L.-P.; Johnston, J. C.; Lan, Z.; Law, S.; MacLean, E.; Trajman, A.; Menzies, D.; Benedetti, A.; Ahmad Khan, F., Diagnostic accuracy of serological tests for covid-19: systematic review and meta-analysis. *BMJ* **2020**, 370, m2516.  
<https://www.bmj.com/content/bmj/370/bmj.m2516.full.pdf>
312. (U) Liu, A., China's CanSino Bio advances COVID-19 vaccine into phase 2 on preliminary safety data. *Fierce Pharma* **2020**. <https://www.fiercepharma.com/vaccines/china-s-cansino-bio-advances-covid-19-vaccine-into-phase-2-preliminary-safety-data>
313. (U) Liu, A., China's Sinopharm touts 100% antibody response for COVID-19 vaccine it's already giving to workers <https://www.fiercepharma.com/pharma-asia/china-s-sinopharm-touts-100-antibody-response-for-covid-19-vaccine-it-s-already-giving>.
314. (U) Liu, L.; To, K. K.-W.; Chan, K.-H.; Wong, Y.-C.; Zhou, R.; Kwan, K.-Y.; Fong, C. H.-Y.; Chen, L.-L.; Choi, C. Y.-K.; Lu, L.; Tsang, O. T.-Y.; Leung, W.-S.; To, W.-K.; Hung, I. F.-N.; Yuen, K.-Y.; Chen, Z., High neutralizing antibody titer in intensive care unit patients with COVID-19. *Emerging Microbes & Infections* **2020**, 1-30. <https://doi.org/10.1080/22221751.2020.1791738>
315. (U) Liu, P.; Chen, W.; Chen, J.-P., Viral Metagenomics Revealed Sendai Virus and Coronavirus Infection of Malayan Pangolins (*Manis javanica*). *Viruses* **2019**, 11 (11), 979.  
<https://www.mdpi.com/1999-4915/11/11/979>
316. (U) Liu, P.; Jiang, J.-Z.; Wan, X.-F.; Hua, Y.; Li, L.; Zhou, J.; Wang, X.; Hou, F.; Chen, J.; Zou, J.; Chen, J., Are pangolins the intermediate host of the 2019 novel coronavirus (SARS-CoV-2)? *PLOS Pathogens* **2020**, 16 (5), e1008421. <https://doi.org/10.1371/journal.ppat.1008421>
317. (U) Liu, P.; Jiang, J.-Z.; Wan, X.-F.; Hua, Y.; Wang, X.; Hou, F.; Chen, J.; Zou, J.; Chen, J., Are pangolins the intermediate host of the 2019 novel coronavirus (2019-nCoV) ? *bioRxiv* **2020**, 2020.02.18.954628.  
<http://biorxiv.org/content/early/2020/02/20/2020.02.18.954628.abstract>



318. (U) Liu, R.; Woo, R., CanSino's COVID-19 vaccine candidate approved for military use in China. <https://uk.reuters.com/article/us-health-coronavirus-china-vaccine/cansinos-covid-19-vaccine-candidate-approved-for-military-use-in-china-idUKKBN2400DZ>.
319. (U) Liu, S. T. H.; Lin, H.-M.; Baine, I.; Wajnberg, A.; Gumprecht, J. P.; Rahman, F.; Rodriguez, D.; Tandon, P.; Bassily-Marcus, A.; Bander, J.; Sanky, C.; Dupper, A.; Zheng, A.; Altman, D. R.; Chen, B. K.; Krammer, F.; Mendu, D. R.; Firpo-Betancourt, A.; Levin, M. A.; Bagiella, E.; Casadevall, A.; Cordon-Cardo, C.; Jhang, J. S.; Arinsburg, S. A.; Reich, D. L.; Aberg, J. A.; Bouvier, N. M., Convalescent plasma treatment of severe COVID-19: A matched control study. *medRxiv* **2020**, 2020.05.20.20102236. <https://www.medrxiv.org/content/medrxiv/early/2020/05/22/2020.05.20.20102236.full.pdf>
320. (U) Liu, W.; Zhang, Q.; Chen, J.; Xiang, R.; Song, H.; Shu, S.; Chen, L.; Liang, L.; Zhou, J.; You, L.; Wu, P.; Zhang, B.; Lu, Y.; Xia, L.; Huang, L.; Yang, Y.; Liu, F.; Semple, M. G.; Cowling, B. J.; Lan, K.; Sun, Z.; Yu, H.; Liu, Y., Detection of Covid-19 in Children in Early January 2020 in Wuhan, China. *New England Journal of Medicine* **2020**. <https://www.nejm.org/doi/full/10.1056/NEJMc2003717>
321. (U) Liu, Y.; Funk, S.; Flasche, S., *The Contribution of Pre-symptomatic Transmission to the COVID-19 Outbreak*; London School of Hygiene and Tropical Medicine: 2020. <https://cmimid.github.io/topics/covid19/control-measures/pre-symptomatic-transmission.html>
322. (U) Liu, Y.; Hu, G.; Wang, Y.; Zhao, X.; Ji, F.; Ren, W.; Gong, M.; Ju, X.; Li, C.; Hong, J.; Zhu, Y.; Cai, X.; Wu, J.; Lan, X.; Xie, Y.; Wang, X.; Yuan, Z.; Zhang, R.; Ding, Q., Functional and Genetic Analysis of Viral Receptor ACE2 Orthologs Reveals a Broad Potential Host Range of SARS-CoV-2. *bioRxiv* **2020**, 2020.04.22.046565. <https://www.biorxiv.org/content/biorxiv/early/2020/05/03/2020.04.22.046565.full.pdf>
323. (U) Liu, Y.; Li, T.; Deng, Y.; Liu, S.; Zhang, D.; Li, H.; Wang, X.; Jia, L.; Han, J.; Bei, Z.; Zhou, Y.; Li, L.; Li, J., Stability of SARS-CoV-2 on environmental surfaces and in human excreta. *medRxiv* **2020**, 2020.05.07.20094805. <https://www.medrxiv.org/content/medrxiv/early/2020/05/12/2020.05.07.20094805.full.pdf>
324. (U) Liu, Y.; Ning, Z.; Chen, Y.; Guo, M.; Liu, Y.; Gali, N. K.; Sun, L.; Duan, Y.; Cai, J.; Westerdahl, D.; Liu, X.; Xu, K.; Ho, K.-f.; Kan, H.; Fu, Q.; Lan, K., Aerodynamic analysis of SARS-CoV-2 in two Wuhan hospitals. *Nature* **2020**. <https://doi.org/10.1038/s41586-020-2271-3>
325. (U) Lokken, E. M.; Walker, C. L.; Delaney, S.; Kachikis, A.; Kretzer, N. M.; Erickson, A.; Resnick, R.; Vanderhoeven, J.; Hwang, J. K.; Barnhart, N.; Rah, J.; McCartney, S. A.; Ma, K. K.; Huebner, E. M.; Thomas, C.; Sheng, J. S.; Paek, B. W.; Retzlaff, K.; Kline, C. R.; Munson, J.; Blain, M.; Lacourse, S. M.; Deutsch, G.; Adams Waldorf, K., Clinical Characteristics of 46 Pregnant Women with a SARS-CoV-2 Infection in Washington State. *Am J Obstet Gynecol* **2020**.
326. (U) Long, Q.-X.; Liu, B.-Z.; Deng, H.-J.; Wu, G.-C.; Deng, K.; Chen, Y.-K.; Liao, P.; Qiu, J.-F.; Lin, Y.; Cai, X.-F.; Wang, D.-Q.; Hu, Y.; Ren, J.-H.; Tang, N.; Xu, Y.-Y.; Yu, L.-H.; Mo, Z.; Gong, F.; Zhang, X.-L.; Tian, W.-G.; Hu, L.; Zhang, X.-X.; Xiang, J.-L.; Du, H.-X.; Liu, H.-W.; Lang, C.-H.; Luo, X.-H.; Wu, S.-B.; Cui, X.-P.; Zhou, Z.; Zhu, M.-M.; Wang, J.; Xue, C.-J.; Li, X.-F.; Wang, L.; Li, Z.-J.; Wang, K.; Niu, C.-C.; Yang, Q.-J.; Tang, X.-J.; Zhang, Y.; Liu, X.-M.; Li, J.-J.; Zhang, D.-C.; Zhang, F.; Liu, P.; Yuan, J.; Li, Q.; Hu, J.-L.; Chen, J.; Huang, A.-L., Antibody responses to SARS-CoV-2 in patients with COVID-19. *Nature Medicine* **2020**. <https://doi.org/10.1038/s41591-020-0897-1>
327. (U) Long, Q.-X.; Tang, X.-J.; Shi, Q.-L.; Li, Q.; Deng, H.-J.; Yuan, J.; Hu, J.-L.; Xu, W.; Zhang, Y.; Lv, F.-J.; Su, K.; Zhang, F.; Gong, J.; Wu, B.; Liu, X.-M.; Li, J.-J.; Qiu, J.-F.; Chen, J.; Huang, A.-L., Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. *Nature Medicine* **2020**. <https://doi.org/10.1038/s41591-020-0965-6>
328. (U) Longcom, A. Z., Phase I Clinical Study of Recombinant Novel Coronavirus Vaccine. <https://clinicaltrials.gov/ct2/show/NCT04445194?term=NCT04445194&draw=2&rank=1>.
329. (U) Lu, J.; Plessis, L. d.; Liu, Z.; Hill, V.; Kang, M.; Lin, H.; Sun, J.; Francois, S.; Kraemer, M. U. G.; Faria, N. R.; McCrone, J. T.; Peng, J.; Xiong, Q.; Yuan, R.; Zeng, L.; Zhou, P.; Liang, C.; Yi, L.; Liu, J.; Xiao, J.; Hu, J.;

- Liu, T.; Ma, W.; Li, W.; Su, J.; Zheng, H.; Peng, B.; Fang, S.; Su, W.; Li, K.; Sun, R.; Bai, R.; Tang, X.; Liang, M.; Quick, J.; Song, T.; Rambaut, A.; Loman, N.; Raghwani, J.; Pybus, O.; Ke, C., Genomic epidemiology of SARS-CoV-2 in Guangdong Province, China. *medRxiv* **2020**, 2020.04.01.20047076.  
<https://www.medrxiv.org/content/medrxiv/early/2020/04/04/2020.04.01.20047076.full.pdf>
330. (U) Lu, R.; Zhao, X.; Li, J.; Niu, P.; Yang, B.; Wu, H.; Wang, W.; Song, H.; Huang, B.; Zhu, N.; Bi, Y.; Ma, X.; Zhan, F.; Wang, L.; Hu, T.; Zhou, H.; Hu, Z.; Zhou, W.; Zhao, L.; Chen, J.; Meng, Y.; Wang, J.; Lin, Y.; Yuan, J.; Xie, Z.; Ma, J.; Liu, W. J.; Wang, D.; Xu, W.; Holmes, E. C.; Gao, G. F.; Wu, G.; Chen, W.; Shi, W.; Tan, W., Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. *The Lancet* **2020**. [https://doi.org/10.1016/S0140-6736\(20\)30251-8](https://doi.org/10.1016/S0140-6736(20)30251-8)
331. (U) Lu, S.; Zhao, Y.; Yu, W.; Yang, Y.; Gao, J.; Wang, J.; Kuang, D.; Yang, M.; Yang, J.; Ma, C.; Xu, J.; Qian, X.; Li, H.; Zhao, S.; Li, J.; Wang, H.; Long, H.; Zhou, J.; Luo, F.; Ding, K.; Wu, D.; Zhang, Y.; Dong, Y.; Liu, Y.; Zheng, Y.; Lin, X.; Jiao, L.; Zheng, H.; Dai, Q.; Sun, Q.; Hu, Y.; Ke, C.; Liu, H.; Peng, X., Comparison of SARS-CoV-2 infections among 3 species of non-human primates. *bioRxiv* **2020**, 2020.04.08.031807.  
<https://www.biorxiv.org/content/biorxiv/early/2020/04/12/2020.04.08.031807.full.pdf>
332. (U) Lu, X.; Zhang, L.; Du, H.; Zhang, J.; Li, Y. Y.; Qu, J.; Zhang, W.; Wang, Y.; Bao, S.; Li, Y.; Wu, C.; Liu, H.; Liu, D.; Shao, J.; Peng, X.; Yang, Y.; Liu, Z.; Xiang, Y.; Zhang, F.; Silva, R. M.; Pinkerton, K. E.; Shen, K.; Xiao, H.; Xu, S.; Wong, G. W. K., SARS-CoV-2 Infection in Children. *New England Journal of Medicine* **2020**. <https://www.nejm.org/doi/full/10.1056/NEJMc2005073>
333. (U) Lu, Y.; Li, Y.; Deng, W.; Liu, M.; He, Y.; Huang, L.; Lv, M.; Li, J.; Du, H., Symptomatic Infection is Associated with Prolonged Duration of Viral Shedding in Mild Coronavirus Disease 2019: A Retrospective Study of 110 Children in Wuhan. *Pediatr Infect Dis J* **2020**.
334. (U) Lui, G.; Lai, C. K. C.; Chen, Z.; Tong, S. L. Y.; Ho, W. C. S.; Yeung, A. C. M.; Boon, S.; Ng, R. W. Y.; Chan, P. K. S., SARS-CoV-2 RNA Detection on Disposable Wooden Chopsticks, Hong Kong. *Emerging Infectious Disease journal* **2020**, 26 (9). [https://wwwnc.cdc.gov/eid/article/26/9/20-2135\\_article](https://wwwnc.cdc.gov/eid/article/26/9/20-2135_article)
335. (U) Luo, W.; Majumder, M. S.; Liu, D.; Poirier, C.; Mandl, K. D.; Lipsitch, M.; Santillana, M., The role of absolute humidity on transmission rates of the COVID-19 outbreak. *medRxiv* **2020**, 2020.02.12.20022467.  
<https://www.medrxiv.org/content/medrxiv/early/2020/02/17/2020.02.12.20022467.full.pdf>
336. (U) Luo, Y.; Trevathan, E.; Qian, Z.; Li, Y.; Li, J.; Xiao, W.; Tu, N.; Zeng, Z.; Mo, P.; Xiong, Y.; Ye, G., Asymptomatic SARS-CoV-2 Infection in Household Contacts of a Healthcare Provider, Wuhan, China. *Emerging Infectious Disease journal* **2020**, 26 (8). [https://wwwnc.cdc.gov/eid/article/26/8/20-1016\\_article](https://wwwnc.cdc.gov/eid/article/26/8/20-1016_article)
337. (U) Lysol, EPA Approves Lysol Disinfectant Spray For Use Against COVID-19. Lysol: 2020.  
<https://www.prnewswire.com/news-releases/epa-approves-lysol-disinfectant-spray-for-use-against-covid-19-301088721.html>
338. (U) MacLean, O. A.; Orton, R. J.; Singer, J. B.; Robertson, D. L., No evidence for distinct types in the evolution of SARS-CoV-2. *Virus Evolution* **2020**. <https://doi.org/10.1093/ve/veaa034>
339. (U) Madariaga, M. L. L.; Guthmiller, J.; Schrantz, S.; Jansen, M.; Christenson, C.; Kumar, M.; Prochaska, M.; Wool, G.; Durkin, A.; Oh, W. H.; Trockman, L.; Vigneswaran, J.; Keskey, R.; Shaw, D. G.; Dugan, H.; Zheng, N.; Cobb, M.; Utset, H.; Wang, J.; Stovicek, O.; Bethel, C.; Matushek, S.; Giurcanu, M.; Beavis, K.; diSabato, D.; Meltzer, D.; Ferguson, M.; Kress, J. P.; Shanmugarajah, K.; Matthews, J.; Fung, J.; Wilson, P.; Alverdy, J. C.; Donington, J., Clinical predictors of donor antibody titer and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial. *medRxiv* **2020**, 2020.06.21.20132944. <http://medrxiv.org/content/early/2020/06/23/2020.06.21.20132944.abstract>
340. (U) Magagnoli, J.; Narendran, S.; Pereira, F.; Cummings, T. H.; Hardin, J. W.; Sutton, S. S.; Ambati, J., Outcomes of hydroxychloroquine usage in United States veterans hospitalized with COVID-19. *Med* **2020**. <https://doi.org/10.1016/j.medj.2020.06.001>

341. (U) Magleby, R.; Westblade, L. F.; Trzebucki, A.; Simon, M. S.; Rajan, M.; Park, J.; Goyal, P.; Safford, M. M.; Satlin, M. J., Impact of SARS-CoV-2 Viral Load on Risk of Intubation and Mortality Among Hospitalized Patients with Coronavirus Disease 2019. *Clinical Infectious Diseases* **2020**.  
<https://doi.org/10.1093/cid/ciaa851>
342. (U) Mahévas, M.; Tran, V.-T.; Roumier, M.; Chabrol, A.; Paule, R.; Guillaud, C.; Fois, E.; Lepeule, R.; Szwebel, T.-A.; Lescure, F.-X.; Schlemmer, F.; Matignon, M.; Khellaf, M.; Crickx, E.; Terrier, B.; Morbieu, C.; Legendre, P.; Dang, J.; Schoindre, Y.; Pawlotsky, J.-M.; Michel, M.; Perrodeau, E.; Carlier, N.; Roche, N.; de Lastours, V.; Ourghanlian, C.; Kerneis, S.; Ménager, P.; Mouthon, L.; Audureau, E.; Ravaud, P.; Godeau, B.; Gallien, S.; Costedoat-Chalumeau, N., Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. *BMJ* **2020**, *369*, m1844. <http://www.bmj.com/content/369/bmj.m1844.abstract>
343. (U) Mahevas, M.; Tran, V.-T.; Roumier, M.; Chabrol, A.; Paule, R.; Guillaud, C.; Gallien, S.; Lepeule, R.; Szwebel, T.-A.; Lescure, X.; Schlemmer, F.; Matignon, M.; Khellaf, M.; Crickx, E.; Terrier, B.; Morbieu, C.; Legendre, P.; Dang, J.; Schoindre, Y.; Pawlotski, J.-M.; Michel, M.; Perrodeau, E.; Carlier, N.; Roche, N.; De Lastours, V.; Mouthon, L.; Audureau, E.; Ravaud, P.; Godeau, B.; Costedoat, N., No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial. *medRxiv* **2020**, 2020.04.10.20060699.  
<https://www.medrxiv.org/content/medrxiv/early/2020/04/14/2020.04.10.20060699.full.pdf>
344. (U) Maier, B. F.; Brockmann, D., Effective containment explains subexponential growth in recent confirmed COVID-19 cases in China. *Science* **2020**, *368* (6492), 742-746.  
<https://science.sciencemag.org/content/sci/368/6492/742.full.pdf>
345. (U) Majmundar, M.; Kansara, T.; Lenik, J. M.; Park, H.; Ghosh, K.; Doshi, R.; Shah, P.; Kumar, A.; Amin, H.; Habtes, I., Efficacy of Corticosteroids in Non-Intensive Care Unit Patients with COVID-19 Pneumonia from the New York Metropolitan region. *medRxiv* **2020**, 2020.07.02.20145565.  
<http://medrxiv.org/content/early/2020/07/04/2020.07.02.20145565.abstract>
346. (U) Majumder, M.; Mandl, K., Early transmissibility assessment of a novel coronavirus in Wuhan, China. *SSRN* **2020**. [https://papers.ssrn.com/sol3/papers.cfm?abstract\\_id=3524675](https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3524675)
347. (U) Mallapaty, S., Coronavirus can infect cats — dogs, not so much. *Nature* **2020**.  
<https://www.nature.com/articles/d41586-020-00984-8>
348. (U) Mao, L.; Jin, H.; Wang, M.; Hu, Y.; Chen, S.; He, Q.; Chang, J.; Hong, C.; Zhou, Y.; Wang, D.; Miao, X.; Li, Y.; Hu, B., Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. *JAMA Neurology* **2020**, *77* (6), 683-690. <https://doi.org/10.1001/jamaneurol.2020.1127>
349. (U) Martinez-Resendez, M. F.; Castilleja-Leal, F.; Torres-Quintanilla, A.; Rojas-Martinez, A.; Garcia-Rivas, G.; Ortiz-Lopez, R.; Trevino, V.; Lara-Medrano, R.; Villanueva-Lozano, H.; Ramirez-Elizondo, T.; Sanchez-Nava, V.; Moreno-Hoyos, F.; Martinez-Thomae, A.; Hernandez-Torre, M.; Diaz-Olachea, C.; Cardona-Huerta, S.; de la Rosa-Pacheco, S.; Diaz-Garza, C.; Reynoso-Lobo, P.; Marroquin-Escamilla, A. R.; Herrera-Gamboa, J. G.; Alvarado-Monroy, F. M.; Aguayo-Millan, C. D.; Villegas-Macedo, F. F.; Flores-Osorio, J. E.; Davila-Gonzalez, D.; Diaz-Sanchez, M. E.; Torre-Amione, G., Initial experience in Mexico with convalescent plasma in COVID-19 patients with severe respiratory failure, a retrospective case series. *medRxiv* **2020**, 2020.07.14.20144469.  
<http://medrxiv.org/content/early/2020/07/20/2020.07.14.20144469.abstract>
350. (U) Martinez-Sanz, J.; Muriel, A.; Ron, R.; Herrera, S.; Ron, R.; Perez-Molina, J. A.; Moreno, S.; Serrano-Villar, S., Effects of Tocilizumab on Mortality in Hospitalized Patients with COVID-19: A Multicenter Cohort Study. *medRxiv* **2020**, 2020.06.08.20125245.  
<http://medrxiv.org/content/early/2020/06/09/2020.06.08.20125245.abstract>

351. (U) Matthay, M. A.; Aldrich, J. M.; Gotts, J. E., Treatment for severe acute respiratory distress syndrome from COVID-19. *The Lancet Respiratory Medicine* **2020**. [https://doi.org/10.1016/S2213-2600\(20\)30127-2](https://doi.org/10.1016/S2213-2600(20)30127-2)
352. (U) Medicago, Safety, Tolerability and Immunogenicity of a Coronavirus-Like Particle COVID-19 Vaccine in Adults Aged 18-55 Years. <https://clinicaltrials.gov/ct2/show/NCT04450004?term=NCT04450004&draw=2&rank=1>.
353. (U) Medicine, U. S. N. L. o., Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older. <https://clinicaltrials.gov/ct2/show/NCT04405076?term=mRNA-1273&draw=2&rank=1>.
354. (U) Medicine, U. S. N. L. o., Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19. <https://clinicaltrials.gov/ct2/show/NCT04334980>.
355. (U) Medicine, U. S. N. L. o., Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant. <https://clinicaltrials.gov/ct2/show/NCT04368988?term=Novavax&draw=2&rank=23>.
356. (U) Medicine, U. S. N. L. o., Immunity and Safety of Covid-19 Synthetic Minigene Vaccine. ClinicalTrials.gov: 2020. <https://clinicaltrials.gov/ct2/show/NCT04276896>
357. (U) Medicine, U. S. N. L. o., Phase Ib-II Trial of Dendritic Cell Vaccine to Prevent COVID-19 in Frontline Healthcare Workers and First Responders. <https://clinicaltrials.gov/ct2/show/NCT04386252?term=Aivita+Biomedical&draw=2&rank=1>.
358. (U) Medicine, U. S. N. L. o., Safety and Immunity of Covid-19 aAPC Vaccine. ClinicalTrials.gov: 2020. <https://clinicaltrials.gov/ct2/show/NCT04299724>
359. (U) Medicine, U. S. N. L. o., SCB-2019 as COVID-19 Vaccine. <https://clinicaltrials.gov/ct2/show/NCT04405908?term=SCB-2019&draw=2&rank=1>.
360. (U) Medicine, U. S. N. L. o., Tabled COVID-19 Therapeutic Vaccine (COVID-19). <https://clinicaltrials.gov/ct2/show/NCT04380532?term=immunitor&draw=2&rank=11>.
361. (U) Melin, A. D.; Janiak, M. C.; Marrone, F.; Arora, P. S.; Higham, J. P., Comparative ACE2 variation and primate COVID-19 risk. *bioRxiv* **2020**, 2020.04.09.034967. <https://www.biorxiv.org/content/biorxiv/early/2020/04/19/2020.04.09.034967.full.pdf>
362. (U) Menachery, V. D.; Dinnon, K. H.; Yount, B. L.; McAnarney, E. T.; Gralinski, L. E.; Hale, A.; Graham, R. L.; Scobey, T.; Anthony, S. J.; Wang, L.; Graham, B.; Randell, S. H.; Lipkin, W. I.; Baric, R. S., Trypsin Treatment Unlocks Barrier for Zoonotic Bat Coronavirus Infection. *Journal of Virology* **2020**, *94* (5), e01774-19. <https://jvi.asm.org/content/jvi/94/5/e01774-19.full.pdf>
363. (U) Meng, Y.; Wu, P.; Lu, W.; Liu, K.; Ma, K.; Huang, L.; Cai, J.; Zhang, H.; Qin, Y.; Sun, H.; Ding, W.; Gui, L.; Wu, P., Sex-specific clinical characteristics and prognosis of coronavirus disease-19 infection in Wuhan, China: A retrospective study of 168 severe patients. *PLoS Pathog* **2020**, *16* (4), e1008520.
364. (U) Mercuro, N. J.; Yen, C. F.; Shim, D. J.; Maher, T. R.; McCoy, C. M.; Zimetbaum, P. J.; Gold, H. S., Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19). *JAMA Cardiology* **2020**. <https://doi.org/10.1001/jamacardio.2020.1834>
365. (U) Merkler, A. E.; Parikh, N. S.; Mir, S.; Gupta, A.; Kamel, H.; Lin, E.; Lantos, J.; Schenck, E. J.; Goyal, P.; Bruce, S. S.; Kahan, J.; Lansdale, K. N.; LeMoss, N. M.; Murthy, S. B.; Stieg, P. E.; Fink, M. E.; Iadecola, C.; Segal, A. Z.; Cusick, M.; Champion, T. R., Jr; Diaz, I.; Zhang, C.; Navi, B. B., Risk of Ischemic Stroke in Patients With Coronavirus Disease 2019 (COVID-19) vs Patients With Influenza. *JAMA Neurology* **2020**. <https://doi.org/10.1001/jamaneurol.2020.2730>
366. (U) Merow, C.; Urban, M. C., Seasonality and uncertainty in COVID-19 growth rates. *medRxiv* **2020**, 2020.04.19.20071951. <https://www.medrxiv.org/content/medrxiv/early/2020/04/22/2020.04.19.20071951.full.pdf>

367. (U) Meyers, L. A., COVID-19 Mortality Projections for US States and Metropolitan Areas. <https://covid-19.tacc.utexas.edu/projections/>.
368. (U) Mikulska, M.; Nicolini, L. A.; Signori, A.; Di Biagio, A.; Sepulcri, C.; Russo, C.; Dettori, S.; Berruti, M.; Sormani, M. P.; Giacobbe, D. R.; Vena, A.; De Maria, A.; Dentone, C.; Taramasso, L.; Mirabella, M.; Magnasco, L.; Mora, S.; Delfino, E.; Toscanini, F.; Balletto, E.; Alessandrini, A. I.; Baldi, F.; Briano, F.; Camera, M.; Dodi, F.; Ferrazin, A.; Labate, L.; Mazzarello, G.; Pincino, R.; Portunato, F.; Tutino, S.; Barisione, E.; Bruzzone, B.; Orsi, A.; Schenone, E.; Rossetti, N.; Sasso, E.; Da Rin, G.; Pelosi, P.; Beltramini, S.; Giacomini, M.; Icardi, G.; Gratarola, A.; Bassetti, M., Tocilizumab and steroid treatment in patients with severe Covid-19 pneumonia. *medRxiv* **2020**, 2020.06.22.20133413. <http://medrxiv.org/content/early/2020/06/26/2020.06.22.20133413.abstract>
369. (U) Millett, G. A.; Jones, A. T.; Benkeser, D.; Baral, S.; Mercer, L.; Beyrer, C.; Honermann, B.; Lankiewicz, E.; Mena, L.; Crowley, J. S.; Sherwood, J.; Sullivan, P., Assessing Differential Impacts of COVID-19 on Black Communities. *Annals of Epidemiology* **2020**. <http://www.sciencedirect.com/science/article/pii/S1047279720301769>
370. (U) MIT, DELPHI Epidemiological Case Predictions. <https://www.covidanalytics.io/projections>.
371. (U) Mizumoto, K.; Kagaya, K.; Zarebski, A.; Chowell, G., Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. *Eurosurveillance* **2020**, 25 (10), 2000180. <https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.10.2000180>
372. (U) Moderna, Moderna Announces Positive Interim Phase 1 Data for its mRNA Vaccine (mRNA-1273) Against Novel Coronavirus. Moderna: 2020. <https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-positive-interim-phase-1-data-its-mrna-vaccine/>
373. (U) Moderna, A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19. <https://clinicaltrials.gov/ct2/show/NCT04470427?term=moderna&cond=covid&draw=2&rank=1>.
374. (U) Montopoli, M.; Zumerle, S.; Vettor, R.; Rugge, M.; Zorzi, M.; Catapano, C. V.; Carbone, G.; Cavalli, A.; Pagano, F.; Ragazzi, E., Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (n= 4532). *Annals of Oncology* **2020**.
375. (U) Morawska, L.; Milton, D. K., It is Time to Address Airborne Transmission of COVID-19. *Clinical Infectious Diseases* **2020**. <https://doi.org/10.1093/cid/ciaa939>
376. (U) Moriarty, L. F.; Plucinski, M. M.; Marston, B. J. e. a., Public Health Responses fo COVID-19 Outbreaks on Cruise Ships - Worldwide, February - March 2020. *MMWR* **2020**, (ePub: 23 March 2020). <https://www.cdc.gov/mmwr/volumes/69/wr/mm6912e3.htm>
377. (U) Morrison, A. R.; Johnson, J. M.; Griebbe, K. M.; Jones, M. C.; Stine, J. J.; Hencken, L. N.; To, L.; Bianchini, M. L.; Vahia, A. T.; Swiderek, J.; Ramesh, M. S.; Peters, M. A.; Smith, Z. R., Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab. *Journal of Autoimmunity* **2020**, 102512. <http://www.sciencedirect.com/science/article/pii/S0896841120301347>
378. (U) Moustafa, A. M.; Planet, P. J., Rapid whole genome sequence typing reveals multiple waves of SARS-CoV-2 spread. *bioRxiv* **2020**, 2020.06.08.139055. <https://www.biorxiv.org/content/biorxiv/early/2020/06/09/2020.06.08.139055.full.pdf>
379. (U) Mulligan, M. J.; Lyke, K. E.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S. P.; Neuzil, K.; Raabe, V.; Bailey, R.; Swanson, K. A.; Li, P.; Koury, K.; Kalina, W.; Cooper, D.; Fonter-Garfias, C.; Shi, P.-Y.; Tuereci, O.; Tompkins, K. R.; Walsh, E. E.; Frenck, R.; Falsey, A. R.; Dormitzer, P. R.; Gruber, W. C.; Sahin, U.; Jansen, K. U., Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report. *medRxiv* **2020**, 2020.06.30.20142570. <https://www.medrxiv.org/content/medrxiv/early/2020/07/01/2020.06.30.20142570.full.pdf>

380. (U) Munster, V. J.; Feldmann, F.; Williamson, B. N.; van Doremalen, N.; Pérez-Pérez, L.; Schulz, J.; Meade-White, K.; Okumura, A.; Callison, J.; Brumbaugh, B.; Avanzato, V. A.; Rosenke, R.; Hanley, P. W.; Saturday, G.; Scott, D.; Fischer, E. R.; de Wit, E., Respiratory disease and virus shedding in rhesus macaques inoculated with SARS-CoV-2. *bioRxiv* **2020**, 2020.03.21.001628.  
<https://www.biorxiv.org/content/biorxiv/early/2020/03/21/2020.03.21.001628.full.pdf>
381. (U) Muoio, D., Scanwell Health, myLAB Box unveil more at-home COVID-19 testing services. *MobiHealthNews* 20 March, 2020. <https://www.mobihealthnews.com/news/scanwell-health-my-lab-box-unveil-more-home-covid-19-testing-services>
382. (U) Nadi, A., An at-home fingerprick blood test may help detect your exposure to coronavirus. *NBC NEWS* 04 April, 2020. <https://www.nbcnews.com/health/health-news/home-fingerprick-blood-test-may-help-detect-your-exposure-coronavirus-n1176086>
383. (U) National Heart, L., and Blood Institute (NHLBI), NIH halts clinical trial of hydroxychloroquine. 2020. <https://www.nih.gov/news-events/news-releases/nih-halts-clinical-trial-hydroxychloroquine>
384. (U) Nepogodiev, D.; Glasbey, J. C.; Li, E.; Omar, O. M.; Simoes, J. F. F.; al., e., Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study. *The Lancet* **2020**. [https://doi.org/10.1016/S0140-6736\(20\)31182-X](https://doi.org/10.1016/S0140-6736(20)31182-X)
385. (U) Ngonghala, C. N.; Iboi, E.; Eikenberry, S.; Scotch, M.; MacIntyre, C. R.; Bonds, M. H.; Gumel, A. B., Mathematical assessment of the impact of non-pharmaceutical interventions on curtailing the 2019 novel Coronavirus. *Mathematical Biosciences* **2020**, 325, 108364.  
<http://www.sciencedirect.com/science/article/pii/S0025556420300560>
386. (U) NIH, Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV).  
<https://www.nih.gov/research-training/medical-research-initiatives/activ>.
387. (U) NIH, *Fact Sheet for Patients And Parent/Caregivers - Emergency Use Authorization (EUA) Of Remdesivir For Coronavirus Disease 2019 (COVID-19)*; National Institutes of Health: 2020.  
<https://www.fda.gov/media/137565/download>
388. (U) Nishiura, H.; Kobayashi, T.; Miyama, T.; Suzuki, A.; Jung, S.-m.; Hayashi, K.; Kinoshita, R.; Yang, Y.; Yuan, B.; Akhmetzhanov, A. R.; Linton, N. M., Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). *International Journal of Infectious Diseases* **2020**, 94, 154-155.  
<http://www.sciencedirect.com/science/article/pii/S1201971220301399>
389. (U) Northeastern, Modeling of COVID-19 epidemic in the United States.  
<https://covid19.gleamproject.org/#icubedproj>.
390. (U) Now, C. A., America's COVID warning system. <https://covidactnow.org/?s=38532>.
391. (U) NYT, Coronavirus in the U.S.: Latest Map and Case Count.  
<https://www.nytimes.com/interactive/2020/us/coronavirus-us-cases.html>.
392. (U) O'Hare, R.; Wighton, K., Imperial to begin first human trials of new COVID-19 vaccine.  
<https://www.imperial.ac.uk/news/198314/imperial-begin-first-human-trials-covid-19/>.
393. (U) Offeddu, V.; Yung, C. F.; Low, M. S. F.; Tam, C. C., Effectiveness of Masks and Respirators Against Respiratory Infections in Healthcare Workers: A Systematic Review and Meta-Analysis. *Clin Infect Dis* **2017**, 65 (11), 1934-1942. <https://www.ncbi.nlm.nih.gov/pubmed/29140516>
394. (U) Okba, N.; Müller, M.; Li, W.; Wang, C.; GeurtsvanKessel, C.; Corman, V.; Lamers, M.; Sikkema, R.; de Bruin, E.; Chandler, F., Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease 2019 Patients. *Emerging infectious diseases* **2020**, 26 (7).
395. (U) Olson, D. R.; Huynh, M.; Fine, A.; Baumgartner, J.; Castro, A.; Chan, H. T.; Daskalakis, D.; Devinney, K.; Guerra, K.; Harper, S.; Kennedy, J.; Konty, K.; Li, W.; McGibbon, E.; Shaff, J.; Thompson, C.; Vora, N. M.; Van Wye, G., Preliminary Estimate of Excess Mortality During the COVID-19 Outbreak — New York City, March 11–May 2, 2020. *Morbidity and Mortality Weekly Report* **2020**, (ePub: 11 May 2020). [https://www.cdc.gov/mmwr/volumes/69/wr/mm6919e5.htm?s\\_cid=mm6919e5\\_w](https://www.cdc.gov/mmwr/volumes/69/wr/mm6919e5.htm?s_cid=mm6919e5_w)

396. (U) Ong, S. W. X.; Tan, Y. K.; Chia, P. Y.; Lee, T. H.; Ng, O. T.; Wong, M. S. Y.; Marimuthu, K., Air, Surface Environmental, and Personal Protective Equipment Contamination by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) From a Symptomatic Patient. *Jama* **2020**.  
[https://jamanetwork.com/journals/jama/articlepdf/2762692/jama\\_ong\\_2020\\_id\\_200016.pdf](https://jamanetwork.com/journals/jama/articlepdf/2762692/jama_ong_2020_id_200016.pdf)
397. (U) Oran, D. P.; Topol, E. J., Prevalence of Asymptomatic SARS-CoV-2 Infection. *Annals of Internal Medicine* **2020**, 0 (0), null. <https://www.acpjournals.org/doi/abs/10.7326/M20-3012>
398. (U) Ortega, J. T.; Serrano, M. L.; Pujol, F. H.; Rangel, H. R., Role of changes in SARS-CoV-2 spike protein in the interaction with the human ACE2 receptor: An in silico analysis. *EXCLI journal* **2020**, 19, 410-417. <https://pubmed.ncbi.nlm.nih.gov/32210742>  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7081066/>
399. (U) Osterrieder, N.; Bertzbach, L. D.; Dietert, K.; Abdelgawad, A.; Vladimirova, D.; Kunec, D.; Hoffmann, D.; Beer, M.; Gruber, A. D.; Trimpert, J., Age-dependent progression of SARS-CoV-2 infection in Syrian hamsters. *bioRxiv* **2020**, 2020.06.10.144188.  
<http://biorxiv.org/content/early/2020/06/10/2020.06.10.144188.abstract>
400. (U) Ou, J.; Zhou, Z.; Dai, R.; Zhang, J.; Lan, W.; Zhao, S.; Wu, J.; Seto, D.; Cui, L.; Zhang, G.; Zhang, Q., Emergence of RBD mutations in circulating SARS-CoV-2 strains enhancing the structural stability and human ACE2 receptor affinity of the spike protein. *bioRxiv* **2020**, 2020.03.15.991844.  
<https://www.biorxiv.org/content/biorxiv/early/2020/04/20/2020.03.15.991844.full.pdf>
401. (U) Oxford, Oxford COVID-19 vaccine to begin phase II/III human trials. University of Oxford: 2020.  
<http://www.ox.ac.uk/news/2020-05-22-oxford-covid-19-vaccine-begin-phase-iii-human-trials>
402. (U) Pan, A.; Liu, L.; Wang, C.; Guo, H.; Hao, X.; Wang, Q.; Huang, J.; He, N.; Yu, H.; Lin, X., Association of Public Health Interventions With the Epidemiology of the COVID-19 Outbreak in Wuhan, China. *JAMA* **2020**.
403. (U) Pan, D.; Sze, S.; Minhas, J. S.; Bangash, M. N.; Pareek, N.; Divall, P.; Williams, C. M. L.; Oggioni, M. R.; Squire, I. B.; Nellums, L. B.; Hanif, W.; Khunti, K.; Pareek, M., The impact of ethnicity on clinical outcomes in COVID-19: A systematic review. *EClinicalMedicine*.  
<https://doi.org/10.1016/j.eclinm.2020.100404>
404. (U) Pan, F.; Ye, T.; Sun, P.; Gui, S.; Liang, B.; Li, L.; Zheng, D.; Wang, J.; Hesketh, R. L.; Yang, L.; Zheng, C., Time Course of Lung Changes On Chest CT During Recovery From 2019 Novel Coronavirus (COVID-19) Pneumonia. *Radiology* **0** (0), 200370. <https://pubs.rsna.org/doi/abs/10.1148/radiol.2020200370>
405. (U) Paranjpe, I.; Fuster, V.; Lala, A.; Russak, A.; Glicksberg, B. S.; Levin, M. A.; Charney, A. W.; Narula, J.; Fayad, Z. A.; Bagiella, E.; Zhao, S.; Nadkarni, G. N., Association of Treatment Dose Anticoagulation with In-Hospital Survival Among Hospitalized Patients with COVID-19. *Journal of the American College of Cardiology* **2020**, 27327.  
<http://www.onlinejacc.org/content/accj/early/2020/05/05/j.jacc.2020.05.001.full.pdf>
406. (U) Paranjpe, I.; Russak, A.; De Freitas, J. K.; Lala, A.; Miotto, R.; Vaid, A.; Johnson, K. W.; Danieleto, M.; Golden, E.; Meyer, D.; Singh, M.; Somani, S.; Manna, S.; Nangia, U.; Kapoor, A.; O'Hagan, R.; O'Reilly, P. F.; Huckins, L. M.; Glowe, P.; Kia, A.; Timsina, P.; Freeman, R. M.; Levin, M. A.; Jhang, J.; Firpo, A.; Kovatch, P.; Finkelstein, J.; Aberg, J. A.; Bagiella, E.; Horowitz, C. R.; Murphy, B.; Fayad, Z. A.; Narula, J.; Nestler, E. J.; Fuster, V.; Cordon-Cardo, C.; Charney, D. S.; Reich, D. L.; Just, A. C.; Bottinger, E. P.; Charney, A. W.; Glicksberg, B. S.; Nadkarni, G., Clinical Characteristics of Hospitalized Covid-19 Patients in New York City. *medRxiv* **2020**, 2020.04.19.20062117.  
<https://www.medrxiv.org/content/medrxiv/early/2020/04/26/2020.04.19.20062117.full.pdf>
407. (U) Park, A., An At-Home Coronavirus Test May Be on the Way in the U.S. *TIME* 25 March, 2020.  
<https://time.com/5809753/at-home-coronavirus-test/>

408. (U) Park, S. W.; Champredon, D.; Earn, D. J. D.; Li, M.; Weitz, J. S.; Grenfell, B. T.; Dushoff, J., Reconciling early-outbreak preliminary estimates of the basic reproductive number and its uncertainty: a new framework and applications to the novel coronavirus (2019-nCoV) outbreak. **2020**, 1-13.
409. (U) Park, S. Y.; Kim, Y.-M.; Yi, S.; Lee, S.; Na, B.-J.; Kim, C. B.; Kim, J.-i.; Kim, H. S.; Kim, Y. B.; Park, Y.; Huh, I. S.; Kim, H. K.; Yoon, H. J.; Jang, H.; Kim, K.; Chang, Y.; Kim, I.; Lee, H.; Gwack, J.; Kim, S. S.; Kim, M.; Kweon, S.; Choe, Y. J.; Park, O.; Park, Y. J.; Jeong, E. K., Coronavirus Disease Outbreak in Call Center, South Korea. *Emerging Infectious Disease journal* **2020**, 26 (8), 1666.  
[https://wwwnc.cdc.gov/eid/article/26/8/20-1274\\_article](https://wwwnc.cdc.gov/eid/article/26/8/20-1274_article)
410. (U) Park, Y. J.; Choe, Y. J.; Park, O.; Park, S. Y.; Kim, Y.-M.; Kim, J.; Kweon, S.; Woo, Y.; Gwack, J.; Kim, S. S.; Lee, J.; Hyun, J.; Ryu, B.; Jang, Y. S.; Kim, H.; Shin, S. H.; Yi, S.; Lee, S.; Kim, H. K.; Lee, H.; Jin, Y.; Park, E.; Choi, S. W.; Kim, M.; Song, J.; Choi, S. W.; Kim, D.; Jeon, B.-H.; Yoo, H.; Jeong, E. K., Contact Tracing during Coronavirus Disease Outbreak, South Korea, 2020. *Emerging Infectious Disease journal* **2020**, 26 (10). [https://wwwnc.cdc.gov/eid/article/26/10/20-1315\\_article](https://wwwnc.cdc.gov/eid/article/26/10/20-1315_article)
411. (U) Parri, N.; Lenge, M.; Buonsenso, D., Children with Covid-19 in Pediatric Emergency Departments in Italy. *New England Journal of Medicine* **2020**. <https://www.nejm.org/doi/full/10.1056/NEJMc2007617>
412. (U) Pastorino, B.; Touret, F.; Gilles, M.; de Lamballerie, X.; Charrel, R., Prolonged viability of SARS-CoV-2 in fomites. **2020**.
413. (U) Paterson, R. W.; Brown, R. L.; Benjamin, L.; Nortley, R.; Wiethoff, S.; Bharucha, T.; Jayaseelan, D. L.; Kumar, G.; Raftopoulos, R. E.; Zambreau, L.; Vivekanandam, V.; Khoo, A.; Gerald, R.; Chinthapalli, K.; Boyd, E.; Tuzlali, H.; Price, G.; Christofi, G.; Morrow, J.; McNamara, P.; McLoughlin, B.; Lim, S. T.; Mehta, P. R.; Levee, V.; Keddie, S.; Yong, W.; Trip, S. A.; Foulkes, A. J. M.; Hotton, G.; Miller, T. D.; Everitt, A. D.; Carswell, C.; Davies, N. W. S.; Yoong, M.; Attwell, D.; Sreedharan, J.; Silber, E.; Schott, J. M.; Chandratheva, A.; Perry, R. J.; Simister, R.; Checkley, A.; Longley, N.; Farmer, S. F.; Carletti, F.; Houlihan, C.; Thom, M.; Lunn, M. P.; Spillane, J.; Howard, R.; Vincent, A.; Werring, D. J.; Hoskote, C.; Jäger, H. R.; Manji, H.; Zandi, M. S.; Neurology, t. U. Q. S. N. H. f.; Group, N. C.-S., The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. *Brain* **2020**.  
<https://doi.org/10.1093/brain/awaa240>
414. (U) Patolia, H.; Pan, J.; Harb, C.; Marr, L. C.; Baffoe-Bonnie, A., Filtration evaluation and clinical use of expired elastomeric P-100 filter cartridges during the COVID-19 pandemic. *Infection Control & Hospital Epidemiology* **2020**, 1-6. <https://www.cambridge.org/core/article/filtration-evaluation-and-clinical-use-of-expired-elastomeric-p100-filter-cartridges-during-the-covid19-pandemic/D5EFCC5EEF65FEA210E1070149CB9DEF>
415. (U) Payne, D. C., SARS-CoV-2 Infections and Serologic Responses from a Sample of US Navy Service Members—USS Theodore Roosevelt, April 2020. *MMWR. Morbidity and Mortality Weekly Report* **2020**, 69.
416. (U) Peltier, R. E.; Wang, J.; Hollenbeck, B. L.; Lanza, J.; Furtado, R. M.; Cyr, J.; Ellison, R.; Kobayashi, K. J., Addressing Decontaminated Respirators: Some Methods Appear to Damage Mask Integrity and Protective Function. *Infection Control & Hospital Epidemiology* **2020**, 1-9.
417. (U) Perchetti, G. A.; Huang, M.-L.; Peddu, V.; Jerome, K. R.; Greninger, A. L., Stability of SARS-CoV-2 in PBS for Molecular Detection. *Journal of Clinical Microbiology* **2020**.
418. (U) Pereda, R.; Gonzalez, D.; Rivero, H.; Rivero, J.; Perez, A.; Lopez, L. d. R.; Mezquia, N.; Venegas, R.; Betancourt, J.; Dominguez, R., Therapeutic effectiveness of interferon-alpha2b against COVID-19: the Cuban experience. *medRxiv* **2020**, 2020.05.29.20109199.  
<http://medrxiv.org/content/early/2020/06/09/2020.05.29.20109199.abstract>
419. (U) Perkins, A.; Espana, G., NotreDame-FRED COVID-19 forecasts.  
[https://github.com/confunguido/covid19\\_ND\\_forecasting/blob/master/README.md](https://github.com/confunguido/covid19_ND_forecasting/blob/master/README.md).
420. (U) Perrone, F.; Piccirillo, M. C.; Ascierio, P. A.; Salvarani, C.; Parrella, R.; Marata, A. M.; Popoli, P.; Ferraris, L.; Marrocco Trischitta, M. M.; Ripamonti, D.; Binda, F.; Bonfanti, P.; Squillace, N.; Castelli, F.;



- Muiesan, M. L.; Lichtner, M.; Calzetti, C.; Salerno, N. D.; Atripaldi, L.; Cascella, M.; costantini, m.; Dolci, G.; Facciolongo, N. C.; Fraganza, F.; Massari, M.; Montesarchio, V.; Mussini, C.; Negri, E. A.; Botti, G.; Cardone, C.; Gargiulo, P.; Gravina, A.; Schettino, C.; Arenare, L.; Chiodini, P.; Gallo, C., Tocilizumab for patients with COVID-19 pneumonia. The TOCOVID-19 phase 2 trial. *medRxiv* **2020**, 2020.06.01.20119149. <http://medrxiv.org/content/early/2020/06/05/2020.06.01.20119149.abstract>
421. (U) Petrakis, D.; Margină, D.; Tsarouhas, K.; Tekos, F.; Stan, M.; Nikitovic, D.; Kouretas, D.; Spandidos, D. A.; Tsatsakis, A., Obesity - a risk factor for increased COVID-19 prevalence, severity and lethality (Review). *Mol Med Rep* **2020**, 22 (1), 9-19. <https://doi.org/10.3892/mmr.2020.11127>
422. (U) Pfizer, BIONTECH AND PFIZER ANNOUNCE REGULATORY APPROVAL FROM GERMAN AUTHORITY PAUL-EHRLICH-INSTITUT TO COMMENCE FIRST CLINICAL TRIAL OF COVID-19 VACCINE CANDIDATES. 2020. [https://www.pfizer.com/news/press-release/press-release-detail/biontech\\_and\\_pfizer\\_announce\\_regulatory\\_approval\\_from\\_german\\_authority\\_paul\\_ehrlich\\_institut\\_to\\_commence\\_first\\_clinical\\_trial\\_of\\_covid\\_19\\_vaccine\\_candidates](https://www.pfizer.com/news/press-release/press-release-detail/biontech_and_pfizer_announce_regulatory_approval_from_german_authority_paul_ehrlich_institut_to_commence_first_clinical_trial_of_covid_19_vaccine_candidates)
423. (U) Pigoga, J. L.; Friedman, A.; Broccoli, M.; Hirner, S.; Naidoo, A. V.; Singh, S.; Werner, K.; Wallis, L. A., Clinical and historical features associated with severe COVID-19 infection: a systematic review. *medRxiv* **2020**, 2020.04.23.20076653. <https://www.medrxiv.org/content/medrxiv/early/2020/04/27/2020.04.23.20076653.full.pdf>
424. (U) plc, S., Synairgen announces positive results from trial of SNG001 in hospitalised COVID-19 patients. 2020. <https://www.synairgen.com/wp-content/uploads/2020/07/200720-Synairgen-announces-positive-results-from-trial-of-SNG001-in-hospitalised-COVID-19-patients.pdf>
425. (U) Pollán, M.; Pérez-Gómez, B.; Pastor-Barriuso, R.; al., e., Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. *The Lancet* **2020**. [https://doi.org/10.1016/S0140-6736\(20\)31483-5](https://doi.org/10.1016/S0140-6736(20)31483-5)
426. (U) Price-Haywood, E. G.; Burton, J.; Fort, D.; Seoane, L., Hospitalization and Mortality among Black Patients and White Patients with Covid-19. *New England Journal of Medicine* **2020**. <https://www.nejm.org/doi/full/10.1056/NEJMsa2011686>
427. (U) Products, B. I. o. B., A phase I/II clinical trial for inactivated novel coronavirus (2019-CoV) vaccine (Vero cells) <http://www.chictr.org.cn/showproj.aspx?proj=53003>.
428. (U) Qiu, H.; Wu, J.; Hong, L.; Luo, Y.; Song, Q.; Chen, D., Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. *The Lancet Infectious Diseases*. [https://doi.org/10.1016/S1473-3099\(20\)30198-5](https://doi.org/10.1016/S1473-3099(20)30198-5)
429. (U) Queensland, U. o., An interventional study to evaluate the safety and immune response of a vaccine against Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2, the virus that causes COVID-19 infection) when given to healthy adult participants. . <https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=379861&isReview=true>.
430. (U) Rabenau, H.; Kampf, G.; Cinatl, J.; Doerr, H., Efficacy of various disinfectants against SARS coronavirus. *Journal of Hospital Infection* **2005**, 61 (2), 107-111. <https://www.sciencedirect.com/science/article/pii/S0195670105000447>
431. (U) Rabenau, H. F.; Cinatl, J.; Morgenstern, B.; Bauer, G.; Preiser, W.; Doerr, H. W., Stability and inactivation of SARS coronavirus. *Med Microbiol Immunol* **2005**, 194 (1-2), 1-6. <https://link.springer.com/content/pdf/10.1007/s00430-004-0219-0.pdf>
432. (U) Rajter, J. C.; Sherman, M.; Fatteh, N.; Vogel, F.; Sacks, J.; Rajter, J.-J., ICON (Ivermectin in COvid Nineteen) study: Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID19. *medRxiv* **2020**, 2020.06.06.20124461. <http://medrxiv.org/content/early/2020/06/10/2020.06.06.20124461.abstract>
433. (U) Rambaut, A., Phylodynamic analysis of nCoV-2019 genomes - 27-Jan-2020. <http://virological.org/t/phylodynamic-analysis-of-ncov-2019-genomes-27-jan-2020/353>.

434. (U) Rapid Expert Consultation, *Rapid Expert Consultation Update on SARS-CoV-2 Surface Stability and Incubation for the COVID-19 Pandemic (March 27, 2020)*. The National Academies Press: Washington, DC, 2020. <https://www.nap.edu/read/25763/chapter/1>
435. (U) Rapkiewicz, A. V.; Mai, X.; Carsons, S. E.; Pittaluga, S.; Kleiner, D. E.; Berger, J. S.; Thomas, S.; Adler, N. M.; Charytan, D. M.; Gasmi, B.; Hochman, J. S.; Reynolds, H. R., Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: A case series. *EClinicalMedicine* **2020**, 100434. <http://www.sciencedirect.com/science/article/pii/S2589537020301784>
436. (U) Ratnesar-Shumate, S.; Williams, G.; Green, B.; Krause, M.; Holland, B.; Wood, S.; Bohannon, J.; Boydston, J.; Freeburger, D.; Hooper, I.; Beck, K.; Yeager, J.; Altamura, L. A.; Biryukov, J.; Yolitz, J.; Schuit, M.; Wahl, V.; Hevey, M.; Dabisch, P., Simulated Sunlight Rapidly Inactivates SARS-CoV-2 on Surfaces. *The Journal of Infectious Diseases* **2020**. <https://doi.org/10.1093/infdis/jiaa274>
437. (U) Regeneron, Regeneron and Sanofi Provide Update on Kevzara® (sarilumab) Phase 3 U.S. Trial in COVID-19 Patients. 2020. <https://www.prnewswire.com/news-releases/regeneron-and-sanofi-provide-update-on-kevzara-sarilumab-phase-3-us-trial-in-covid-19-patients-301087849.html>
438. (U) Reich, N., Ensemble. <https://reichlab.io/>.
439. (U) Remuzzi, A.; Remuzzi, G., COVID-19 and Italy: what next? *The Lancet* **2020**. [https://doi.org/10.1016/S0140-6736\(20\)30627-9](https://doi.org/10.1016/S0140-6736(20)30627-9)
440. (U) Ren, X.; Liu, Y.; Chen, H.; Liu, W.; Guo, Z.; Chen, C.; Zhou, J.; Xiao, Q.; Jiang, G.-M.; Shan, H., Application and Optimization of RT-PCR in Diagnosis of SARS-CoV-2 Infection. *medRxiv* **2020**.
441. (U) Rengasamy, S.; Eimer, B.; Shaffer, R. E., Simple respiratory protection--evaluation of the filtration performance of cloth masks and common fabric materials against 20-1000 nm size particles. *Ann Occup Hyg* **2010**, *54* (7), 789-98. <https://www.ncbi.nlm.nih.gov/pubmed/20584862>
442. (U) Richard, M.; Kok, A.; de Meulder, D.; Bestebroer, T. M.; Lamers, M. M.; Okba, N. M. A.; Fentener van Vlissingen, M.; Rockx, B.; Haagmans, B. L.; Koopmans, M. P. G.; Fouchier, R. A. M.; Herfst, S., SARS-CoV-2 is transmitted via contact and via the air between ferrets. *bioRxiv* **2020**, 2020.04.16.044503. <https://www.biorxiv.org/content/biorxiv/early/2020/04/17/2020.04.16.044503.full.pdf>
443. (U) Richard, M.; Kok, A.; de Meulder, D.; Bestebroer, T. M.; Lamers, M. M.; Okba, N. M. A.; Fentener van Vlissingen, M.; Rockx, B.; Haagmans, B. L.; Koopmans, M. P. G.; Fouchier, R. A. M.; Herfst, S., SARS-CoV-2 is transmitted via contact and via the air between ferrets. *Nature Communications* **2020**, *11* (1), 3496. <https://doi.org/10.1038/s41467-020-17367-2>
444. (U) Richardson, S.; Hirsch, J. S.; Narasimhan, M.; Crawford, J. M.; McGinn, T.; Davidson, K. W.; Consortium, a. t. N. C.-R., Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. *JAMA* **2020**. <https://doi.org/10.1001/jama.2020.6775>
445. (U) Richter, W.; Hofacre, K.; Willenberg, Z., *Final Report for the Bioquell Hydrogen Peroxide Vapor (HPV) Decontamination for Reuse of N95 Respirators*; Battelle Memorial Institute: 2016. <http://wayback.archive-it.org/7993/20170113034232/http://www.fda.gov/downloads/EmergencyPreparedness/Counterterrorism/MedicalCountermeasures/MCMRegulatoryScience/UCM516998.pdf>
446. (U) Rickman, H. M.; Rampling, T.; Shaw, K.; Martinez-Garcia, G.; Hail, L.; Coen, P.; Shahmanesh, M.; Shin, G. Y.; Nastouli, E.; Houlihan, C. F., Nosocomial transmission of COVID-19: a retrospective study of 66 hospital-acquired cases in a London teaching hospital. *Clinical Infectious Diseases* **2020**. <https://doi.org/10.1093/cid/ciaa816>
447. (U) Riou, J.; Althaus, C. L., Pattern of early human-to-human transmission of Wuhan 2019 novel coronavirus (2019-nCoV), December 2019 to January 2020. *Eurosurveillance* **2020**, *25* (4), 2000058. <https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.4.2000058>

448. (U) Riphagen, S.; Gomez, X.; Gonzalez-Martinez, C.; Wilkinson, N.; Theocharis, P., Hyperinflammatory shock in children during COVID-19 pandemic. *The Lancet*.  
[https://doi.org/10.1016/S0140-6736\(20\)31094-1](https://doi.org/10.1016/S0140-6736(20)31094-1)
449. (U) Rivers, C.; Martin, E.; Watson, C.; Schoch-Spana, M.; Mullen, L.; Sell, T. K.; Gottlieb, S.; Warmbrod, K. L.; Hosangadi, D.; Kobokovich, A.; Potter, C.; Cicero, A.; Inglesby, T. V., *Public Health Principles for a Phased Reopening During COVID-19: Guidance for Governors*; Johns Hopkins Center for Health Security: 2020. [https://www.centerforhealthsecurity.org/our-work/pubs\\_archive/pubs-pdfs/2020/reopening-guidance-governors.pdf](https://www.centerforhealthsecurity.org/our-work/pubs_archive/pubs-pdfs/2020/reopening-guidance-governors.pdf)
450. (U) Robba, C.; Battaglini, D.; Ball, L.; Patroniti, N.; Loconte, M.; Brunetti, I.; Vena, A.; Giacobbe, D. R.; Bassetti, M.; Rocco, P. R. M.; Pelosi, P., Distinct phenotypes require distinct respiratory management strategies in severe COVID-19. *Respiratory Physiology & Neurobiology* **2020**, *279*, 103455.  
<http://www.sciencedirect.com/science/article/pii/S1569904820301130>
451. (U) Robertson, D., nCoV's relationship to bat coronaviruses & recombination signals (no snakes) **2020**. <http://virological.org/t/ncovs-relationship-to-bat-coronaviruses-recombination-signals-no-snakes/331>
452. (U) Rockx, B.; Kuiken, T.; Herfst, S.; Bestebroer, T.; Lamers, M. M.; Oude Munnink, B. B.; de Meulder, D.; van Amerongen, G.; van den Brand, J.; Okba, N. M. A.; Schipper, D.; van Run, P.; Leijten, L.; Sikkema, R.; Verschoor, E.; Verstrepen, B.; Bogers, W.; Langermans, J.; Drosten, C.; Fentener van Vlissingen, M.; Fouchier, R.; de Swart, R.; Koopmans, M.; Haagmans, B. L., Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model. *Science* **2020**, eabb7314.  
<https://science.sciencemag.org/content/sci/early/2020/04/16/science.abb7314.full.pdf>
453. (U) Rokkas, T., Gastrointestinal involvement in COVID-19: a systematic review and meta-analysis. *Annals of Gastroenterology* **2020**, *33* (4), 355-365.  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7315709/>
454. (U) Rosenberg, E. S.; Dufort, E. M.; Blog, D. S.; Hall, E. W.; Hoefler, D.; Backenson, B. P.; Muse, A. T.; Kirkwood, J. N.; George, K. S.; Holtgrave, D. R.; Hutton, B. J.; Zucker, H. A.; Team, N. Y. S. C. R., COVID-19 Testing, Epidemic Features, Hospital Outcomes, and Household Prevalence, New York State—March 2020. *Clinical Infectious Diseases* **2020**. <https://doi.org/10.1093/cid/ciaa549>
455. (U) Rossi, B.; Nguyen, L. S.; Zimmermann, P.; Boucenna, F.; Baucher, L.; Dubret, L.; Guillot, H.; Bouldouyre, M.-a.; Allenbach, Y.; Salem, J.-E.; Barsoum, P.; Oufella, A.; Gros, H., Effect of tocilizumab in hospitalized patients with severe pneumonia COVID-19: a cohort study. *medRxiv* **2020**, 2020.06.06.20122341. <http://medrxiv.org/content/early/2020/06/09/2020.06.06.20122341.abstract>
456. (U) Rothe, C.; Schunk, M.; Sothmann, P.; Bretzel, G.; Froeschl, G.; Wallrauch, C.; Zimmer, T.; Thiel, V.; Janke, C.; Guggemos, W.; Seilmaier, M.; Drosten, C.; Vollmar, P.; Zwirgmaier, K.; Zange, S.; Wölfel, R.; Hoelscher, M., Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany. *New England Journal of Medicine* **2020**. <https://www.nejm.org/doi/full/10.1056/NEJMc2001468>  
<https://www.nejm.org/doi/10.1056/NEJMc2001468>
457. (U) Ruan, Q.; Yang, K.; Wang, W.; Jiang, L.; Song, J., Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. *Intensive Care Medicine* **2020**.  
<https://doi.org/10.1007/s00134-020-05991-x>
458. (U) Rubino, F.; Amiel, S. A.; Zimet, P.; Alberti, G.; Bornstein, S.; Eckel, R. H.; Mingrone, G.; Boehm, B.; Cooper, M. E.; Chai, Z.; Del Prato, S.; Ji, L.; Hopkins, D.; Herman, W. H.; Khunti, K.; Mbanya, J.-C.; Renard, E., New-Onset Diabetes in Covid-19. *New England Journal of Medicine* **2020**.  
<https://www.nejm.org/doi/full/10.1056/NEJMc2018688>
459. (U) Ruktanonchai, N. W.; Floyd, J. R.; Lai, S.; Ruktanonchai, C. W.; Sadilek, A.; Rente-Lourenco, P.; Ben, X.; Carioli, A.; Gwinn, J.; Steele, J. E.; Prosper, O.; Schneider, A.; Oplinger, A.; Eastham, P.; Tatem, A.

- J., Assessing the impact of coordinated COVID-19 exit strategies across Europe. *Science* **2020**, eabc5096. <https://science.sciencemag.org/content/sci/early/2020/07/16/science.abc5096.full.pdf>
460. (U) Rundle, A., Severe COVID-19 Risk Mapping. <https://columbia.maps.arcgis.com/apps/webappviewer/index.html?id=ade6ba85450c4325a12a5b9c09ba796c>.
461. (U) Russell, T. W.; Hellewell, J.; Abbott, S.; Golding, N.; Gibbs, H.; Jarvis, C. I.; van Zandvoort, K.; group, C. n. w.; Flasche, S.; Eggo, R. M.; Edmunds, W. J.; Kucharski, A. J., Using a delay-adjusted case fatality ratio to estimate under-reporting. CMMID: 2020. [https://cmmid.github.io/topics/covid19/severity/global\\_cfr\\_estimates.html](https://cmmid.github.io/topics/covid19/severity/global_cfr_estimates.html)
462. (U) Ryan, K. A.; Bewley, K. R.; Fotheringham, S. A.; Brown, P.; Hall, Y.; Marriott, A. C.; Tree, J. A.; Allen, L.; Aram, M. J.; Brunt, E.; Buttigieg, K. R.; Cavell, B. E.; Carter, D. P.; Cobb, R.; Coombes, N. S.; Godwin, K. J.; Gooch, K. E.; Gouriet, J.; Halkerston, R.; Harris, D. J.; Humphries, H. E.; Hunter, L.; Ho, C. M. K.; Kennard, C. L.; Leung, S.; Ngabo, D.; Osman, K. L.; Paterson, J.; Penn, E. J.; Pullan, S. T.; Rayner, E.; Slack, G. S.; Steeds, K.; Taylor, I.; Tipton, T.; Thomas, S.; Wand, N. I.; Watson, R. J.; Wiblin, N. R.; Charlton, S.; Hallis, B.; Hiscox, J. A.; Funnell, S.; Dennis, M. J.; Whittaker, C. J.; Catton, M. G.; Druce, J.; Salguero, F. J.; Carroll, M. W., Dose-dependent response to infection with SARS-CoV-2 in the ferret model: evidence of protection to re-challenge. *bioRxiv* **2020**, 2020.05.29.123810. <https://www.biorxiv.org/content/biorxiv/early/2020/05/29/2020.05.29.123810.full.pdf>
463. (U) Saknimit, M.; Inatsuki, I.; Sugiyama, Y.; Yagami, K., Virucidal efficacy of physico-chemical treatments against coronaviruses and parvoviruses of laboratory animals. *Jikken Dobutsu* **1988**, 37 (3), 341-5. [https://www.jstage.jst.go.jp/article/expanim1978/37/3/37\\_3\\_341/pdf](https://www.jstage.jst.go.jp/article/expanim1978/37/3/37_3_341/pdf)
464. (U) Salazar, E.; Perez, K. K.; Ashraf, M.; Chen, J.; Castillo, B.; Christensen, P. A.; Eubank, T.; Bernard, D. W.; Eagar, T. N.; Long, S. W.; Subedi, S.; Olsen, R. J.; Leveque, C.; Schwartz, M. R.; Dey, M.; Chavez-East, C.; Rogers, J.; Shehabeldin, A.; Joseph, D.; Williams, G.; Thomas, K.; Masud, F.; Talley, C.; Dlouhy, K. G.; Lopez, B. V.; Hampton, C.; Lavinder, J.; Gollihar, J. D.; Maranhao, A. C.; Ippolito, G. C.; Saavedra, M. O.; Cantu, C. C.; Yerramilli, P.; Pruitt, L.; Musser, J. M., Treatment of COVID-19 Patients with Convalescent Plasma. *Am J Pathol* **2020**.
465. (U) Saloner, B.; Parish, K.; Ward, J. A.; DiLaura, G.; Dolovich, S., COVID-19 Cases and Deaths in Federal and State Prisons. *Jama* **2020**.
466. (U) Salton, F.; Confalonieri, P.; Santus, P.; Harari, S.; Scala, R.; Lanini, S.; Vertui, V.; Oggionni, T.; Caminati, A.; Patruno, V.; Tamburrini, M.; Scartabellati, A.; Parati, M.; Villani, M.; Radovanovic, D.; Tomassetti, S.; Ravaglia, C.; Poletti, V.; Vianello, A.; Gaccione, A. T.; Guidelli, L.; Raccanelli, R.; Lacedonia, D.; Lucernoni, P.; Foschino Barbaro, M. P.; Centanni, S.; Mondoni, M.; Davi, M.; Fantin, A.; Cao, X.; Torelli, L.; Zucchetto, A.; Montico, M.; Casarin, A.; Romagnoli, M.; Gasparini, S.; Bonifazi, M.; Agaro, P.; Marcello, A.; Licastro, D.; Ruaro, B.; Volpe, M. C.; Umberger, R.; Meduri, G. U.; Confalonieri, M., Prolonged low-dose methylprednisolone in patients with severe COVID-19 pneumonia. *medRxiv* **2020**, 2020.06.17.20134031. <http://medrxiv.org/content/early/2020/06/20/2020.06.17.20134031.abstract>
467. (U) Sanche, S.; Lin, Y. T.; Xu, C.; Romero-Severson, E.; Hengartner, N. W.; Ke, R., The novel coronavirus, 2019-nCoV, is highly contagious and more infectious than initially estimated. *arXiv preprint arXiv:2002.03268* **2020**.
468. (U) Sanchez, G. V.; Biedron, C.; Fink, L. R.; al., e., Initial and Repeated Point Prevalence Surveys to Inform SARS-CoV-2 Infection Prevention in 26 Skilled Nursing Facilities — Detroit, Michigan, March–May 2020. *Morbidity and Mortality Weekly Report* **2020**, *ePub: 1 July 2020*. [https://www.cdc.gov/mmwr/volumes/69/wr/mm6927e1.htm?s\\_cid=mm6927e1\\_w#suggestedcitation](https://www.cdc.gov/mmwr/volumes/69/wr/mm6927e1.htm?s_cid=mm6927e1_w#suggestedcitation)
469. (U) Santarpia, J. L.; Rivera, D. N.; Herrera, V.; Morwitzer, M. J.; Creager, H.; Santarpia, G. W.; Crown, K. K.; Brett-Major, D.; Schnaubelt, E.; Broadhurst, M. J.; Lawler, J. V.; Reid, S. P.; Lowe, J. J., Transmission Potential of SARS-CoV-2 in Viral Shedding Observed at the University of Nebraska Medical Center.

medRxiv 2020, 2020.03.23.20039446.

<https://www.medrxiv.org/content/medrxiv/early/2020/03/26/2020.03.23.20039446.1.full.pdf>

470. (U) Sanz Herrero, F.; Puchades Gimeno, F.; Ortega García, P.; Ferrer Gómez, C.; Ocete Mochón, M. D.; García Deltoro, M., Methylprednisolone added to tocilizumab reduces mortality in SARS-CoV-2 pneumonia: An observational study. *Journal of Internal Medicine* 2020, n/a (n/a).

<https://doi.org/10.1111/joim.13145>

471. (U) Sauter, J. L.; Baine, M. K.; Butnor, K. J.; Buonocore, D. J.; Chang, J. C.; Jungbluth, A. A.; Szabolcs, M. J.; Morjaria, S.; Mount, S. L.; Rekhman, N.; Selbs, E.; Sheng, Z.-M.; Xiao, Y.; Kleiner, D. E.; Pittaluga, S.; Taubenberger, J. K.; Rapkiewicz, A. V.; Travis, W. D., Insights into pathogenesis of fatal COVID-19 pneumonia from histopathology with immunohistochemical and viral RNA studies. *Histopathology* n/a (n/a). <https://onlinelibrary.wiley.com/doi/abs/10.1111/his.14201>

472. (U) Schaefer, I. M.; Padera, R. F.; Solomon, I. H.; Kanjilal, S.; Hammer, M. M.; Hornick, J. L.; Sholl, L. M., In situ detection of SARS-CoV-2 in lungs and airways of patients with COVID-19. *Mod Pathol* 2020, 1-11.

473. (U) Schlottau, K.; Rissmann, M.; Graaf, A.; Schön, J.; Sehl, J.; Wylezich, C.; Höper, D.; Mettenleiter, T. C.; Balkema-Buschmann, A.; Harder, T.; Grund, C.; Hoffmann, D.; Breithaupt, A.; Beer, M., SARS-CoV-2 in fruit bats, ferrets, pigs, and chickens: an experimental transmission study. *The Lancet Microbe* 2020.

[https://doi.org/10.1016/S2666-5247\(20\)30089-6](https://doi.org/10.1016/S2666-5247(20)30089-6)

474. (U) Schnirring, L., New coronavirus infects health workers, spreads to Korea.

<http://www.cidrap.umn.edu/news-perspective/2020/01/new-coronavirus-infects-health-workers-spreads-korea>.

475. (U) Schuit, M.; Ratnesar-Shumate, S.; Yolitz, J.; Williams, G.; Weaver, W.; Green, B.; Miller, D.; Krause, M.; Beck, K.; Wood, S.; Holland, B.; Bohannon, J.; Freeburger, D.; Hooper, I.; Biryukov, J.; Altamura, L. A.; Wahl, V.; Hevey, M.; Dabisch, P., Airborne SARS-CoV-2 is Rapidly Inactivated by Simulated Sunlight. *The Journal of Infectious Diseases* 2020. <https://doi.org/10.1093/infdis/jiaa334>

476. (U) Schwartz, D. A., An analysis of 38 pregnant women with COVID-19, their newborn infants, and maternal-fetal transmission of SARS-CoV-2: maternal coronavirus infections and pregnancy outcomes. *Archives of Pathology & Laboratory Medicine* 2020.

477. (U) Sciences, C. A. o. M., Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19. Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19.

478. (U) Security, J. C. f. H., 2019-nCoV resources and updates on the emerging novel coronavirus. 2020.

<http://www.centerforhealthsecurity.org/resources/2019-nCoV/>

479. (U) Sekine, T.; Perez-Potti, A.; Rivera-Ballesteros, O.; Strålin, K.; Gorin, J.-B.; Olsson, A.; Llewellyn-Lacey, S.; Kamal, H.; Bogdanovic, G.; Muschiol, S.; Wullimann, D. J.; Kammann, T.; Emgård, J.; Parrot, T.; Folkesson, E.; Rooyackers, O.; Eriksson, L. I.; Sönnernborg, A.; Allander, T.; Albert, J.; Nielsen, M.; Klingström, J.; Gredmark-Russ, S.; Björkström, N. K.; Sandberg, J. K.; Price, D. A.; Ljunggren, H.-G.; Aleman, S.; Buggert, M., Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. *bioRxiv* 2020, 2020.06.29.174888.

<https://www.biorxiv.org/content/biorxiv/early/2020/06/29/2020.06.29.174888.full.pdf>

480. (U) Seow, J.; Graham, C.; Merrick, B.; Acors, S.; Steel, K. J. A.; Hemmings, O.; O'Bryne, A.; Kouphou, N.; Pickering, S.; Galao, R.; Betancor, G.; Wilson, H. D.; Signell, A. W.; Winstone, H.; Kerridge, C.; Temperton, N.; Snell, L.; Bisnauthsing, K.; Moore, A.; Green, A.; Martinez, L.; Stokes, B.; Honey, J.; Izquierdo-Barras, A.; Arbane, G.; Patel, A.; O'Connell, L.; O'Hara, G.; MacMahon, E.; Douthwaite, S.; Nebbia, G.; Batra, R.; Martinez-Nunez, R.; Edgeworth, J. D.; Neil, S. J. D.; Malim, M. H.; Doores, K., Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection. *medRxiv* 2020, 2020.07.09.20148429.

<https://www.medrxiv.org/content/medrxiv/early/2020/07/11/2020.07.09.20148429.full.pdf>

481. (U) Sharma, A.; Kumar Sharma, S.; Shi, Y.; Bucci, E.; Carafoli, E.; Melino, G.; Bhattacharjee, A.; Das, G., BCG vaccination policy and preventive chloroquine usage: do they have an impact on COVID-19 pandemic? *Cell Death & Disease* **2020**, *11* (7), 516. <https://doi.org/10.1038/s41419-020-2720-9>
482. (U) Shekerdemian, L. S.; Mahmood, N. R.; Wolfe, K. K.; Riggs, B. J.; Ross, C. E.; McKiernan, C. A.; Heidemann, S. M.; Kleinman, L. C.; Sen, A. I.; Hall, M. W.; Priestley, M. A.; McGuire, J. K.; Boukas, K.; Sharron, M. P.; Burns, J. P.; Collaborative, f. t. I. C.-P., Characteristics and Outcomes of Children With Coronavirus Disease 2019 (COVID-19) Infection Admitted to US and Canadian Pediatric Intensive Care Units. *JAMA Pediatrics* **2020**. <https://doi.org/10.1001/jamapediatrics.2020.1948>
483. (U) Shen, C.; Wang, Z.; Zhao, F.; Yang, Y.; Li, J.; Yuan, J.; Wang, F.; Li, D.; Yang, M.; Xing, L.; Wei, J.; Xiao, H.; Yang, Y.; Qu, J.; Qing, L.; Chen, L.; Xu, Z.; Peng, L.; Li, Y.; Zheng, H.; Chen, F.; Huang, K.; Jiang, Y.; Liu, D.; Zhang, Z.; Liu, Y.; Liu, L., Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. *JAMA* **2020**. <https://doi.org/10.1001/jama.2020.4783>
484. (U) Shen, Y.; Xu, W.; Li, C.; Handel, A.; Martinez, L.; Ling, F.; Ebell, M.; Fu, X.; Pan, J.; Ren, J.; Gu, W.; Chen, E., A cluster of COVID-19 infections indicating person-to-person transmission among casual contacts from social gatherings: An outbreak case-contact investigation. *Open Forum Infectious Diseases* **2020**. <https://doi.org/10.1093/ofid/ofaa231>
485. (U) Sheridan, C., Convalescent serum lines up as first-choice treatment for coronavirus. *Nature Biotechnology* **2020**. <https://www.nature.com/articles/d41587-020-00011-1>
486. (U) Sheridan, C., Coronavirus and the race to distribute reliable diagnostics. <https://www.nature.com/articles/d41587-020-00002-2>.
487. (U) Shi, J.; Wen, Z.; Zhong, G.; Yang, H.; Wang, C.; Huang, B.; Liu, R.; He, X.; Shuai, L.; Sun, Z.; Zhao, Y.; Liu, P.; Liang, L.; Cui, P.; Wang, J.; Zhang, X.; Guan, Y.; Tan, W.; Wu, G.; Chen, H.; Bu, Z., Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS–coronavirus 2. *Science* **2020**, eabb7015. <https://science.sciencemag.org/content/sci/early/2020/04/07/science.abb7015.full.pdf>
488. (U) Shi, S.; Qin, M.; Shen, B.; Cai, Y.; Liu, T.; Yang, F.; Gong, W.; Liu, X.; Liang, J.; Zhao, Q.; Huang, H.; Yang, B.; Huang, C., Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. *JAMA Cardiology* **2020**. <https://doi.org/10.1001/jamacardio.2020.0950>
489. (U) Sia, S. F.; Yan, L. M.; Chin, A. W. H.; Fung, K.; Choy, K. T.; Wong, A. Y. L.; Kaewpreedee, P.; Perera, R.; Poon, L. L. M.; Nicholls, J. M.; Peiris, M.; Yen, H. L., Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. *Nature* **2020**.
490. (U) Silverman, J. D.; Hupert, N.; Washburne, A. D., Using influenza surveillance networks to estimate state-specific prevalence of SARS-CoV-2 in the United States. *Science Translational Medicine* **2020**, eabc1126. <https://stm.sciencemag.org/content/scitransmed/early/2020/06/22/scitranslmed.abc1126.full.pdf>
491. (U) Sinovac, Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals (PROFISCOV). <https://clinicaltrials.gov/ct2/show/NCT04456595?term=vaccine&cond=covid-19&draw=2&rank=1>.
492. (U) Sinovac, Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19). <https://clinicaltrials.gov/ct2/show/NCT04352608?term=sinovac&draw=2&rank=12>.
493. (U) Sinovac, Sinovac reports positive data from Phase I/II trials of CoronaVac. <https://www.clinicaltrialsarena.com/news/sinovac-coronavac-data/>.
494. (U) Sit, T. H. C.; Brackman, C. J.; Ip, S. M.; Tam, K. W. S.; Law, P. Y. T.; To, E. M. W.; Yu, V. Y. T.; Sims, L. D.; Tsang, D. N. C.; Chu, D. K. W.; Perera, R.; Poon, L. L. M.; Peiris, M., Infection of dogs with SARS-CoV-2. *Nature* **2020**.
495. (U) Skalina, K. A.; Goldstein, D. Y.; Sulail, J.; Hahm, E.; Narlieva, M.; Szymczak, W.; Fox, A. S., Extended Storage of SARS-CoV2 Nasopharyngeal Swabs Does Not Negatively Impact Results of

Molecular-Based Testing. *medRxiv* **2020**, 2020.05.16.20104158.

<https://www.medrxiv.org/content/medrxiv/early/2020/05/20/2020.05.16.20104158.full.pdf>

496. (U) Skipper, C. P.; Pastick, K. A.; Engen, N. W.; Bangdiwala, A. S.; Abassi, M.; Lofgren, S. M.; Williams, D. A.; Okafor, E. C.; Pullen, M. F.; Nicol, M. R.; Nascene, A. A.; Hullsiek, K. H.; Cheng, M. P.; Luke, D.; Lother, S. A.; MacKenzie, L. J.; Drobot, G.; Kelly, L. E.; Schwartz, I. S.; Zarychanski, R.; McDonald, E. G.; Lee, T. C.; Rajasingham, R.; Boulware, D. R., Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19. *Annals of Internal Medicine* **2020**, 0 (0), null.

<https://www.acpjournals.org/doi/abs/10.7326/M20-4207>

497. (U) Somers, E. C.; Eschenauer, G. A.; Troost, J. P.; Golob, J. L.; Gandhi, T. N.; Wang, L.; Zhou, N.; Petty, L. A.; Baang, J. H.; Dillman, N. O.; Frame, D.; Gregg, K. S.; Kaul, D. R.; Nagel, J.; Patel, T. S.; Zhou, S.; Luring, A. S.; Hanauer, D. A.; Martin, E.; Sharma, P.; Fung, C. M.; Pogue, J. M., Tocilizumab for treatment of mechanically ventilated patients with COVID-19. *Clinical Infectious Diseases* **2020**.

<https://doi.org/10.1093/cid/ciaa954>

498. (U) Song, J.-Y.; Yun, J.-G.; Noh, J.-Y.; Cheong, H.-J.; Kim, W.-J., Covid-19 in South Korea — Challenges of Subclinical Manifestations. *New England Journal of Medicine* **2020**.

<https://www.nejm.org/doi/full/10.1056/NEJMc2001801>

499. (U) Stadnytskyi, V.; Bax, C. E.; Bax, A.; Anfinrud, P., The airborne lifetime of small speech droplets and their potential importance in SARS-CoV-2 transmission. *Proceedings of the National Academy of Sciences* **2020**, 202006874. <https://www.pnas.org/content/pnas/early/2020/05/12/2006874117.full.pdf>

500. (U) Stubblefield, W. B.; Talbot, H. K.; Feldstein, L.; Tenforde, M. W.; Rasheed, M. A. U.; Mills, L.; Lester, S. N.; Freeman, B.; Thornburg, N. J.; Jones, I. D.; Ward, M. J.; Lindsell, C. J.; Baughman, A.; Halasa, N.; Grijalva, C. G.; Rice, T. W.; Patel, M. M.; Self, W. H.; Investigators, I. V. E. i. t. C. I., Seroprevalence of SARS-CoV-2 Among Frontline Healthcare Personnel During the First Month of Caring for COVID-19 Patients — Nashville, Tennessee. *Clinical Infectious Diseases* **2020**. <https://doi.org/10.1093/cid/ciaa936>

501. (U) Su, H.; Yang, M.; Wan, C.; Yi, L.-X.; Tang, F.; Zhu, H.-Y.; Yi, F.; Yang, H.-C.; Fogo, A. B.; Nie, X.; Zhang, C., Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. *Kidney International*. <https://doi.org/10.1016/j.kint.2020.04.003>

502. (U) Su, Y. C.; Anderson, D. E.; Young, B. E.; Zhu, F.; Linster, M.; Kalimuddin, S.; Low, J. G.; Yan, Z.; Jayakumar, J.; Sun, L.; Yan, G. Z.; Mendenhall, I. H.; Leo, Y.-S.; Lye, D. C.; Wang, L.-F.; Smith, G. J., Discovery of a 382-nt deletion during the early evolution of SARS-CoV-2. *bioRxiv* **2020**, 2020.03.11.987222.

<https://www.biorxiv.org/content/biorxiv/early/2020/03/12/2020.03.11.987222.full.pdf>

503. (U) Suarez, D. L.; Pantin-Jackwood, M. J.; Swayne, D. E.; Lee, S. A.; DeBlois, S. M.; Spackman, E., Lack of susceptibility of poultry to SARS-CoV-2 and MERS-CoV. *bioRxiv* **2020**, 2020.06.16.154658.

<http://biorxiv.org/content/early/2020/06/16/2020.06.16.154658.abstract>

504. (U) Sukhyun, R.; Seikh Taslim, A.; Cheolsun, J.; Baekjin, K.; Benjamin, J. C., Effect of Nonpharmaceutical Interventions on Transmission of Severe Acute Respiratory Syndrome Coronavirus 2, South Korea, 2020. *Emerging Infectious Disease journal* **2020**, 26 (10).

[https://wwwnc.cdc.gov/eid/article/26/10/20-1886\\_article](https://wwwnc.cdc.gov/eid/article/26/10/20-1886_article)

505. (U) Sun, J.; Zhu, A.; Li, H.; Zheng, K.; Zhuang, Z.; Chen, Z.; Shi, Y.; Zhang, Z.; Chen, S. B.; Liu, X.; Dai, J.; Li, X.; Huang, S.; Huang, X.; Luo, L.; Wen, L.; Zhuo, J.; Li, Y.; Wang, Y.; Zhang, L.; Zhang, Y.; Li, F.; Feng, L.; Chen, X.; Zhong, N.; Yang, Z.; Huang, J.; Zhao, J.; Li, Y. M., Isolation of Infectious SARS-CoV-2 from Urine of a COVID-19 Patient. *Emerg Microbes Infect* **2020**, 1-8.

506. (U) Sun, S.; Cai, X.; Wang, H.; He, G.; Lin, Y.; Lu, B.; Chen, C.; Pan, Y.; Hu, X., Abnormalities of peripheral blood system in patients with COVID-19 in Wenzhou, China. *Clinica Chimica Acta* **2020**, 507, 174-180. <http://www.sciencedirect.com/science/article/pii/S0009898120301790>

507. (U) Sun, S. H.; Chen, Q.; Gu, H. J.; Yang, G.; Wang, Y. X.; Huang, X. Y.; Liu, S. S.; Zhang, N. N.; Li, X. F.; Xiong, R.; Guo, Y.; Deng, Y. Q.; Huang, W. J.; Liu, Q.; Liu, Q. M.; Shen, Y. L.; Zhou, Y.; Yang, X.; Zhao, T. Y.;

- Fan, C. F.; Zhou, Y. S.; Qin, C. F.; Wang, Y. C., A Mouse Model of SARS-CoV-2 Infection and Pathogenesis. *Cell Host Microbe* **2020**.
508. (U) Suthar, M. S.; Zimmerman, M. G.; Kauffman, R. C.; Mantus, G.; Linderman, S. L.; Hudson, W. H.; Vanderheiden, A.; Nyhoff, L.; Davis, C. W.; Adekunle, S.; Affer, M.; Sherman, M.; Reynolds, S.; Verkerke, H. P.; Alter, D. N.; Guarner, J.; Bryksin, J.; Horwath, M.; Arthur, C. M.; Saakadze, N.; Smith, G. H.; Edupuganti, S.; Scherer, E. M.; Hellmeister, K.; Cheng, A.; Morales, J. A.; Neish, A. S.; Stowell, S. R.; Frank, F.; Ortlund, E.; Anderson, E.; Menachery, V. D.; Roupheal, N.; Mehta, A.; Stephens, D. S.; Ahmed, R.; Roback, J. D.; Wrarmert, J., Rapid generation of neutralizing antibody responses in COVID-19 patients. *Cell Reports Medicine* **2020**. <https://doi.org/10.1016/j.xcrm.2020.100040>
509. (U) Tabata, S.; Imai, K.; Kawano, S.; Ikeda, M.; Kodama, T.; Miyoshi, K.; Obinata, H.; Mimura, S.; Kodaera, T.; Kitagaki, M.; Sato, M.; Suzuki, S.; Ito, T.; Uwabe, Y.; Tamura, K., Clinical characteristics of COVID-19 in 104 people with SARS-CoV-2 infection on the <em>Diamond Princess</em> cruise ship: a retrospective analysis. *The Lancet Infectious Diseases*. [https://doi.org/10.1016/S1473-3099\(20\)30482-5](https://doi.org/10.1016/S1473-3099(20)30482-5)
510. (U) Taboada, B.; Vazquez-Perez, J. A.; Muñoz Medina, J. E.; Ramos Cervantes, P.; Escalera-Zamudio, M.; Boukadida, C.; Sanchez-Flores, A.; Isa, P.; Mendieta Condado, E.; Martínez-Orozco, J. A.; Becerril-Vargas, E.; Salas-Hernández, J.; Grande, R.; González-Torres, C.; Gaytán-Cervantes, F. J.; Vazquez, G.; Pulido, F.; Araiza Rodríguez, A.; Garcés Ayala, F.; González Bonilla, C. R.; Grajales Muñiz, C.; Borja Aburto, V. H.; Barrera Badillo, G.; López, S.; Hernández Rivas, L.; Perez-Padilla, R.; López Martínez, I.; Ávila-Ríos, S.; Ruiz-Palacios, G.; Ramírez-González, J. E.; Arias, C. F., Genomic Analysis of Early SARS-CoV-2 Variants Introduced in Mexico. *Journal of Virology* **2020**, JVI.01056-20. <https://jvi.asm.org/content/jvi/early/2020/07/02/JVI.01056-20.full.pdf>
511. (U) Tan, W.; Lu, Y.; Zhang, J.; Wang, J.; Dan, Y.; Tan, Z.; He, X.; Qian, C.; Sun, Q.; Hu, Q.; Liu, H.; Ye, S.; Xiang, X.; Zhou, Y.; Zhang, W.; Guo, Y.; Wang, X.-H.; He, W.; Wan, X.; Sun, F.; Wei, Q.; Chen, C.; Pan, G.; Xia, J.; Mao, Q.; Chen, Y.; Deng, G., Viral Kinetics and Antibody Responses in Patients with COVID-19. *medRxiv* **2020**, 2020.03.24.20042382. <https://www.medrxiv.org/content/medrxiv/early/2020/03/26/2020.03.24.20042382.full.pdf>
512. (U) Tang, W.; Cao, Z.; Han, M.; Wang, Z.; Chen, J.; Sun, W.; Wu, Y.; Xiao, W.; Liu, S.; Chen, E.; Chen, W.; Wang, X.; Yang, J.; Lin, J.; Zhao, Q.; Yan, Y.; Xie, Z.; Li, D.; Yang, Y.; Liu, L.; Qu, J.; Ning, G.; Shi, G.; Xie, Q., Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. *BMJ* **2020**, *369*, m1849. <http://www.bmj.com/content/369/bmj.m1849.abstract>
513. (U) Temesgen, Z.; Assi, M.; Vergidis, P.; Rizza, S. A.; Bauer, P. R.; Pickering, B. W.; Razonable, R. R.; Libertin, C. R.; Burger, C. D.; Orenstein, R.; Vargas, H. E.; Varatharaj Palraj, B. R.; Dababneh, A. S.; Chappell, G.; Chappell, D.; Ahmed, O.; Sakemura, R.; Durrant, C.; Kenderian, S. S.; Badley, A., First Clinical Use of Lenzilumab to Neutralize GM-CSF in Patients with Severe COVID-19 Pneumonia. *medRxiv* **2020**, 2020.06.08.20125369. <http://medrxiv.org/content/early/2020/06/14/2020.06.08.20125369.abstract>
514. (U) The Novel Coronavirus Pneumonia Emergency Response Epidemiology, T., The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020. *China CDC Weekly* **2020**, *2*, 1-10. <http://weekly.chinacdc.cn//article/id/e53946e2-c6c4-41e9-9a9b-fea8db1a8f51>
515. (U) Thomas, P.; Alexander, P. E.; Ahmed, U.; Elderhorst, E.; El-Khechen, H.; Mammen, M. J.; Debono, V. B.; Aponte Torres, Z.; Aryal, K.; Brocard, E.; Sagastuy, B.; Alhazzani, W., Vertical transmission risk of SARS-CoV-2 infection in the third trimester: a systematic scoping review. *The Journal of Maternal-Fetal & Neonatal Medicine* **2020**, 1-8. <https://doi.org/10.1080/14767058.2020.1786055>
516. (U) Thomas, P. R.; Karriker, L. A.; Ramirez, A.; Zhang, J.; Ellingson, J. S.; Crawford, K. K.; Bates, J. L.; Hammen, K. J.; Holtkamp, D. J., Evaluation of time and temperature sufficient to inactivate porcine epidemic diarrhea virus in swine feces on metal surfaces. *Journal of Swine Health and Production* **2015**, *23* (2), 84.



517. (U) Thomas, P. R.; Ramirez, A.; Zhang, J.; Ellingson, J. S.; Myers, J. N., Methods for inactivating PEDV in Hog Trailers. *Animal Industry Report* **2015**, 661 (1), 91.
518. (U) To, K. K.-W.; Tsang, O. T.-Y.; Leung, W.-S.; Tam, A. R.; Wu, T.-C.; Lung, D. C.; Yip, C. C.-Y.; Cai, J.-P.; Chan, J. M.-C.; Chik, T. S.-H., Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. *The Lancet Infectious Diseases* **2020**.
519. (U) Treibel, T. A.; Manisty, C.; Burton, M.; McKnight, Á.; Lambourne, J.; Augusto, J. B.; Couto-Parada, X.; Cutino-Moguel, T.; Noursadeghi, M.; Moon, J. C., COVID-19: PCR screening of asymptomatic health-care workers at London hospital. *The Lancet*. [https://doi.org/10.1016/S0140-6736\(20\)31100-4](https://doi.org/10.1016/S0140-6736(20)31100-4)
520. (U) Tsay, C.; Lejarza, F.; Stadtherr, M. A.; Baldea, M., Modeling, state estimation, and optimal control for the US COVID-19 outbreak. *Scientific Reports* **2020**, 10 (1), 10711. <https://doi.org/10.1038/s41598-020-67459-8>
521. (U) Ucciferri, C.; Barone, M.; Vecchiet, J.; Falasca, K., Pidotimod in Paucisymptomatic SARS-CoV2 Infected Patients. *Mediterr J Hematol Infect Dis* **2020**, 12 (1), e2020048.
522. (U) UCLA, COVID-19 Cases in the United States. <https://covid19.uclaml.org/model.html>.
523. (U) Unger, S.; Christie-Holmes, N.; Guvenc, F.; Budyłowski, P.; Mubareka, S.; Gray-Owen, S. D.; O'Connor, D. L., Holder pasteurization of donated human milk is effective in inactivating SARS-CoV-2. *Canadian Medical Association Journal* **2020**, cmaj.201309. <https://www.cmaj.ca/content/cmaj/early/2020/07/09/cmaj.201309.1.full.pdf>
524. (U) Unwin, H. J. T.; Mishra, S.; Bradley, V. C.; Gandy, A.; Vollmer, M.; Mellan, T.; Coupland, H.; Ainslie, K.; Whittaker, C.; Ish-Horowicz, J., State-level tracking of COVID-19 in the United States. **2020**.
525. (U) van der Sande, M.; Teunis, P.; Sabel, R., Professional and Home-Made Face Masks Reduce Exposure to Respiratory Infections among the General Population. *Plos One* **2008**, 3 (7). <Go to ISI>://WOS:000264065800020
526. (U) van Doremalen, N.; Bushmaker, T.; Morris, D. H.; Holbrook, M. G.; Gamble, A.; Williamson, B. N.; Tamin, A.; Harcourt, J. L.; Thornburg, N. J.; Gerber, S. I.; Lloyd-Smith, J. O.; de Wit, E.; Munster, V. J., Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. *New England Journal of Medicine* **2020**. <https://doi.org/10.1056/NEJMc2004973>
527. (U) van Doremalen, N.; Lambe, T.; Spencer, A.; Belij-Rammerstorfer, S.; Purushotham, J. N.; Port, J. R.; Avanzato, V.; Bushmaker, T.; Flaxman, A.; Ulaszewska, M.; Feldmann, F.; Allen, E. R.; Sharpe, H.; Schulz, J.; Holbrook, M.; Okumura, A.; Meade-White, K.; Pérez-Pérez, L.; Bissett, C.; Gilbride, C.; Williamson, B. N.; Rosenke, R.; Long, D.; Ishwarbhai, A.; Kailath, R.; Rose, L.; Morris, S.; Powers, C.; Lovaglio, J.; Hanley, P. W.; Scott, D.; Saturday, G.; de Wit, E.; Gilbert, S. C.; Munster, V. J., ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques. *bioRxiv* **2020**, 2020.05.13.093195. <https://www.biorxiv.org/content/biorxiv/early/2020/05/13/2020.05.13.093195.full.pdf>
528. (U) van Dorp, L.; Acman, M.; Richard, D.; Shaw, L. P.; Ford, C. E.; Ormond, L.; Owen, C. J.; Pang, J.; Tan, C. C. S.; Boshier, F. A. T.; Ortiz, A. T.; Balloux, F., Emergence of genomic diversity and recurrent mutations in SARS-CoV-2. *Infection, Genetics and Evolution* **2020**, 104351. <http://www.sciencedirect.com/science/article/pii/S1567134820301829>
529. (U) Varatharaj, A.; Thomas, N.; Ellul, M. A.; al., e., Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. *The Lancet Psychiatry* **2020**. [https://doi.org/10.1016/S2215-0366\(20\)30287-X](https://doi.org/10.1016/S2215-0366(20)30287-X)
530. (U) Varga, Z.; Flammer, A. J.; Steiger, P.; Haberecker, M.; Andermatt, R.; Zinkernagel, A. S.; Mehra, M. R.; Schuepbach, R. A.; Ruschitzka, F.; Moch, H., Endothelial cell infection and endotheliitis in COVID-19. *The Lancet* **2020**, 395 (10234), 1417-1418. [https://doi.org/10.1016/S0140-6736\(20\)30937-5](https://doi.org/10.1016/S0140-6736(20)30937-5)
531. (U) Vaxine, Monovalent Recombinant COVID19 Vaccine (COVAX19). <https://clinicaltrials.gov/ct2/show/NCT04453852?term=NCT04453852&draw=2&rank=1>.

532. (U) Verdict, Cepheid to develop automated molecular test for coronavirus. Verdict Medical Devices: 2020. <https://www.medicaldevice-network.com/news/cepheid-automated-test-coronavirus/>
533. (U) Vivanti, A. J.; Vauloup-Fellous, C.; Prevot, S.; Zupan, V.; Suffee, C.; Do Cao, J.; Benachi, A.; De Luca, D., Transplacental transmission of SARS-CoV-2 infection. *Nature Communications* **2020**, *11* (1), 3572. <https://doi.org/10.1038/s41467-020-17436-6>
534. (U) von Weyhern, C. H.; Kaufmann, I.; Neff, F.; Kremer, M., Early evidence of pronounced brain involvement in fatal COVID-19 outcomes. *The Lancet* **2020**. [https://doi.org/10.1016/S0140-6736\(20\)31282-4](https://doi.org/10.1016/S0140-6736(20)31282-4)
535. (U) Walsh, K. A.; Jordan, K.; Clyne, B.; Rohde, D.; Drummond, L.; Byrne, P.; Ahern, S.; Carty, P. G.; O'Brien, K. K.; O'Murchu, E.; O'Neill, M.; Smith, S. M.; Ryan, M.; Harrington, P., SARS-CoV-2 Detection, Viral Load and Infectivity over the Course of an Infection: SARS-CoV-2 Detection, Viral Load and Infectivity. *The Journal of infection* **2020**, S0163-4453(20)30449-7. <https://pubmed.ncbi.nlm.nih.gov/32615199>  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7323671/>
536. (U) Wambier, C. G.; Vaño-Galván, S.; McCoy, J.; Gomez-Zubiaur, A.; Herrera, S.; Hermosa-Gelbard, Á.; Moreno-Arrones, O. M.; Jiménez-Gómez, N.; González-Cantero, A.; Pascual, P. F.; Segurado-Miravalles, G.; Shapiro, J.; Pérez-García, B.; Goren, A., Androgenetic Alopecia Present in the Majority of Hospitalized COVID-19 Patients &#x2013; the &#x201c;Gabrin sign&#x201d. *Journal of the American Academy of Dermatology*. <https://doi.org/10.1016/j.jaad.2020.05.079>
537. (U) Wan, Y.; Shang, J.; Graham, R.; Baric, R. S.; Li, F., Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS. *Journal of Virology* **2020**, JVI.00127-20. <https://jvi.asm.org/content/jvi/early/2020/01/23/JVI.00127-20.full.pdf>
538. (U) Wang, B.; Hu, M.; Ren, Y.; Xu, X.; Wang, Z.; Lyu, X.; Wu, W.; Li, Z.; Gong, X.; Xiang, Z.; Tang, L.; Peng, Y.; Wang, M., Evaluation of seven commercial SARS-CoV-2 RNA detection kits based on real-time polymerase chain reaction (PCR) in China. *Clinical Chemistry and Laboratory Medicine (CCLM)* **2020**, (0), 000010151520200271. <https://www.degruyter.com/view/journals/cclm/ahead-of-print/article-10.1515-cclm-2020-0271/article-10.1515-cclm-2020-0271.xml>
539. (U) Wang, B.; Wang, L.; Kong, X.; Geng, J.; Xiao, D.; Ma, C.; Jiang, X. M.; Wang, P. H., Long-term Coexistence of SARS-CoV-2 with Antibody Response in COVID-19 Patients. *J Med Virol* **2020**.
540. (U) Wang, D.; Hu, B.; Hu, C.; Zhu, F.; Liu, X.; Zhang, J.; Wang, B.; Xiang, H.; Cheng, Z.; Xiong, Y.; Zhao, Y.; Li, Y.; Wang, X.; Peng, Z., Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. *JAMA* **2020**.  
<https://doi.org/10.1001/jama.2020.1585>  
[https://jamanetwork.com/journals/jama/articlepdf/2761044/jama\\_wang\\_2020\\_oi\\_200019.pdf](https://jamanetwork.com/journals/jama/articlepdf/2761044/jama_wang_2020_oi_200019.pdf)
541. (U) Wang, D.; Li, R.; Wang, J.; Jiang, Q.; Gao, C.; Yang, J.; Ge, L.; Hu, Q., Correlation analysis between disease severity and clinical and biochemical characteristics of 143 cases of COVID-19 in Wuhan, China: a descriptive study. *BMC Infectious Diseases* **2020**, *20* (1), 519. <https://doi.org/10.1186/s12879-020-05242-w>
542. (U) Wang, D.; You, Y.; Zhou, X.; Zong, Z.; Huang, H.; Zhang, H.; Yong, X.; Cheng, Y.; Yang, L.; Guo, Q.; Long, Y.; Liu, Y.; Huang, J.; Du, L., Selection of homemade mask materials for preventing transmission of COVID-19: a laboratory study. *medRxiv* **2020**.
543. (U) Wang, K.; Zhao, S.; Li, H.; Song, Y.; Wang, L.; Wang, M. H.; Peng, Z.; Li, H.; He, D., Real-time estimation of the reproduction number of the novel coronavirus disease (COVID-19) in China in 2020 based on incidence data. *Annals of Translational Medicine* **2020**, *8* (11), 689.  
<http://atm.amegroups.com/article/view/43447>

544. (U) Wang, S.; Ma, P.; Zhang, S.; Song, S.; Wang, Z.; Ma, Y.; Xu, J.; Wu, F.; Duan, L.; Yin, Z.; Luo, H.; Xiong, N.; Xu, M.; Zeng, T.; Jin, Y., Fasting blood glucose at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes: a multi-centre retrospective study. *Diabetologia* **2020**. <https://doi.org/10.1007/s00125-020-05209-1>
545. (U) Wang, W.; Xu, Y.; Gao, R.; Lu, R.; Han, K.; Wu, G.; Tan, W., Detection of SARS-CoV-2 in Different Types of Clinical Specimens. *JAMA* **2020**. <https://doi.org/10.1001/jama.2020.3786>
546. (U) Wang, X.; Ferro, E. G.; Zhou, G.; Hashimoto, D.; Bhatt, D. L., Association Between Universal Masking in a Health Care System and SARS-CoV-2 Positivity Among Health Care Workers. *JAMA* **2020**. <https://doi.org/10.1001/jama.2020.12897>
547. (U) Wang, Y.; Teunis, P., Strongly Heterogeneous Transmission of COVID-19 in Mainland China: Local and Regional Variation. *Frontiers in Medicine* **2020**, 7 (329). <https://www.frontiersin.org/article/10.3389/fmed.2020.00329>
548. (U) Wang, Y.; Tian, H.; Zhang, L.; Zhang, M.; Guo, D.; Wu, W.; Zhang, X.; Kan, G. L.; Jia, L.; Huo, D.; Liu, B.; Wang, X.; Sun, Y.; Wang, Q.; Yang, P.; MacIntyre, C. R., Reduction of secondary transmission of SARS-CoV-2 in households by face mask use, disinfection and social distancing: a cohort study in Beijing, China. *BMJ Global Health* **2020**, 5 (5), e002794. <https://gh.bmj.com/content/bmjgh/5/5/e002794.full.pdf>
549. (U) Wang, Y.; Zhang, D.; Du, G.; Du, R.; Zhao, J.; Jin, Y.; Fu, S.; Gao, L.; Cheng, Z.; Lu, Q.; Hu, Y.; Luo, G.; Wang, K.; Lu, Y.; Li, H.; Wang, S.; Ruan, S.; Yang, C.; Mei, C.; Wang, Y.; Ding, D.; Wu, F.; Tang, X.; Ye, X.; Ye, Y.; Liu, B.; Yang, J.; Yin, W.; Wang, A.; Fan, G.; Zhou, F.; Liu, Z.; Gu, X.; Xu, J.; Shang, L.; Zhang, Y.; Cao, L.; Guo, T.; Wan, Y.; Qin, H.; Jiang, Y.; Jaki, T.; Hayden, F. G.; Horby, P. W.; Cao, B.; Wang, C., Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. *The Lancet* **2020**, 395 (10236), 1569-1578. <http://www.sciencedirect.com/science/article/pii/S0140673620310229>
550. (U) Wang, Y.; Zhang, D.; Du, G.; Du, R.; Zhao, J.; Jin, Y.; Fu, S.; Gao, L.; Cheng, Z.; Lu, Q.; Hu, Y.; Luo, G.; Wang, K.; Lu, Y.; Li, H.; Wang, S.; Ruan, S.; Yang, C.; Mei, C.; Wang, Y.; Ding, D.; Wu, F.; Tang, X.; Ye, X.; Ye, Y.; Liu, B.; Yang, J.; Yin, W.; Wang, A.; Fan, G.; Zhou, F.; Liu, Z.; Gu, X.; Xu, J.; Shang, L.; Zhang, Y.; Cao, L.; Guo, T.; Wan, Y.; Qin, H.; Jiang, Y.; Jaki, T.; Hayden, F. G.; Horby, P. W.; Cao, B.; Wang, C., Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. *The Lancet*. [https://doi.org/10.1016/S0140-6736\(20\)31022-9](https://doi.org/10.1016/S0140-6736(20)31022-9)
551. (U) Watson, C.; Cicero, A.; Blumenstock, J.; Fraser, M., *A National Plan to Enable Comprehensive COVID-19 Case Finding and Contact*; Johns Hopkins Center for Health Security: 2020. [https://www.centerforhealthsecurity.org/our-work/pubs\\_archive/pubs-pdfs/2020/a-national-plan-to-enable-comprehensive-COVID-19-case-finding-and-contact-tracing-in-the-US.pdf](https://www.centerforhealthsecurity.org/our-work/pubs_archive/pubs-pdfs/2020/a-national-plan-to-enable-comprehensive-COVID-19-case-finding-and-contact-tracing-in-the-US.pdf)
552. (U) WCS, A Tiger at Bronx Zoo Tests Positive for COVID-19; The Tiger and the Zoo's Other Cats Are Doing Well at This Time. <https://newsroom.wcs.org/News-Releases/articleType/ArticleView/articleId/14010/A-Tiger-at-Bronx-Zoo-Tests-Positive-for-COVID-19-The-Tiger-and-the-Zoos-Other-Cats-Are-Doing-Well-at-This-Time.aspx> (accessed April 6, 2020).
553. (U) Wei, W. E.; Li, Z.; Chiew, C. J.; Yong, S. E.; Toh, M. P.; Lee, V. J., Presymptomatic transmission of SARS-CoV-2 - Singapore, January 23 - March 16, 2020. *Morbidity and Mortality Weekly Report* **2020**, ePub (1 April 2020). <https://www.cdc.gov/mmwr/volumes/69/wr/mm6914e1.htm>
554. (U) Wei, Y.; Wei, L.; Liu, Y.; Huang, L.; Shen, S.; Zhang, R.; Chen, J.; Zhao, Y.; Shen, H.; Chen, F., A systematic review and meta-analysis reveals long and dispersive incubation period of COVID-19. *medRxiv* **2020**, 2020.06.20.20134387. <https://www.medrxiv.org/content/medrxiv/early/2020/06/22/2020.06.20.20134387.full.pdf>
555. (U) Weissman, D. N.; de Perio, M. A.; Radonovich, L. J., Jr, COVID-19 and Risks Posed to Personnel During Endotracheal Intubation. *JAMA* **2020**. <https://doi.org/10.1001/jama.2020.6627>

556. (U) Wen, W.; Su, W.; Tang, H.; Le, W.; Zhang, X.; Zheng, Y.; Liu, X.; Xie, L.; Li, J.; Ye, J.; Dong, L.; Cui, X.; Miao, Y.; Wang, D.; Dong, J.; Xiao, C.; Chen, W.; Wang, H., Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing. *Cell Discov* **2020**, *6*, 31.
557. (U) Whitman, J. D.; Hiatt, J.; Mowrey, C. T.; al., e., Test performance evaluation of SARS-CoV-2 serological assays. *Unpublished Preprint* **2020**. [https://www.dropbox.com/s/cd1628cau09288a/SARS-CoV-2\\_Serology\\_Manuscript.pdf?dl=0](https://www.dropbox.com/s/cd1628cau09288a/SARS-CoV-2_Serology_Manuscript.pdf?dl=0)
558. (U) Whitworth, J., U.S. FDA 'aware' of China testing food for coronavirus. <https://www.foodsafetynews.com/2020/06/u-s-fda-aware-of-china-testing-food-for-coronavirus/> (accessed 06/22/2020).
559. (U) WHO, *Advice on the use of masks on the context of COVID-19. Interim Guidance. 5 June 2020.*; World Health Organization: 2020. <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public/when-and-how-to-use-masks>
560. (U) WHO, *COVID-19 Strategy Update*; World Health Organization: 2020. <https://www.who.int/publications-detail/strategic-preparedness-and-response-plan-for-the-new-coronavirus>
561. (U) WHO, Diagnostic detection of Wuhan coronavirus 2019 by real-time RTPCR -Protocol and preliminary evaluation as of Jan 13, 2020. [https://www.who.int/docs/default-source/coronaviruse/wuhan-virus-assay-v1991527e5122341d99287a1b17c111902.pdf?sfvrsn=d381fc88\\_2](https://www.who.int/docs/default-source/coronaviruse/wuhan-virus-assay-v1991527e5122341d99287a1b17c111902.pdf?sfvrsn=d381fc88_2) (accessed 01/26/2020).
562. (U) WHO, "Immunity passports" in the context of COVID-19; World Health Organization: 2020. <https://www.who.int/news-room/commentaries/detail/immunity-passports-in-the-context-of-covid-19>
563. (U) WHO, *Infection prevention and control during health care when novel coronavirus (nCoV) infection is suspected*; 2020. [https://www.who.int/publications-detail/infection-prevention-and-control-during-health-care-when-novel-coronavirus-\(ncov\)-infection-is-suspected-20200125](https://www.who.int/publications-detail/infection-prevention-and-control-during-health-care-when-novel-coronavirus-(ncov)-infection-is-suspected-20200125)
564. (U) WHO, Laboratory testing for 2019 novel coronavirus (2019-nCoV) in suspected human cases.
565. (U) WHO, Multisystem inflammatory syndrome in children and adolescents temporally related to COVID-19. World Health Organization: 2020. <https://www.who.int/news-room/commentaries/detail/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19>
566. (U) WHO, Novel Coronavirus (2019-nCoV) Situation Report-5 25 January 2020. [https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200125-sitrep-5-2019-ncov.pdf?sfvrsn=429b143d\\_4](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200125-sitrep-5-2019-ncov.pdf?sfvrsn=429b143d_4).
567. (U) WHO, Novel Coronavirus (2019-nCoV) technical guidance: Laboratory testing for 2019-nCoV in humans. <https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/laboratory-guidance>.
568. (U) WHO, *Transmission of SARS-CoV-2: implications for infection prevention precautions*; World Health Organization: 2020. <https://www.who.int/news-room/commentaries/detail/transmission-of-sars-cov-2-implications-for-infection-prevention-precautions>
569. (U) Wiersinga, W. J.; Rhodes, A.; Cheng, A. C.; Peacock, S. J.; Prescott, H. C., Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review. *JAMA* **2020**. <https://doi.org/10.1001/jama.2020.12839>
570. (U) Williamson, E. J.; Walker, A. J.; Bhaskaran, K.; Bacon, S.; Bates, C.; Morton, C. E.; Curtis, H. J.; Mehrkar, A.; Evans, D.; Inglesby, P.; Cockburn, J.; McDonald, H. I.; MacKenna, B.; Tomlinson, L.; Douglas, I. J.; Rentsch, C. T.; Mathur, R.; Wong, A. Y. S.; Grieve, R.; Harrison, D.; Forbes, H.; Schultze, A.; Croker, R.; Parry, J.; Hester, F.; Harper, S.; Perera, R.; Evans, S. J. W.; Smeeth, L.; Goldacre, B., OpenSAFELY: factors associated with COVID-19 death in 17 million patients. *Nature* **2020**. <https://doi.org/10.1038/s41586-020-2521-4>

571. (U) Wise, J., Covid-19: Remdesivir is recommended for authorisation by European Medicines Agency. *Bmj* **2020**, 369, m2610.
572. (U) Wölfel, R.; Corman, V. M.; Guggemos, W.; Seilmaier, M.; Zange, S.; Müller, M. A.; Niemeyer, D.; Jones, T. C.; Vollmar, P.; Rothe, C.; Hoelscher, M.; Bleicker, T.; Brünink, S.; Schneider, J.; Ehmann, R.; Zwirgmaier, K.; Drosten, C.; Wendtner, C., Virological assessment of hospitalized patients with COVID-2019. *Nature* **2020**. <https://doi.org/10.1038/s41586-020-2196-x>
573. (U) Wolff, M. H.; Sattar, S. A.; Adegunrin, O.; Tetro, J., Environmental survival and microbicide inactivation of coronaviruses. In *Coronaviruses with special emphasis on first insights concerning SARS*, Springer: 2005; pp 201-212.
574. (U) Wong, M. C.; Javornik Cregeen, S. J.; Ajami, N. J.; Petrosino, J. F., Evidence of recombination in coronaviruses implicating pangolin origins of nCoV-2019. *bioRxiv* **2020**, 2020.02.07.939207. <https://www.biorxiv.org/content/biorxiv/early/2020/02/13/2020.02.07.939207.full.pdf>
575. (U) Wong, Y. C.; Lau, S. Y.; Wang To, K. K.; Mok, B. W. Y.; Li, X.; Wang, P.; Deng, S.; Woo, K. F.; Du, Z.; Li, C.; Zhou, J.; Woo Chan, J. F.; Yuen, K. Y.; Chen, H.; Chen, Z., Natural transmission of bat-like SARS-CoV-2 PRRA variants in COVID-19 patients. *Clinical Infectious Diseases* **2020**. <https://doi.org/10.1093/cid/cia953>
576. (U) Woolf, S. H.; Chapman, D. A.; Sabo, R. T.; Weinberger, D. M.; Hill, L., Excess Deaths From COVID-19 and Other Causes, March-April 2020. *JAMA* **2020**. <https://doi.org/10.1001/jama.2020.11787>
577. (U) Woolsey, C. B.; Borisevich, V.; Prasad, A. N.; Agans, K. N.; Deer, D. J.; Dobias, N. S.; Heymann, J. C.; Foster, S. L.; Levine, C. B.; Medina, L.; Melody, K.; Geisbert, J. B.; Fenton, K. A.; Geisbert, T. W.; Cross, R. W., Establishment of an African green monkey model for COVID-19. *bioRxiv* **2020**, 2020.05.17.100289. <http://biorxiv.org/content/early/2020/05/17/2020.05.17.100289.abstract>
578. (U) Worobey, M.; Pekar, J.; Larsen, B. B.; Nelson, M. I.; Hill, V.; Joy, J. B.; Rambaut, A.; Suchard, M. A.; Wertheim, J. O.; Lemey, P., The emergence of SARS-CoV-2 in Europe and the US. *bioRxiv* **2020**, 2020.05.21.109322. <https://www.biorxiv.org/content/biorxiv/early/2020/05/23/2020.05.21.109322.full.pdf>
579. (U) Worthham, J. M.; Lee, J. T.; Althomsons, S.; al., e., Characteristics of Persons Who Died with COVID-19 — United States, February 12–May 18, 2020. *Morbidity and Mortality Weekly Report* **2020**, ePub: July 10, 2020 (69). <https://www.cdc.gov/mmwr/volumes/69/wr/mm6928e1.htm>
580. (U) Wrapp, D.; Wang, N.; Corbett, K. S.; Goldsmith, J. A.; Hsieh, C.-L.; Abiona, O.; Graham, B. S.; McLellan, J. S., Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion Conformation. *bioRxiv* **2020**, 2020.02.11.944462. <https://www.biorxiv.org/content/biorxiv/early/2020/02/15/2020.02.11.944462.full.pdf>
581. (U) Wright, E. S.; Lakdawala, S. S.; Cooper, V. S., SARS-CoV-2 genome evolution exposes early human adaptations. *bioRxiv* **2020**, 2020.05.26.117069. <https://www.biorxiv.org/content/biorxiv/early/2020/05/26/2020.05.26.117069.full.pdf>
582. (U) Wu, F.; Wang, A.; Liu, M.; Wang, Q.; Chen, J.; Xia, S.; Ling, Y.; Zhang, Y.; Xun, J.; Lu, L.; Jiang, S.; Lu, H.; Wen, Y.; Huang, J., Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. *medRxiv* **2020**, 2020.03.30.20047365. <https://www.medrxiv.org/content/medrxiv/early/2020/04/06/2020.03.30.20047365.full.pdf>
583. (U) Wu, G.; Yang, P.; Xie, Y.; Woodruff, H. C.; Rao, X.; Guiot, J.; Frix, A.-N.; Louis, R.; Moutschen, M.; Li, J.; Li, J.; Yan, C.; Du, D.; Zhao, S.; Ding, Y.; Liu, B.; Sun, W.; Albarello, F.; D'Abramo, A.; Schininà, V.; Nicastri, E.; Occhipinti, M.; Barisione, G.; Barisione, E.; Halilaj, I.; Lovinfosse, P.; Wang, X.; Wu, J.; Lambin, P., Development of a Clinical Decision Support System for Severity Risk Prediction and Triage of COVID-19 Patients at Hospital Admission: an International Multicenter Study. *European Respiratory Journal* **2020**, 2001104. <https://erj.ersjournals.com/content/erj/early/2020/06/25/13993003.01104-2020.full.pdf>

584. (U) Wu, H.; Zhu, H.; Yuan, C.; Yao, C.; Luo, W.; Shen, X.; Wang, J.; Shao, J.; Xiang, Y., Clinical and Immune Features of Hospitalized Pediatric Patients With Coronavirus Disease 2019 (COVID-19) in Wuhan, China. *JAMA Network Open* **2020**, 3 (6), e2010895-e2010895. <https://doi.org/10.1001/jamanetworkopen.2020.10895>
585. (U) Wu, J. T.; Leung, K.; Leung, G. M., Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. *The Lancet* **2020**. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(20\)30260-9/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30260-9/fulltext)
586. (U) Wu, L.-P.; Wang, N.-C.; Chang, Y.-H.; Tian, X.-Y.; Na, D.-Y.; Zhang, L.-Y.; Zheng, L.; Lan, T.; Wang, L.-F.; Liang, G.-D., Duration of antibody responses after severe acute respiratory syndrome. *Emerging infectious diseases* **2007**, 13 (10), 1562. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2851497/pdf/07-0576\\_finalD.pdf](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2851497/pdf/07-0576_finalD.pdf)
587. (U) Wu, P.; Duan, F.; Luo, C.; Liu, Q.; Qu, X.; Liang, L.; Wu, K., Characteristics of Ocular Findings of Patients With Coronavirus Disease 2019 (COVID-19) in Hubei Province, China. *JAMA Ophthalmology* **2020**. <https://doi.org/10.1001/jamaophthalmol.2020.1291>
588. (U) Wuhan, A randomized, double-blind, placebo parallel-controlled phase I/II clinical trial for inactivated Novel Coronavirus Pneumonia vaccine (Vero cells) (Wuhan Institute of Biological Products). <http://www.chictr.org.cn/showprojen.aspx?proj=52227>.
589. (U) Wyllie, A. L.; Fournier, J.; Casanovas-Massana, A.; Campbell, M.; Tokuyama, M.; Vijayakumar, P.; Geng, B.; Muenker, M. C.; Moore, A. J.; Vogels, C. B. F.; Petrone, M. E.; Ott, I. M.; Lu, P.; Lu-Culligan, A.; Klein, J.; Venkataraman, A.; Earnest, R.; Simonov, M.; Datta, R.; Handoko, R.; Naushad, N.; Sewanan, L. R.; Valdez, J.; White, E. B.; Lapidus, S.; Kalinich, C. C.; Jiang, X.; Kim, D. J.; Kudo, E.; Linehan, M.; Mao, T.; Moriyama, M.; Oh, J. E.; Park, A.; Silva, J.; Song, E.; Takahashi, T.; Taura, M.; Weizman, O.-E.; Wong, P.; Yang, Y.; Bermejo, S.; Odio, C.; Omer, S. B.; Dela Cruz, C. S.; Farhadian, S.; Martinello, R. A.; Iwasaki, A.; Grubaugh, N. D.; Ko, A. I., Saliva is more sensitive for SARS-CoV-2 detection in COVID-19 patients than nasopharyngeal swabs. *medRxiv* **2020**, 2020.04.16.20067835. <https://www.medrxiv.org/content/medrxiv/early/2020/04/22/2020.04.16.20067835.full.pdf>
590. (U) Xiao, F.; Sun, J.; Xu, Y.; Li, F.; Huang, X.; Li, H.; Zhao, J.; Huang, J.; Zhao, J., Infectious SARS-CoV-2 in Feces of Patient with Severe COVID-19. *Emerging Infectious Diseases* **2020**, 26. [https://wwwnc.cdc.gov/eid/article/26/8/20-0681\\_article](https://wwwnc.cdc.gov/eid/article/26/8/20-0681_article)
591. (U) Xiao, K.; Zhai, J.; Feng, Y.; Zhou, N.; Zhang, X.; Zou, J. J.; Li, N.; Guo, Y.; Li, X.; Shen, X.; Zhang, Z.; Shu, F.; Huang, W.; Li, Y.; Zhang, Z.; Chen, R. A.; Wu, Y. J.; Peng, S. M.; Huang, M.; Xie, W. J.; Cai, Q. H.; Hou, F. H.; Chen, W.; Xiao, L.; Shen, Y., Isolation of SARS-CoV-2-related coronavirus from Malayan pangolins. *Nature* **2020**.
592. (U) Xinhua, China detects large quantity of novel coronavirus at Wuhan seafood market [http://www.xinhuanet.com/english/2020-01/27/c\\_138735677.htm](http://www.xinhuanet.com/english/2020-01/27/c_138735677.htm).
593. (U) Xu, X.; Han, M.; Li, T.; Sun, W.; Wang, D.; Fu, B.; Zhou, Y.; Zheng, X.; Yang, Y.; Li, X.; Zhang, X.; Pan, A.; Wei, H., Effective treatment of severe COVID-19 patients with tocilizumab. *Proceedings of the National Academy of Sciences* **2020**, 202005615. <https://www.pnas.org/content/pnas/early/2020/04/27/2005615117.full.pdf>
594. (U) Xu, X. K.; Liu, X. F.; Wu, Y.; Ali, S. T.; Du, Z.; Bosetti, P.; Lau, E. H. Y.; Cowling, B. J.; Wang, L., Reconstruction of Transmission Pairs for novel Coronavirus Disease 2019 (COVID-19) in mainland China: Estimation of Super-spreading Events, Serial Interval, and Hazard of Infection. *Clin Infect Dis* **2020**.
595. (U) Xue, K. S.; Bloom, J. D., Reconciling disparate estimates of viral genetic diversity during human influenza infections. *Nature Genetics* **2019**, 51 (9), 1298-1301. <https://doi.org/10.1038/s41588-019-0349-3>
596. (U) Yan, C. H.; Faraji, F.; Prajapati, D. P.; Boone, C. E.; DeConde, A. S., In Association of chemosensory dysfunction and Covid-19 in patients presenting with influenza-like symptoms, International Forum of Allergy & Rhinology, Wiley Online Library: 2020.

597. (U) Yang, H.; Wang, C.; Poon, L., Novel coronavirus infection and pregnancy. *Ultrasound in Obstetrics & Gynecology* **2020**.
598. (U) Yang, L.; Dai, J.; Zhao, J.; Wang, Y.; Deng, P.; Wang, J., Estimation of incubation period and serial interval of COVID-19: analysis of 178 cases and 131 transmission chains in Hubei province, China. *Epidemiology and Infection* **2020**, *148*, e117. <https://www.cambridge.org/core/article/estimation-of-incubation-period-and-serial-interval-of-covid19-analysis-of-178-cases-and-131-transmission-chains-in-hubei-province-china/C1B194C01268F005AAFBE8D50CB5F945>
599. (U) Yang, P.; Qi, J.; Zhang, S.; Bi, G.; Wang, X.; Yang, Y.; Sheng, B.; Mao, X., Feasibility of Controlling COVID-19 Outbreaks in the UK by Rolling Interventions. *medRxiv* **2020**, 2020.04.05.20054429. <https://www.medrxiv.org/content/medrxiv/early/2020/04/07/2020.04.05.20054429.full.pdf>
600. (U) Yehya, N.; Venkataramani, A.; Harhay, M. O., Statewide Interventions and Covid-19 Mortality in the United States: An Observational Study. *Clinical Infectious Diseases* **2020**. <https://doi.org/10.1093/cid/ciaa923>
601. (U) Yu, B.; Li, C.; Chen, P.; Zhou, N.; Wang, L.; Li, J.; Jiang, H.; Wang, D. W., Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19. *Sci China Life Sci* **2020**, 1-7.
602. (U) Yu, N.; Li, W.; Kang, Q.; Zeng, W.; Feng, L.; Wu, J., No SARS-CoV-2 detected in amniotic fluid in mid-pregnancy. *The Lancet Infectious Diseases*. [https://doi.org/10.1016/S1473-3099\(20\)30320-0](https://doi.org/10.1016/S1473-3099(20)30320-0)
603. (U) Yu, W.-B.; Tang, G.-D.; Zhang, L.; Corlett, R. T., Decoding evolution and transmissions of novel pneumonia coronavirus using the whole genomic data. *ChinaXiv* **2020**. <http://www.chinaxiv.org/abs/202002.00033>
604. (U) Yu, W. B.; Tang, G. D.; Zhang, L.; Corlett, R. T., Decoding the evolution and transmissions of the novel pneumonia coronavirus (SARS-CoV-2 / HCoV-19) using whole genomic data. *Zool Res* **2020**, *41* (3), 247-257.
605. (U) Yuan, B.; Liu, H.-Q.; Yang, Z.-R.; Chen, Y.-X.; Liu, Z.-Y.; Zhang, K.; Wang, C.; Li, W.-X.; An, Y.-W.; Wang, J.-C.; Song, S., Recurrence of positive SARS-CoV-2 viral RNA in recovered COVID-19 patients during medical isolation observation. *Scientific Reports* **2020**, *10* (1), 11887. <https://doi.org/10.1038/s41598-020-68782-w>
606. (U) Yuki, F.; Eiichiro, S.; Naho, T.; Reiko, M.; Ikkoh, Y.; Yura, K. K.; Mayuko, S.; Konosuke, M.; Takeaki, I.; Yugo, S.; Shohei, N.; Kazuaki, J.; Tadatsugu, I.; Tomimasa, S.; Motoi, S.; Hiroshi, N.; Hitoshi, O., Clusters of Coronavirus Disease in Communities, Japan, January–April 2020. *Emerging Infectious Disease journal* **2020**, *26* (9). [https://wwwnc.cdc.gov/eid/article/26/9/20-2272\\_article](https://wwwnc.cdc.gov/eid/article/26/9/20-2272_article)
607. (U) Yung, C. F.; Kam, K.-Q.; Chong, C. Y.; Nadua, K. D.; Li, J.; Hui Tan, N. W.; Ganapathy, S.; Lee, K. P.; Ng, K. C.; Chan, Y. H.; Thoon, K. C., Household Transmission of SARS-CoV-2 from Adults to Children. *The Journal of Pediatrics* **2020**, S0022-3476(20)30852-0. <https://pubmed.ncbi.nlm.nih.gov/32634405>  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7334921/>
608. (U) Zachariah, P.; Johnson, C. L.; Halabi, K. C.; Ahn, D.; Sen, A. I.; Fischer, A.; Banker, S. L.; Giordano, M.; Manice, C. S.; Diamond, R.; Sewell, T. B.; Schweickert, A. J.; Babineau, J. R.; Carter, R. C.; Fenster, D. B.; Orange, J. S.; McCann, T. A.; Kernie, S. G.; Saiman, L.; Group, f. t. C. P. C.-M., Epidemiology, Clinical Features, and Disease Severity in Patients With Coronavirus Disease 2019 (COVID-19) in a Children’s Hospital in New York City, New York. *JAMA Pediatrics* **2020**, e202430-e202430. <https://doi.org/10.1001/jamapediatrics.2020.2430>
609. (U) Zaigham, M.; Andersson, O., Maternal and perinatal outcomes with COVID-19: A systematic review of 108 pregnancies. *Acta Obstet Gynecol Scand* **2020**.
610. (U) Zangmeister, C. D.; Radney, J. G.; Vicenzi, E. P.; Weaver, J. L., Filtration Efficiencies of Nanoscale Aerosol by Cloth Mask Materials Used to Slow the Spread of SARS CoV-2. *ACS Nano* **2020**. <https://doi.org/10.1021/acsnano.0c05025>

611. (U) Zhan, C.; Chi, K. T.; Lai, Z.; Chen, X.; Mo, M., General Model for COVID-19 Spreading with Consideration of Intercity Migration, Insufficient Testing and Active Intervention: Application to Study of Pandemic Progression in Japan and USA. *medRxiv* **2020**.
612. (U) Zhang, J.; Litvinova, M.; Liang, Y.; Wang, Y.; Wang, W.; Zhao, S.; Wu, Q.; Merler, S.; Viboud, C.; Vespignani, A.; Ajelli, M.; Yu, H., Changes in contact patterns shape the dynamics of the COVID-19 outbreak in China. *Science* **2020**, eabb8001.  
<https://science.sciencemag.org/content/sci/early/2020/05/04/science.abb8001.full.pdf>
613. (U) Zhang, J.; Litvinova, M.; Wang, W.; Wang, Y.; Deng, X.; Chen, X.; Li, M.; Zheng, W.; Yi, L.; Chen, X.; Wu, Q.; Liang, Y.; Wang, X.; Yang, J.; Sun, K.; Longini, I. M., Jr.; Halloran, M. E.; Wu, P.; Cowling, B. J.; Merler, S.; Viboud, C.; Vespignani, A.; Ajelli, M.; Yu, H., Evolving epidemiology and transmission dynamics of coronavirus disease 2019 outside Hubei province, China: a descriptive and modelling study. *The Lancet Infectious Diseases*. [https://doi.org/10.1016/S1473-3099\(20\)30230-9](https://doi.org/10.1016/S1473-3099(20)30230-9)
614. (U) Zhang, J.; Wu, J.; Sun, X.; Xue, H.; Shao, J.; Cai, W.; Jing, Y.; Yue, M.; Dong, C., Associations of hypertension with the severity and fatality of SARS-CoV-2 infection: A meta-analysis. *Epidemiology and Infection* **2020**, 1-19. <https://www.cambridge.org/core/article/associations-of-hypertension-with-the-severity-and-fatality-of-sarscov2-infection-a-metaanalysis/4116FAD7D866737099F976E7E7FAEB15>
615. (U) Zhang, L.; Jackson, C. B.; Mou, H.; Ojha, A.; Rangarajan, E. S.; Izard, T.; Farzan, M.; Choe, H., The D614G mutation in the SARS-CoV-2 spike protein reduces S1 shedding and increases infectivity. *bioRxiv* **2020**, 2020.06.12.148726. <http://biorxiv.org/content/early/2020/06/12/2020.06.12.148726.abstract>
616. (U) Zhang, Q.; Zhang, H.; Huang, K.; Yang, Y.; Hui, X.; Gao, J.; He, X.; Li, C.; Gong, W.; Zhang, Y.; Peng, C.; Gao, X.; Chen, H.; Zou, Z.; Shi, Z.; Jin, M., SARS-CoV-2 neutralizing serum antibodies in cats: a serological investigation. *bioRxiv* **2020**, 2020.04.01.021196.  
<http://biorxiv.org/content/early/2020/04/03/2020.04.01.021196.abstract>
617. (U) Zhang, T.; Wu, Q.; Zhang, Z., Probable Pangolin Origin of SARS-CoV-2 Associated with the COVID-19 Outbreak. *Current Biology* **2020**, 30 (7), 1346-1351.e2.  
<http://www.sciencedirect.com/science/article/pii/S0960982220303602>
618. (U) Zhang, X.; Tan, Y.; Ling, Y.; Lu, G.; Liu, F.; Yi, Z.; Jia, X.; Wu, M.; Shi, B.; Xu, S.; Chen, J.; Wang, W.; Chen, B.; Jiang, L.; Yu, S.; Lu, J.; Wang, J.; Xu, M.; Yuan, Z.; Zhang, Q.; Zhang, X.; Zhao, G.; Wang, S.; Chen, S.; Lu, H., Viral and host factors related to the clinical outcome of COVID-19. *Nature* **2020**.  
<https://doi.org/10.1038/s41586-020-2355-0>
619. (U) Zhao; Musa; Lin; Ran; Yang; Wang; Lou; Yang; Gao; He; Wang, Estimating the Unreported Number of Novel Coronavirus (2019-nCoV) Cases in China in the First Half of January 2020: A Data-Driven Modelling Analysis of the Early Outbreak. *Journal of Clinical Medicine* **2020**, 9 (2), 388.
620. (U) Zhao, G.; Jiang, Y.; Qiu, H.; Gao, T.; Zeng, Y.; Guo, Y.; Yu, H.; Li, J.; Kou, Z.; Du, L.; Tan, W.; Jiang, S.; Sun, S.; Zhou, Y., Multi-Organ Damage in Human Dipeptidyl Peptidase 4 Transgenic Mice Infected with Middle East Respiratory Syndrome-Coronavirus. *PLoS One* **2015**, 10 (12), e0145561.  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4689477/pdf/pone.0145561.pdf>
621. (U) Zhao, J.; Yuan, Q.; Wang, H.; Liu, W.; Liao, X.; Su, Y.; Wang, X.; Yuan, J.; Li, T.; Li, J.; Qian, S.; Hong, C.; Wang, F.; Liu, Y.; Wang, Z.; He, Q.; He, B.; Zhang, T.; Ge, S.; Liu, L.; Zhang, J.; Xia, N.; Zhang, Z., Antibody Responses to SARS-CoV-2 in Patients of Novel Coronavirus Disease 2019. *SSRN* **2020**.  
[https://papers.ssrn.com/sol3/papers.cfm?abstract\\_id=3546052#](https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3546052#)
622. (U) Zhen-Dong, T.; An, T.; Ke-Feng, L.; Peng, L.; Hong-Ling, W.; Jing-Ping, Y.; Yong-Li, Z.; Jian-Bo, Y., Potential Presymptomatic Transmission of SARS-CoV-2, Zhejiang Province, China, 2020. *Emerging Infectious Disease Journal* **2020**, 26 (5). [https://wwwnc.cdc.gov/eid/article/26/5/20-0198\\_article](https://wwwnc.cdc.gov/eid/article/26/5/20-0198_article)
623. (U) Zheng, S.; Fan, J.; Yu, F.; Feng, B.; Lou, B.; Zou, Q.; Xie, G.; Lin, S.; Wang, R.; Yang, X.; Chen, W.; Wang, Q.; Zhang, D.; Liu, Y.; Gong, R.; Ma, Z.; Lu, S.; Xiao, Y.; Gu, Y.; Zhang, J.; Yao, H.; Xu, K.; Lu, X.; Wei, G.; Zhou, J.; Fang, Q.; Cai, H.; Qiu, Y.; Sheng, J.; Chen, Y.; Liang, T., Viral load dynamics and disease



- severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study. *BMJ* **2020**, 369, m1443. <https://www.ncbi.nlm.nih.gov/pubmed/32317267>
624. (U) Zhongchu, L., The sixth press conference of "Prevention and Control of New Coronavirus Infected Pneumonia". Hubei Provincial Government: 2020.  
[http://www.hubei.gov.cn/hbfb/xwfbh/202001/t20200128\\_2015591.shtml](http://www.hubei.gov.cn/hbfb/xwfbh/202001/t20200128_2015591.shtml)
625. (U) Zhou, F.; Yu, T.; Du, R.; Fan, G.; Liu, Y.; Liu, Z.; Xiang, J.; Wang, Y.; Song, B.; Gu, X.; Guan, L.; Wei, Y.; Li, H.; Wu, X.; Xu, J.; Tu, S.; Zhang, Y.; Chen, H.; Cao, B., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet*.  
[https://doi.org/10.1016/S0140-6736\(20\)30566-3](https://doi.org/10.1016/S0140-6736(20)30566-3)
626. (U) Zhou, H.; Chen, X.; Hu, T.; Li, J.; Song, H.; Liu, Y.; Wang, P.; Liu, D.; Yang, J.; Holmes, E. C.; Hughes, A. C.; Bi, Y.; Shi, W., A novel bat coronavirus reveals natural insertions at the S1/S2 cleavage site of the Spike protein and a possible recombinant origin of HCoV-19. *bioRxiv* **2020**, 2020.03.02.974139.  
<https://www.biorxiv.org/content/biorxiv/early/2020/03/11/2020.03.02.974139.full.pdf>
627. (U) Zhou, P.; Yang, X.-L.; Wang, X.-G.; Hu, B.; Zhang, L.; Zhang, W.; Si, H.-R.; Zhu, Y.; Li, B.; Huang, C.-L.; Chen, H.-D.; Chen, J.; Luo, Y.; Guo, H.; Jiang, R.-D.; Liu, M.-Q.; Chen, Y.; Shen, X.-R.; Wang, X.; Zheng, X.-S.; Zhao, K.; Chen, Q.-J.; Deng, F.; Liu, L.-L.; Yan, B.; Zhan, F.-X.; Wang, Y.-Y.; Xiao, G.; Shi, Z.-L., Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. *bioRxiv* **2020**, 2020.01.22.914952.  
<https://www.biorxiv.org/content/biorxiv/early/2020/01/23/2020.01.22.914952.1.full.pdf>
628. (U) Zhu, F.-C.; Li, Y.-H.; Guan, X.-H.; Hou, L.-H.; Wang, W.-J.; Li, J.-X.; Wu, S.-P.; Wang, B.-S.; Wang, Z.; Wang, L.; Jia, S.-Y.; Jiang, H.-D.; Wang, L.; Jiang, T.; Hu, Y.; Gou, J.-B.; Xu, S.-B.; Xu, J.-J.; Wang, X.-W.; Wang, W.; Chen, W., Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. *The Lancet* **2020**. [https://doi.org/10.1016/S0140-6736\(20\)31208-3](https://doi.org/10.1016/S0140-6736(20)31208-3)
629. (U) Zhu, Y.; Chen, Y. Q., On a Statistical Transmission Model in Analysis of the Early Phase of COVID-19 Outbreak. *Statistics in Biosciences* **2020**, 1-17.  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113380/>
630. (U) Zou, L.; Ruan, F.; Huang, M.; Liang, L.; Huang, H.; Hong, Z.; Yu, J.; Kang, M.; Song, Y.; Xia, J.; Guo, Q.; Song, T.; He, J.; Yen, H.-L.; Peiris, M.; Wu, J., SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. *New England Journal of Medicine* **2020**.  
<https://www.nejm.org/doi/full/10.1056/NEJMc2001737>
631. (U) Zydus, Novel Corona Virus-2019-nCov vaccine by intradermal route in healthy subjects. .  
<http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=45306&EncHid=&userName=vaccine>